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Abstract
The Notch pathway is an evolutionarily conserved signaling cascade that regulates many cell fate
decisions. Recent work has revealed that Notch plays critical roles in the control of skeletal muscle
development and regeneration. In the embryo, Notch maintains a pool of myogenic progenitor cells and
prevents their premature differentiation. In the adult, after muscle injury, Notch signaling is essential for
the initial expansion of muscle stem cells, or satellite cells.
While it has been known for over a decade that Notch activity represses myogenic differentiation, the
molecular mechanisms by which this inhibition occurs are poorly defined. In this thesis, I sought to
identify the key transcriptional effectors of Notch in muscle and explore how these proteins repress the
myogenic program. Using the mouse myoblast cell line C2C12, I identified 82 transcripts upregulated
after six hours of ligand-mediated Notch stimulation. When constitutively expressed in myoblasts, several
of these genes (Nrarp, HeyL, Trib2) had no apparent impact on differentiation, while at least two of them,
the canonical effector Hey1 and the novel Notch-responsive gene MyoR, were capable of recapitulating
the pathway’s inhibitory effects. Interestingly, siRNA knockdown of Hey1 or MyoR, or the two factors in
combination, failed to rescue the differentiation of myoblasts exposed to Notch ligands. These results
support a model in which Notch acts through multiple, potentially redundant pathways to repress
myogenesis.
In subsequent work, I focused on the mechanistic question of how the Notch effector Hey1 interferes with
myogenic transcription. My functional and biochemical data revealed that Hey1 does not target the
inherent transcriptional activity of the skeletal muscle master regulator MyoD. I found that Hey1
repressed only a subset of MyoD target genes, and consistently, did not disrupt dimerization of MyoD with
its obligate binding partner E47. My results indicated that Hey1 is recruited to the promoter regions of
Myogenin and Mef2C, two genes whose induction is critical for differentiation. Expression of Hey1 in
C2C12 myoblasts correlated with reduced recruitment of MyoD to these promoters, arguing that Hey1
inhibits myogenesis by associating with and repressing expression of key myogenic targets.
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ABSTRACT
MECHANISMS OF NOTCH-MEDIATED INHIBITION
OF SKELETAL MYOGENESIS

Matthew F. Buas
Tom Kadesch, Ph.D.

The Notch pathway is an evolutionarily conserved signaling cascade that
regulates many cell fate decisions. Recent work has revealed that Notch plays critical
roles in the control of skeletal muscle development and regeneration. In the embryo,
Notch maintains a pool of myogenic progenitor cells and prevents their premature
differentiation. In the adult, after muscle injury, Notch signaling is essential for the initial
expansion of muscle stem cells, or satellite cells.
While it has been known for over a decade that Notch activity represses myogenic
differentiation, the molecular mechanisms by which this inhibition occurs are poorly
defined. In this thesis, I sought to identify the key transcriptional effectors of Notch in
muscle and explore how these proteins repress the myogenic program. Using the mouse
myoblast cell line C2C12, I identified 82 transcripts upregulated after six hours of ligandmediated Notch stimulation. When constitutively expressed in myoblasts, several of these
genes (Nrarp, HeyL, Trib2) had no apparent impact on differentiation, while at least two
of them, the canonical effector Hey1 and the novel Notch-responsive gene MyoR, were
capable of recapitulating the pathway’s inhibitory effects. Interestingly, siRNA
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knockdown of Hey1 or MyoR, or the two factors in combination, failed to rescue the
differentiation of myoblasts exposed to Notch ligands. These results support a model in
which Notch acts through multiple, potentially redundant pathways to repress
myogenesis.
In subsequent work, I focused on the mechanistic question of how the Notch
effector Hey1 interferes with myogenic transcription. My functional and biochemical
data revealed that Hey1 does not target the inherent transcriptional activity of the skeletal
muscle master regulator MyoD. I found that Hey1 repressed only a subset of MyoD
target genes, and consistently, did not disrupt dimerization of MyoD with its obligate
binding partner E47. My results indicated that Hey1 is recruited to the promoter regions
of Myogenin and Mef2C, two genes whose induction is critical for differentiation.
Expression of Hey1 in C2C12 myoblasts correlated with reduced recruitment of MyoD to
these promoters, arguing that Hey1 inhibits myogenesis by associating with and
repressing expression of key myogenic targets.
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Chapter I. Introduction
Part 1: Skeletal myogenesis
The generation of skeletal muscle tissue is a highly regulated, step-wise process that is
controlled in vertebrates by a family of four homologous transcription factors, known as
muscle regulatory factors (MRFs). The founding member of this family, MyoD, was
discovered over twenty years ago and shown to exhibit the remarkable ability to convert a
wide range of non-muscle cell lines into the muscle lineage (Davis et al., 1987;
Weintraub et al., 1989). Since the initial cloning and characterization of this master
regulator, skeletal muscle has become one of the best studied systems of cellular
differentiation. The availability of cell culture models, which recapitulate many aspects
of in vivo myogenesis, has greatly facilitated the molecular and biochemical dissection of
the myogenic transcriptional program.

Muscle regulatory factors
MyoD was discovered by Weintraub and colleagues, who first made the
intriguing observation that rare colonies of 10T1/2 fibroblasts transfected with DNA from
5’azacytidine-treated fibroblasts were converted to a muscle phenotype (Lassar et al.,
1986). This finding was interpreted to suggest that a structural change, likely
demethylation, of a single, normally-silent DNA locus within fibroblasts was capable of
inducing myogenesis. Subtractive cDNA hybridization was then employed to identify a
cDNA, MyoD, that exhibited this potential and shared sequence homology to the
transcription factors myc and achaete-scute (Davis et al., 1987). Consistent with a role as
1

skeletal muscle master regulator, MyoD was found to be expressed exclusively in this
lineage in vivo, and only in myogenic cell lines in vitro. Soon after the identification of
MyoD, three other homologous muscle-specific transcription factors—Myf-5, Myogenin,
and MRF4—were also cloned and shown capable of converting cultured fibroblasts to a
muscle phenotype (Braun et al., 1990; Braun et al., 1989; Wright et al., 1989).
MyoD and the other MRFs belong to a family of transcription factors known as
basic helix-loop-helix (bHLH) proteins (Figure 1.1). These factors bind to E-box
elements (CANNTG) within DNA to activate transcription. MyoD requires both its basic
domain, for DNA binding, and its HLH motif, for dimerization with other bHLH factors
known as E-proteins, such as E2A, E2-2, and HEB. While MyoD homodimers may
assemble and function with low efficiency, an important role for heterodimerization was
suggested by several lines of evidence—MyoD-E protein heterodimers are the
predominant species in myoblast nuclear extracts, E proteins synergize with MyoD in
transcriptional reporter assays, and anti-sense E47 impairs MyoD-mediated conversion of
fibroblasts (Lassar et al., 1991).
One of the early puzzles in transcriptional control by MyoD was the fact that its
DNA recognition element, the E-box, was found not only in myogenic target gene
promoters, but also in many promoters not activated in muscle. Conversely, nonmyogenic bHLH proteins, such as ubiquitously expressed E proteins, were found to bind
to myogenic E-boxes but failed to activate these promoters. In vitro DNA binding
capacity alone did not account for transcriptional activity. The basis for specificity was
first explored by Weintraub and coworkers, who demonstrated that two residues present
within the MyoD basic domain but absent from other bHLH proteins, an alanine and
2
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Acidic

H/C

bHLH
Helix III

Figure 1.1. Structure of the MyoD protein. The N-terminal acidic domain
functions in transcriptional activation, the H/C and Helix III motifs participate
in chromatin remodeling, and the bHLH (basic helix-loop-helix) domain
mediates DNA binding and dimerization. Adapted from Berkes et al. (2004).
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threonine, were critical for transcriptional activity on myogenic promoters (Davis and
Weintraub, 1992; Weintraub et al., 1991). It was proposed, and later demonstrated, that
these residues are important for collaboration of MyoD with critical cofactors, namely
members of the Mef2 family of transcription factors (Molkentin et al., 1995). In parallel,
other work suggested that the inability of MyoD to activate E-box-containing non-muscle
promoters, such as the immunoglobulin heavy chain (IgH) enhancer, was in part due to
the presence of negatively acting cis-elements. It was postulated that nucleotides flanking
the E-box could potentially recruit a repressor acting specifically on MyoD but not E47
(Weintraub et al., 1994).

Skeletal muscle development
During mammalian embryogenesis, skeletal muscle tissue of the body and limbs
is derived from the somites, regularly patterned blocks of paraxial mesoderm adjacent to
the neural tube. Somites are subdivided into a ventral compartment, the sclerotome, and a
dorsal compartment, the dermomyotome. While the sclerotome gives rise to ribs,
vertebrae, and discs, the dermomyotome gives rise to skin and skeletal muscle. The
dermomyotome can be further divided into a medial portion, from which epaxial muscles
of the back and intercostals are derived, and a lateral portion, from which hypaxial
muscles of the ventral body wall and limbs are derived. Myogenesis is a step-wise
process whereby proliferating myogenic progenitors give rise to a population of
myoblasts, which continue to divide before exiting the cell cycle, differentiating, and
fusing into multinucleated myotubes (Figure 1.2). Bundles of parallel myotubes then
form a mature myofiber, the basic contractile unit of skeletal muscle. The myotome, a
34

Myogenic progenitor

Myoblast

Myotube

Figure 1.2. Skeletal myogenesis. Myogenic progenitors proliferate and give rise to
a population of myoblasts, which continue to divide before exiting the cell cycle,
differentiating, and fusing to form multinucleated myotubes.
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sheet of muscle precursors between the sclerotome and dermomyotome, represents the
first skeletal muscle mass to be formed. Primary myofibers arise from the fusion of
embryonic myoblasts and are thought to serve as a framework on which myoblasts
continue to proliferate before fusing into secondary myofibers during fetal development
(Kelly and Zacks, 1969).
Gene knockout studies in the 1990s established critical roles for the MRFs in
controlling skeletal myogenesis in the embryo. While muscle development proceeded
normally in MyoD or Myf-5 single knockout animals, MyoD/Myf-5 double knockouts
died soon after birth with virtually a complete absence of skeletal muscle (Braun et al.,
1992; Rudnicki et al., 1992; Rudnicki et al., 1993). This initial finding implied that
MyoD and Myf-5 can compensate for each other in myogenic specification. In stark
contrast to the single knockouts above, deletion of Myogenin resulted in a severe
reduction of skeletal muscle, and an apparent block in the ability of myoblasts to
terminally differentiate (Hasty et al., 1993; Nabeshima et al., 1993). The MRF4 knockout
was viable and fertile, and a significant upregulation of Myogenin was observed,
suggesting potential compensation by this pro-differentiation factor (Zhang et al., 1995).
Later studies suggested that MRF4 may also contribute to specification in parallel with
MyoD and Myf-5 (Kassar-Duchossoy et al., 2004). The picture that emerged from these
genetic studies was a hierarchical relationship among the MRFs, in which MyoD and
Myf-5 (and likely MRF4) were involved in the initial specification of myogenic
precursors, while Myogenin functioned downstream in promoting terminal
differentiation.
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One interesting question raised by the MRF knockout studies was whether the
divergent phenotypes observed were a consequence of inherent functional differences
among these four proteins, or were merely a reflection of differences in expression
patterns. For example, it was possible that Myogenin (or MRF4) was unable to rescue
myogenic specification in the MyoD/Myf-5 double knockout simply because its
expression in embryogenesis is delayed relative to Myf-5 (Ott et al., 1991; Sassoon et al.,
1989). To address this possibility genetically, the Myogenin coding region was knocked
in to the Myf-5 locus, and resulting mice were crossed to the MyoD knockout.
Importantly, in this background, expression of Myogenin in the same spatiotemporal
pattern as Myf-5 only partially rescued myogenesis and was not sufficient to prevent
perinatal lethality resulting from compromised muscle formation (Wang and Jaenisch,
1997). This result indicated that Myogenin was not as intrinsically capable as Myf-5 in
the process of specifying or maintaining muscle precursors. Consistent with the idea of
functional divergence, later studies by Tapscott and colleagues in cultured fibroblasts
further revealed that MyoD and Myf-5 were markedly more efficient than Myogenin in
remodeling chromatin and inducing transcription at endogenous muscle promoters
(Gerber et al., 1997). By contrast, the MRFs were equivalent in their ability to activate
transfected reporters driven by E-boxes. These results suggested that the capacity of
MyoD and Myf-5 to function efficiently in myogenic specification might derive from an
ability to activate genes in silent chromatin. Mapping experiments indicated that the
remodeling activity of MyoD could be localized to a histidine/cysteine (H/C)-rich Nterminal domain and a C-terminal alpha-helix (Helix III), conserved in the Myf-5 but not
Myogenin coding sequence (Figure 1.1). Domain swapping confirmed that these motifs
57

within MyoD could render Myogenin capable of efficiently inducing silent endogenous
genes (Bergstrom and Tapscott, 2001). Interestingly, instead of encoding chromatin
remodeling activity, the Myogenin C-terminus was shown to contain a general
transcriptional activation domain, further providing a molecular explanation for the
distinct activity exhibited by this downstream pro-differentiation MRF.
Other work revealed the upstream signals responsible for initiating MRF
expression within the developing somite. Explant studies showed that the inducing
activities of axial structures such as the floor plate and dorsal neural tube could be
mimicked by the signaling molecules sonic hedgehog and Wnt1, 3, 4, respectively
(Munsterberg et al., 1995). Wnts and Shh were further shown to act upstream of two
paired-box family transcription factors, Pax3 and Pax7. Forced retroviral expression of
Pax3 in chick somite explants was capable of activating expression of Myf-5 and MyoD
in the absence of axial tissues (Maroto et al., 1997). Conversely, mice homozygous null
for both Pax3 and Myf-5 lacked body muscles and MyoD expression, suggesting that
Pax3 and Myf-5 lie genetically upstream of MyoD activation; consistently, Myf-5 RNA
is induced approximately two days prior to MyoD during development (Tajbakhsh et al.,
1997). Interestingly, Pax3 single knockout animals lacked limb muscles (Bober et al.,
1994; Goulding et al., 1994), likely a consequence of impaired induction of c-met, a
receptor critical for the proper migration of muscle precursors from the somite to the limb
bud (Epstein et al., 1996; Yang et al., 1996). Within the somite, the domain of Pax3
activity is further restricted to the dorsal medial lip (DML) of the dermomyotome by
signaling through bone morphogenic proteins (BMPs). Specifically, BMPs inhibit
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MyoD/Myf5 activation in Pax3+ cells, except in the DML, where the BMP antagonist
noggin relieves this repression and allows for MRF expression (Reshef et al., 1998).

Post-natal myogenesis: satellite cells
Skeletal muscle has long been known to possess the ability to regenerate in
response to injury (Carlson, 1973). This regenerative capacity has been ascribed to the
presence of a normally quiescent population of mononuclear cells known as satellite cells
(SCs), situated between the basal lamina and the muscle fiber membrane (Mauro, 1961).
In response to tissue damage, SCs exit quiescence, become activated, proliferate, and
either differentiate and fuse to form new myofibers or return to their ground state and
repopulate the SC niche (Figure 1.3). A number of independent studies provided support
for the notion that satellite cells possess the hallmark properties of stem cells—the ability
to self-renew and differentiate to maintain tissue homeostasis (Collins et al., 2005;
Montarras et al., 2005; Sacco et al., 2008). An emerging theme from this work is that
despite the original definition of a satellite cell based on anatomic location, all satellite
cells are not equivalent, and only a subset may exhibit true stem-cell properties.
Various markers have been used to identify satellite cells prospectively, but one
of the first and most commonly employed is the transcription factor Pax7. Initial studies
demonstrated that mice homozygous null for Pax7 exhibit grossly normal muscle, but
completely lack satellite cells, fail to thrive, and die after two weeks (Seale et al., 2000).
The defect was originally postulated to be at the level of SC specification, but later work
argued instead that Pax7 is required for SC maintenance and survival, potentially acting
to inhibit SC apoptosis (Oustanina et al., 2004; Relaix et al., 2006). It now appears that
79

Differentiation
INJURY

Quiescence

Activation

Proliferation

Quiescence
Figure 1.3. Satellite cell-mediated muscle regeneration. Upon injury, satellite cells
exit quiescence, become activated, proliferate, and either differentiate and fuse to
form multinucleated myotubes or return to quiescence.
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Pax7 is necessary for satellite cell survival and function only during the first few weeks
of postnatal life, when SCs are still making the transition to their ultimate state of
quiescence (Lepper et al., 2009). Recent studies have established that satellite cells and
embryonic muscle progenitors share a common embryological origin, a proliferating pool
of Pax3+/Pax7+ cells that arise within the central dermomyotome of the somite (Gros et
al., 2005; Kassar-Duchossoy et al., 2005; Relaix et al., 2005). Pax7 appears to be
uniformly retained in SCs after birth, whereas Pax3 expression is only detected in subsets
of SCs in certain muscles, and apparently cannot compensate for Pax7’s functions in SCs
maintenance (Relaix et al., 2006).
While satellite cells have long been considered a resident stem cell pool and the
primary source of muscle regenerative potential, conclusive evidence for this notion was
obtained only in the last five years. Multiple groups have prospectively isolated satellite
cells from mice and demonstrated their ability to engraft into the endogenous SC
compartment of injured mice and contribute to repair (Cerletti et al., 2008; Montarras et
al., 2005). Single myofibers with their associated satellite cells have also been
transplanted into injured muscles, and SC contributions to regeneration have been
verified (Collins et al., 2005). In such studies, donor SCs are often isolated from
transgenic animals such that they are marked, for example with GFP, and can easily be
tracked in vivo upon engraftment into host animals. Importantly, such work has shown
that engrafted satellite cells not only contribute to formation of regenerating muscle, but
also reseed the SC niche and can participate in multiple rounds of repair after repeated
injury (Cerletti et al., 2008; Collins et al., 2005; Sacco et al., 2008). These findings argue
strongly that SCs exhibit self-renewal and the ability to maintain an adult tissue.
811

Interestingly, other cellular reservoirs—bone marrow-derived cells, “side population”
muscle cells, and CD45+Sca1+ resident myogenic cells—have also been proposed to
contribute to the muscle repair process (Ferrari et al., 1998; Gussoni et al., 1999;
Polesskaya et al., 2003); these populations, however, do not exhibit the equivalent
properties of satellite cells and are now believed to play only a negligible role in
regeneration (Sherwood et al., 2004).
Studies on cultured myofibers and associated satellite cells in vitro in combination
with in vivo injury experiments have helped define the sequence of molecular events
accompanying SC activation. In the quiescent state, SCs are Pax7+ but devoid of MRF
expression; upon activation, they first upregulate MyoD and/or Myf-5 (Cooper et al.,
1999; Cornelison and Wold, 1997). While most of these cells continue to proliferate,
downregulate Pax7, and ultimately express Myogenin/MRF4 upon entry into the
differentiation pathway, some retain Pax7 and lose MRF expression (Cornelison and
Wold, 1997; Zammit et al., 2004; Zammit et al., 2006). It is these Pax7+/MRF− cells that
exit the cell cycle and return to a state of quiescence to replenish the stem cell niche.
Interestingly, as in the embryo, MyoD/Myf-5 and Myogenin/MRF4 appear to play
divergent roles, with the first two proteins apparently functioning in the
activation/specification phase of satellite cell-mediated regeneration, and the latter two
factors operating downstream in promoting differentiation. In contrast to the largely
redundant functions of MyoD and Myf-5 during embryogenesis, however, MyoD was
found to play a unique role in postnatal regeneration, as the MyoD knockout mouse
displayed a significantly impaired response to muscle injury (Megeney et al., 1996). In
the absence of MyoD, there appeared to be a defect in the proliferative expansion of
912

activated, committed satellite cells, suggesting that MyoD is required for SCs to enter the
proliferative phase and progress down the lineage pathway.
A recent study provided compelling evidence that satellite cells as defined
anatomically are a heterogeneous population, only a small fraction of which may exhibit
true stem-cell potential (Kuang et al., 2007). By crossing the ROSA26-YFP mouse to a
Myf-5-Cre line, Rudnicki and colleagues were able to permanently mark cells that at any
point in their history expressed Myf-5. Strikingly, they found that ~10% of sublaminar
Pax7+ SCs were YFP−. It was later demonstrated in single fiber cultures that YFP− SCs
divide asymmetrically to generate a YFP+ daughter cell in apposition to the muscle fiber
membrane, and a YFP− daughter adjacent to the basal lamina. Upon transplantation,
purified YFP− SCs expanded rapidly and contributed both to myofiber differentiation and
to the endogenous SC niche, while YFP+ SCs failed to expand or reseed the niche. These
results imply that satellite cells comprise at least two populations, one of which never
expresses Myf-5, remains in continuous contact with the basal lamina during cell
division, and likely represents the pool of muscle stem cells. Interestingly, follow-up
studies in the past year have revealed that non-canonical Wnt signaling, initiated by
Wnt7a, appears to stimulate the symmetric expansion of satellite stem cells (YFP−) and
thereby enhance the regenerative process (Le Grand et al., 2009).

The myogenic transcriptional program
Cell culture-based models of myogenesis have greatly facilitated the investigation
of how MRFs initiate and drive forward a transcriptional differentiation program on a
molecular level. Myogenic transcription proceeds in a strict temporal sequence from early
13
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to late gene expression (Andres and Walsh, 1996; Bergstrom et al., 2002). This cascade is
highly regulated by positively acting feedback loops and finely tuned by a variety of
signaling pathways that ultimately target individual transcription factors and/or bring
about key chromatin alterations.
Much work has been directed at elucidating the transcriptional control of the
Myogenin locus, as this gene plays an essential role in inducing differentiation, and its
regulation has illustrated important general concepts about myogenic transcription. In the
early 1990s, studies in transgenic reporter mice revealed that a 133-bp proximal promoter
was sufficient to recapitulate the normal temporal and spatial pattern of Myogenin
expression in the developing embryo (Yee and Rigby, 1993). Two DNA binding
elements, an E-box (E1) and Mef2 element, were found to be essential for the induction
of Myogenin transcription (Cheng et al., 1993), while a third element, Mef3, was later
shown also to be necessary (Spitz et al., 1998) (Figure 1.4). The presence of a paired Ebox and Mef2 element is a common motif present within many myogenic promoters and
facilitates cooperation between the MRFs and the Mef2 family of transcription factors. In
mammals, there are four Mef2 factors (Mef2A, B, C, and D), all of which share a
common MADS box and MEF2 domain which allow for DNA binding and dimerization
(Black and Olson, 1998). MRFs and Mef2 factors physically interact and can synergize
with one another (Molkentin et al., 1995). Importantly, Mef2C is itself a direct
transcriptional target of MyoD (Dodou et al., 2003; Wang et al., 2001). Once expressed,
Mef2C collaborates with MyoD in the activation of the Myogenin promoter (Figure 1.5)
(Edmondson et al., 1992), setting up what has been proposed as a “feed forward” model
underlying the myogenic program (Tapscott, 2005). This concept of MyoD collaborating
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Figure 1.4. Myogenin proximal 133-bp promoter. DNA binding sites are shown
for muscle regulatory factors (E-box E1), Mef2, Six1,4 (Mef3), and Pbx/Meis.
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Figure 1.5. Myogenic transcriptional circuitry. The Myogenin and Mef2C
promoters both contain E-box and Mef2 DNA binding elements. MyoD directly
induces the expression of Mef2C, and the two factors cooperatively induce
Myogenin. Positive feedback occurs as shown.
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with downstream mediators to drive forward sequential gene expression represents a
recurrent theme in myogenic transcription. To add another layer of control, Myogenin
also feeds back to enhance expression of Mef2C, and MRFs themselves have been shown
capable of inducing their own transcription (Ridgeway et al., 2000; Thayer et al., 1989).
The net result is that initial, small expression changes become amplified and selfreinforced and enable a robust transcriptional output. In addition to the synergistic
regulation conferred by MRFs and Mef2, members of the Six family of homeodomain
proteins (Six1, Six4) have also been implicated in the control of Myogenin transcription
(Spitz et al., 1998). Six factors associate with the essential Mef3 DNA binding element
located distal to the Mef2 site and are thought to participate in cooperative induction.

Regulation of MyoD
A long-studied and still-relevant challenge in the field of myogenesis has been to
unravel the multiple modes of regulation that control MyoD transcriptional activity. In
cultured myoblasts, MyoD is expressed, yet the induction of Myogenin and downstream
targets does not occur until differentiation is triggered either by removing serum or by
allowing cells to reach confluence, both of which initiate cell cycle exit. This implies that
the proliferative state of myoblasts may exert negative control over MyoD-mediated
transcription. Consistent with this idea, forced expression of cyclin D1 inhibits MyoD
activity and correlates with MyoD phosphorylation, although the functional significance
of this phosphorylation has yet to be clearly established (Skapek et al., 1995). A basic but
controversial question has been whether MyoD in myoblasts is regulated at the level of
DNA binding to its target gene promoters. Some reports employing chromatin
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immunoprecipitation (chIP) assays have shown that MyoD does indeed occupy the
Myogenin promoter in myoblasts, but may be kept inactive by its association with
repressive chromatin modifying enzymes such as histone deacetylases (HDACs) or
histone methyltransferases (HMTs) (Mal and Harter, 2003; Mal et al., 2001; Mal, 2006).
Additional work has built on this model by suggesting that upon cell cycle exit, the
hypophosphorylated form of the tumor suppressor protein Rb may titrate HDAC1 away
from MyoD to help alleviate repression (Puri et al., 2001). It has not been demonstrated,
however, that inhibition of HDACs or HMTs results in significant derepression of
myogenic targets in myoblasts, implying that additional regulatory mechanisms are at
play (Mal, 2006). Other studies failed even to detect appreciable MyoD recruitment to
target promoters under proliferative conditions (Caretti et al., 2004; Serra et al., 2007)
One early finding that supported an alternative model of restricted MyoD DNA
binding in myoblasts was the identification of Id proteins. Ids, expressed in growth
conditions and downregulated upon differentiation, are helix-loop-helix factors which
lack a basic domain and can sequester MyoD and E-proteins into inactive heterodimers
(Benezra et al., 1990; Jen et al., 1992). More recent studies have pointed to a role for
chromatin structure in controlling MyoD’s access to DNA. Multiple reports have
demonstrated that myogenic promoters undergo chromatin changes at the level of both
histone acetylation and nucleosome remodeling over the course of gene activation.
Enzymes involved in both processes, such as p300 and PCAF for acetylation, and the
SWI/SNF factors BRG1 and BRM for remodeling, are required for transcriptional
induction (de la Serna et al., 2001; Puri et al., 1997). Importantly, Tapscott and
colleagues showed that hyperacetylation of histone H4 and recruitment of BRG1 to
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myogenic loci appeared to precede the detectable binding of MyoD (by chIP) at these
promoters (de la Serna et al., 2005). The implication was that MyoD could only access
DNA after such chromatin alterations had already occurred. Additional studies helped
formulate an interesting model consistent with the “feed-forward” paradigm in
myogenesis, in which MyoD itself helps bring about the chromatin transition required for
its own (stable) recruitment. Specifically, it was proposed that MyoD gains access to the
Myogenin promoter in two stages, first weakly through association with DNA-bound
protein intermediates, and then later directly via E-box DNA occupancy (Berkes et al.,
2004). MyoD/E47 was found to physically interact with the homeodomain proteins
Pbx1/Meis, constitutively bound factors just upstream of the Mef3 element (Figure 1.4).
This interaction requires the same domains within MyoD that are essential for its ability
to activate genes within silent chromatin in fibroblasts, suggesting that Pbx1/Meis could
serve as a “molecular beacon” for initial MyoD recruitment. Under this model, declining
Id protein levels would lead to increased MyoD/E47 association with Pbx1/Meis. Since
past work had demonstrated that MyoD physically interacts with acetyltransferases and
BRG1 (Puri et al., 1997; Sartorelli et al., 1997; Simone et al., 2004), recruitment of these
enzymes would likely accompany association of MyoD and ultimately result in
alterations necessary for its stable binding to the E-box (detectable by chIP).
Chromatin structure likely also plays an important role in determining why MyoD
activates subsets of target genes in different temporal windows following the initiation of
myogenesis. A plausible model posits that target promoters induced at later times may
require more extensive chromatin alterations prior to activation, and/or the activities of
additional MyoD cofactors. The work of Sartorelli and coworkers, for example, has
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demonstrated that in myoblasts, the Polycomb methyltransferase Ezh2 deposits the
repressive histone H3-K27-methyl mark specifically on the promoters of late-phase
genes, such as myosin heavy chain (MHC) and muscle creatine kinase (MCK) (Caretti et
al., 2004). Activation of these late-phase genes presumably requires the activity of a
demethylase enzyme to remove this modification and facilitate gene induction. In other
work, Tapscott and colleagues have shown that MyoD recruitment to target gene
promoters generally tracks with the timing of gene expression, supporting the notion that
MyoD DNA binding is rate-limiting (Bergstrom et al., 2002). These studies have
suggested that induction of late-phase genes may require the concerted actions of Mef2D
and the mitogen-activated protein kinase (MAPK) p38, a molecule that promotes
myogenesis through multiple mechanisms, including chromatin remodeling (Penn et al.,
2004). Given that Mef2D expression and p38 activity increase over the course of
differentiation, these results again point to a model in which MyoD works in tandem with
downstream partners to orchestrate a cascade of myogenic gene transcription.

Signaling inputs to the myogenic program
A wide range of signaling cascades has been implicated in the control of
embryonic and post-natal myogenesis. Signaling downstream of the MAPK p38 is one of
the best characterized. p38 is essential for myogenesis in the embryo and for effective
satellite cell function in the adult (de Angelis et al., 2005; Jones et al., 2005). This kinase
can be thought of as a master potentiator of myogenesis that positively influences the
transcriptional apparatus on multiple, complementary levels. While phospho-p38 (the
activated form) has been known for some time to increase over the course of myogenesis,
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the mechanism by which this MAPK becomes activated was only recently explored.
Work by Krauss and colleagues revealed that the myogenic transmembrane protein CDO,
a member of the immunoglobulin superfamily, plays a critical role in p38 activation via
the scaffold proteins JLP and Bnip-2, and the Abl tyrosine kinase (Bae et al., 2009; Kang
et al., 2008). Initial studies had demonstrated that CDO promotes myogenesis in vitro by
enhancing MRF:E protein heterodimer formation via the hyperphosphorylation of E
proteins (Cole et al., 2004). Interestingly, CDO was shown to be a target of MyoD,
adding yet another layer of positive feedback. Subsequent studies showed that p38 itself
was responsible for phosphorylating E47 on serine 140 (Lluis et al., 2005). p38 also
directly phosphorylates Mef2A and Mef2C and thereby promotes their transcriptional
activity (Wu et al., 2000b). Another important and surprising role for p38 was revealed in
its ability to associate with myogenic promoters and help recruit the SWI/SNF chromatin
remodeling complex (Simone et al., 2004). Finally, separate work has demonstrated that
p38 may also function post-transcriptionally by phosphorylating and inactivating the
protein KSRP, which binds to selected myogenic transcripts and directs them to
exosome-mediated degradation (Briata et al., 2005).
A second signaling cascade of particular importance in muscle is that initiated by
the insulin-like growth factors (IGF1/IGF2). IGFs act through multiple pathways to
promote myoblast proliferation, differentiation, and hypertrophy and have been
implicated in both muscle development and regeneration (Barton-Davis et al., 1998; Liu
et al., 1993; Musaro et al., 2001). The use of pharmacological inhibitors on cultured
myoblasts suggested early on that signaling downstream of IGF1 diverges into at least
two arms, one of which works through ERK to maintain proliferation, and one of which
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acts via PI3K to induce differentiation (Coolican et al., 1997). ERK activity was
postulated to be a transient response that declines to allow for cell cycle exit. Signaling
downstream of PI3K serves to enhance the transcriptional activities of both MRFs and
Mef2 proteins. A recent study has provided evidence that an important target of PI3K,
acting via the downstream kinases Akt1 and Akt2, is the coactivator and histone
acetyltransferase p300 (Serra et al., 2007). Akt was shown to directly phosphorylate
p300, resulting in enhanced physical interaction with MyoD. Past work had demonstrated
that p300 facilitates the formation of a trimeric complex with MyoD and the
acetyltransferase PCAF, which directly acetylates MyoD to augment its DNA binding
(Puri et al., 1997; Sartorelli et al., 1999). PI3K also appears to positively affect Mef2 via
phosphorylation, although the actual kinase responsible has not been identified and does
not appear to be Akt (Tamir and Bengal, 2000; Xu and Wu, 2000). Interestingly, IGF’s
hypertrophic effects derive in part from its ability to counteract catabolic pathways via
the phosphorylation and inactivation of Foxo transcription factors, known activators of
atrophy-promoting E3 ligases (Sandri et al., 2004; Stitt et al., 2004).
While p38 and IGF are both pro-myogenic, they appear to act through
independent pathways. Inhibition of PI3K does not affect the normal increase in
phospho-p38 that accompanies differentiation, and inhibition of p38 does not influence
Akt phosphorylation (Tamir and Bengal, 2000; Wu et al., 2000b). Nevertheless, recent
evidence suggests that these signals may ultimately converge or integrate on the
chromatin of myogenic target genes. Past work had demonstrated that p38 inhibition
blocked chromatin remodeling at these promoters, apparently a consequence of impaired
SWI/SNF recruitment (Simone et al., 2004). But interestingly, it has now been shown
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that PI3K inhibition also results in compromised chromatin remodeling, despite normal
recruitment of SWI/SNF (Serra et al., 2007). This finding suggests that PI3K activity,
perhaps due to its requirement for histone acetylation via p300, appears essential for
enabling the DNA-associated SWI/SNF enzyme to carry out its biological functions.

Part 2: The Notch signaling pathway
Notch: The core pathway
The Notch signaling cascade has emerged as another critical regulator of in vivo
muscle development and regeneration. Notch derives its name from the phenotype of a
mutant fly with notched wings, identified in the early 1900s by T. H. Morgan (Mohr,
1919). Only decades later, in 1985, was the Notch locus cloned and characterized in
Drosophila by Artavanis-Tsakonas and colleagues and shown to encode a single-pass
transmembrane protein (Wharton et al., 1985). Two additional membrane-bound proteins,
Delta and Serrate, were cloned shortly thereafter (Fleming et al., 1990; Vassin et al.,
1987) and found to physically interact with the Notch protein (Fehon et al., 1990; Rebay
et al., 1991). It was quickly appreciated that Notch functions as a cell-surface receptor
and mediates cell-cell communication by engaging with its ligands (Delta, Serrate) on
neighboring cells to initiate an intracellular signaling cascade.
In mammals, there are four Notch receptors (Notch1-4) and five Notch ligands
(Jagged1,2 and Delta-like-1,3,4). Notch exists as a heterodimer on the cell membrane, a
result of a cleavage event (S1) mediated by a furin-like protease in the Golgi apparatus
(Figure 1.6) (Blaumueller et al., 1997; Logeat et al., 1998). Structurally, the extracellular
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Figure 1.6. Proteolytic cleavages of the Notch receptor. S1 cleavage is mediated
by a furin-like protease in the Golgi apparatus to generate the Notch
heterodimer. S2 cleavage by ADAM family metalloproteases occurs after
engagement of receptor by ligand. S3 cleavage by the γ-secretase complex
liberates the Notch intracellular domain (NICD). LNR, Lin12-Notch repeats;
HD, heterodimerization domain. Adapted from Gordon et al. (2007).
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portion of the receptor is characterized by a series of Epidermal Growth Factor (EGF)like repeats and three Lin12-Notch repeats (LNR), followed by the heterodimerization
(HD) domain. The Notch intracellular domain (NICD) contains two protein-protein
interaction motifs (RAM” and ankyrin repeats), a nuclear localization signal, a
transcriptional activation domain (in Notch1,2), and PEST motif.
One of the early challenges in the Notch field was to define the mechanism by
which ligand-receptor engagement resulted in signal activation within the receptorexpressing cell. It soon became apparent that proteolysis of the receptor itself was an
essential aspect of signaling, resulting in the liberation of NICD and its subsequent
translocation to the nucleus (Figures 1.6 & 1.7). Early studies that addressed how such
proteolysis occurred were facilitated by the use of a truncated form of Notch lacking the
extracellular domain, NotchΔΕ, which for reasons unknown at the time exhibited
signaling activity in the absence of ligand stimulation. By transfecting cells with a doubly
tagged NotchΔΕ construct, in which an HA epitope was fused to the N-terminus, and a
Myc epitope was fused at the C-terminus, Kopan and colleagues demonstrated that HA
reactivity was detectable on the cell surface, while Myc reactivity was localized to the
nucleus (Kopan et al., 1996). Struhl and coworkers obtained evidence of NICD liberation
and translocation via a different approach, showing that a Notch-Gal4-VP16 fusion
construct elicited transcriptional activation only if Gal4-VP16 was placed in the
intracellular domain of the receptor (Struhl and Adachi, 1998). Subsequent work used
protein microsequencing on receptor fragments to ascertain that a cleavage event
occurred at Valine 1744, which lies within the transmembrane domain. Strikingly,
mutation of this specific residue of the truncated receptor compromised signaling activity
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Figure 1.7. The Notch signaling pathway. Engagement of receptor by ligand (1)
results in two proteolytic cleavages that liberate the Notch intracellular domain
(NICD) and allow for its nuclear translocation (2). In the off state, Notch target
genes are bound by the transcription factor CSL, complexed with corepressors.
Upon association of NICD with CSL, corepressors are replaced by coactivators,
and gene activation occurs (3). Adapted from Kadesch (2004).
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as evaluated by a Notch-responsive reporter construct (Schroeter et al., 1998). More
significantly, knock-in mice carrying this single mutation in the endogenous Notch1
locus exhibited comparable phenotypes as Notch1 knockout animals (Huppert et al.,
2000). While this result initially suggested that cleavage at Valine 1744 was essential for
NICD generation, later work revealed that S3 proteolysis can also occur at Leucines
1745-1746 and Serine 1747 (Tagami et al., 2008). The NICD molecules generated from
these alternative cleavages, however, are far less stable than NICD-Valine 1744 and
apparently cannot compensate for its absence in vivo. Genetic data from both Drosophila
and mouse identified presinilin, a component of the γ-secretase complex, as the protease
required for S3 proteolysis (De Strooper et al., 1999; Struhl and Greenwald, 1999).
While these studies explained the mechanics of NICD processing, it remained
unclear why a truncated Notch receptor allowed for constitutive NICD generation, while
the full-length receptor required ligand engagement for activation. Kopan and Israel
provided an explanation by discovering an additional cleavage event, S2, that occurs
within the extracellular juxtamembrane domain of Notch (Figure 1.6) (Brou et al., 2000;
Mumm et al., 2000). Normally inhibited by the presence of the extracellular domain, S2
cleavage only proceeds after a presumed conformational change following ligandreceptor engagement (Gordon et al., 2007). Separate work has established that a critical
event in Notch activation is the endocytosis of the Notch ligand (Delta) and transendocytosis of the receptor extracellular domain into the signal-sending cell (Itoh et al.,
2003; Koo et al., 2005; Parks et al., 2000). It has been speculated that the mechanical
force generated by these endocytotic movements may in fact drive the conformational
transition that allows for S2 cleavage. Mediated by ADAM-family metalloproteases
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(Brou et al., 2000), this processing step precedes and is required for the presinilinmediated cleavage (S3). Truncation of the receptor alleviates auto-inhibitory control over
S2 cleavage, allowing for constitutive production of NICD. Interestingly, treatment of
Notch-expressing cultured cells with the calcium chelator EDTA also results in
unregulated S2 cleavage and NICD processing. It appears that stability of the Notch
heterodimer on the membrane depends on calcium, and its depletion results in
dissociation of the extracellular portion of the receptor (Rand et al., 2000).
Genetic studies from fly combined with biochemical assays in cultured cells
helped define the molecular events that occur downstream of Notch proteolysis (Figure
1.7) (Fortini and Artavanis-Tsakonas, 1994; Jarriault et al., 1995). Once translocated to
the nucleus, NICD associates with the transcription factor CSL (CBF1, Suppressor of
Hairless, Lag-1), which typically is constitutively bound to the promoters of Notchresponsive genes. In the absence of ligand stimulation, CSL associates with corepressors.
In mammals, these include N-CoR, SMRT, SHARP, and CtIP/CtBP (Kao et al., 1998;
Oswald et al., 2002; Oswald et al., 2005), while in flies, the adaptor protein Hairless
allows for indirect association with Groucho and CtBP (Barolo et al., 2002). It is thought
that CSL-dependent recruitment of these corepressors may play a role in silencing the
expression of Notch target genes in the absence of signaling activity. Binding of NICD
results in the displacement of these corepressors and the recruitment of coactivators such
as Mastermind-like (MAML) and p300 (Oswald et al., 2001; Wu et al., 2000a). Crystal
structures of the CSL-NICD-MAML ternary complex revealed that association of the
NICD RAM domain with CSL may result in a conformational change important for
corepressor displacement, while binding of the NICD Ankyrin repeats to the CSL C28
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terminus creates a novel interface for MAML recruitment (Nam et al., 2006; Wilson and
Kovall, 2006). Interestingly, recent work from Drosophila has added a new twist to the
conventional view of Notch activation. Studies by Bray and colleagues in cultured insect
cell lines have demonstrated that at least at a subset of Notch-responsive promoters, CSL
DNA binding increases significantly but transiently following EDTA-mediated signal
initiation (Krejci and Bray, 2007). While not yet confirmed in vertebrate or ligand-based
systems, these results suggest the possibility that NICD may play a role in facilitating
CSL recruitment to DNA at specific target promoters.
While much attention has focused on the mechanisms of Notch activation, an
equally important question relates to how activity is terminated to ensure proper temporal
control of signaling. The work of Jones and coworkers has contributed important insights
into this problem by proposing a model in which activation and termination are
intimately linked through regulation of NICD protein stability. An intriguing initial
observation was that in cells transfected with NICD, CSL, and MAML, less NICD
protein was detectable as compared to that seen in cells transfected with NICD and CSL
alone (Fryer et al., 2002). Mutation of the NICD PEST domain, a motif known to
regulate protein stability, eliminated this effect, as did truncation of the MAML Cterminus. The implication was that MAML, a factor primarily thought of as a
transcriptional coactivator, might also contribute to NICD turnover. Indeed, further
studies revealed that MAML appears to recruit a specific kinase (CDK8) that
phosphorylates the NICD PEST domain and marks it for subsequent ubiquitin-mediated
proteasomal degradation (Fryer et al., 2004). These findings suggested a general
mechanism also observed in yeast whereby inducible activators such as NICD may
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participate in mediating their own destruction to finely limit the temporal widow of their
transcriptional activity.

In vivo functions of Notch
Since the cloning of the Notch receptor almost twenty-five years ago, Notch
signaling has been shown to play vital roles in the control of cell fate determination in
animals ranging from worms to mammals (Artavanis-Tsakonas et al., 1999). One of the
first described and most iconic roles for Notch was in mediating a process called “lateral
inhibition” in Drosophila (Cabrera, 1990; Chitnis, 1995; Heitzler and Simpson, 1991). In
the developing central nervous system of the fly, an initially equivalent group of cells
known as a proneural cluster ultimately gives rise to a single neuroblast surrounded by
cells of the epidermal lineage. Loss of function mutations in a group of “neurogenic
genes”, which includes Notch, disrupt this specification process and result in a phenotype
of neural hypertrophy. Cells normally fated to the epidermal lineage instead convert to
neuroblasts. The implication was that Notch signaling normally inhibits the adoption of
the neural fate in the cluster of cells surrounding the single neurally-fated cell. A model
of “lateral inhibition” was proposed, in which the single cell destined to become a
neuroblast comes to express high levels of Notch ligands but low levels of receptor,
rendering it capable of sending but not receiving a Notch signal. Conversely, its
neighboring cells acquire the opposite expression profile and exhibit the ability to receive
the signal but not initiate it. These expression disparities arise due to the amplification of
very small initial differences in the original proneural cluster, resulting from
transcriptional feedback effects of signaling on the expression of the receptor and ligands
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themselves. Cells experiencing slightly higher initial signaling activity relative to a
neighbor, for example, tend to downregulate expression of Notch ligands and upregulate
the receptor, while cells with lower initial activity do the opposite. The net result is the
eventual clustering of many signal-receiving cells around a single signal-sending cell.
In mammals, Notch signaling regulates the development of a vast array of cell
lineages. Genetic knockouts of core Notch pathway components in the 1990s revealed
that Notch plays critical early roles in somitogenesis and vascular remodeling during
mouse embryonic development (Conlon et al., 1995; Hrabe de Angelis et al., 1997; Xue
et al., 1999). Given that animals homozygous null for several of the individual Notch
ligands or receptors exhibit early embryonic lethality, conditional deletion approaches
have been employed to probe tissue-specific functions of the pathway at later
developmental stages. In the immune system, such work demonstrated a genetic
requirement for Notch signaling in the specification of T lymphocytes and the generation
of Th2 helper T cells (Amsen et al., 2007; Radtke et al., 1999). The pathway’s effects on
lymphocyte development were also revealed by a gain-of function approach in the case of
T-cell commitment (Pui et al., 1999), or via the use of a lineage-specific dominant
negative MAML transgenic mouse in the case of Th2 differentiation (Fang et al., 2007).
In the skin, deletion of Notch1 results in epidermal hyperplasia, impaired differentiation,
and the development of basal-cell carcinoma-like tumors, suggesting tumor suppressor
functions (Nicolas et al., 2003; Rangarajan et al., 2001). By contrast, in the nervous
system, conditional Notch1 ablation results in premature differentiation of neuroepithelial
cells followed by their apoptotic elimination (Lutolf et al., 2002). These studies have
highlighted the pathway’s functional versatility in different tissues. While in some
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contexts, Notch primarily acts to inhibit cellular differentiation of one cell type and
perhaps allow for progression down an alternative pathway, in others it actively helps
specify or promote the differentiation of a particular lineage. A central challenge has been
to understand the molecular circuitry downstream of Notch activation that underlies these
diverse biological effects.

Transcriptional effectors of Notch: Enhancer of split/Hes genes
Early genetic studies in Drosophila first illustrated the concept that Notch often
controls cell fate decisions through the initiation of a transcriptional cascade, in which
primary effectors themselves function as transcriptional repressors that target lineagedetermination genes. The inhibitory effects of Notch on the neural fate in the fly were
shown to result from the transcriptional induction of a series of basic helix-loop-helix
repressor proteins of the Enhancer of Split (E(spl)) locus (Bailey and Posakony, 1995;
Jennings et al., 1994; Lecourtois and Schweisguth, 1995). These factors are present in the
ectodermal cells surrounding neuroblasts. E(spl) expression is eliminated by loss-offunction mutations in either Notch or Suppressor of Hairless (CSL), while it is expanded
under conditions of ectopic Notch activation. The promoters of E(spl) genes contain CSL
binding sites which are required for induction (Bailey and Posakony, 1995; Lecourtois
and Schweisguth, 1995). Importantly, loss-of-function mutations in genes of the E(spl)
locus recapitulate the Notch neural hypertrophy phenotype, with the severity of the
hypertrophy dependent upon how many of the genes are mutated (Jennings et al., 1994).
Together, these results provided strong evidence that Notch signals through inhibitory
E(spl) proteins to restrict neural fate determination.
32
25

Further studies suggested that the E(spl) factors and a closely related bHLH
protein, hairy, primarily function by repressing the expression of achaete (ac), a proneural
bHLH transcription factor. Hairy and E(spl) proteins associate with the Groucho
corepressor via a C-terminal WRPW motif and are thought to repress ac transcription via
direct DNA binding to an E-box within its promoter (Ohsako et al., 1994; Paroush et al.,
1994; Van Doren et al., 1994). This work was quickly extended to vertebrate systems,
where a family of several Hairy and Enhancer of Split (Hes) homologues was identified
(Sasai et al., 1992). In mammals, the bHLH repressors Hes1, Hes5, and Hes7 are all
direct canonical targets of Notch (Figure 1.8) (Bessho et al., 2001; Jarriault et al., 1995;
Nishimura et al., 1998). The role of E(spl) proteins in repressing neurogenesis appears to
be conserved across species, as the Hes1 knockout mouse exhibits elevated levels of
proneural bHLH proteins such as MASH1 (the ac orthologue) and accelerated
neurogenesis before perinatal death (Ishibashi et al., 1995). Conversely, retroviral
overexpression of Hes1 blocks neural differentiation in vitro and in vivo (Ishibashi et al.,
1994). Hes5 partially compensates for Hes1 function in repressing the neural fate, as the
Hes1/Hes5 double knockout neural phenotype was more severe than the Hes1 single
knockout. Furthermore, forced activation of Notch blocked the differentiation of single
knockout, but not double knockout, neural precursors in culture (Ohtsuka et al., 1999).

Transcriptional effectors of Notch: Hey genes
While Hes proteins appear to account for Notch’s primary phenotypic effects in
the nervous system, these factors by no means represent the full range of Notch
transcriptional output. The Hey/Hesr/HERP/CHF family of bHLH repressors (Hey1,
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Figure 1.8. Canonical Notch target genes. Hes and Hey transcriptional
repressors share a conserved basic helix-loop-helix (bHLH) motif that mediates
DNA binding and dimerization, and an Orange domain implicated in proteinprotein interactions. Hes proteins contain a C-terminal WRPW tetrapeptide that
facilitates recruitment of Groucho/TLE corepressors. Adapted from Iso et al.
(2003).
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Hey2, HeyL) is another closely related group of transcription factors that are directly
activated by Notch in a CSL-dependent fashion (Iso et al., 2002; Iso et al., 2001a; Maier
and Gessler, 2000). Hey proteins, like Hes factors, dimerize with one another (and other
bHLH proteins) via their HLH motif and bind to E-box or N-box elements within DNA
via their basic domain (Figure 1.8) (Fischer et al., 2002; Iso et al., 2001b; Pichon et al.,
2004). Hes and Hey proteins also share a conserved Orange domain downstream of the
bHLH motif, which is thought to mediate protein interactions and potentially serve as an
extended dimerization interface (Taelman et al., 2004). In contrast to Hes family
members, Hey factors lack the C-terminal WRPW interaction motif and associate with
the corepressors mSin3A, N-CoR, and HDAC1 by way of their basic domain (Iso et al.,
2001b).
Gene knockout studies have shown that Hey factors play critical early roles in the
developing heart and vasculature and likely represent the prime Notch effectors in these
tissues (Fischer et al., 2004; Fischer et al., 2007; Gessler et al., 2002). As with Hes1 and
Hes5 in the nervous system, functional redundancy exists among Hey proteins, as single
knockout animals are either normal or display less severe phenotypes than double
knockouts (Fischer et al., 2004; Fischer et al., 2007). The detailed molecular mechanisms
by which Hey proteins function in specific biological contexts are not well defined.
While Hey family members are capable of binding to DNA in-vitro, several reports have
shown that binding to E-boxes within target promoters either does not occur or is not
required for Hey-directed repression (Fischer et al., 2005; Holderfield et al., 2006; Huang
et al., 2004; Nakagawa et al., 2000). Instead, Hey proteins often may physically associate
with and antagonize the activity of other transcription factors. Hey family members are
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capable of binding to GATA4/6 and inhibiting GATA-driven cardiac gene expression,
which could partially account for important functions in the cardiovascular system
(Fischer et al., 2005). In other contexts, inhibitory physical interactions between Hey
proteins and Runx2 may explain Notch-mediated protection against aortic calcification
(Garg et al., 2005), while associations between Hey factors and Ptf1-p48 may underlie
Notch-directed inhibition of pancreatic exocrine differentiation (Ghosh and Leach, 2006).
Beyond the canonical Hes/Hey target genes, recent studies have revealed that
Notch likely induces the expression of a much broader set of genes in various tissues. For
example, in helper T-cell differentiation, direct induction of the transcription factor Gata3
downstream of Notch is required for the pathway’s ability to promote Th2 specification
(Amsen et al., 2007; Fang et al., 2007). In T-cell leukemia and mammary tumorigenesis,
by contrast, Notch’s oncogenic effects have been linked to the direct induction of c-myc
(Klinakis et al., 2006; Weng et al., 2006). And in skin, Notch-mediated upregulation of
the cell cycle inhibitor p21 is required for the pathway’s growth suppressive effects
(Rangarajan et al., 2001). The Notch-E(spl)-ac axis from Drosophila provides an
appealingly simple illustration of how Notch influences cell fate, but clearly represents
only one of many possible signaling modules employed by the pathway to bring about its
diverse biological effects.

Modulation of the Notch signal
A large number of regulatory controls have evolved to restrict and finely tune
Notch activity and ensure a spatially and temporally appropriate signaling response.
These modulators function at all levels of the pathway, from ligand-receptor engagement,
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to receptor processing, to NICD stability and activity (Kadesch, 2004; Kopan and Ilagan,
2009). Two of the earliest identified modulators were the glycosyltransferase enzyme
Fringe and the cytoplasmic protein Numb. Work in Drosophila originally demonstrated
that Fringe potentiates the response of Notch-expressing cells to the ligand Delta, but
inhibits responsiveness to Serrate (Panin et al., 1997). This effect was only observed if
Fringe was expressed in the cells expressing the Notch receptor. Later studies showed
that Fringe acts in the Golgi as a glycosyltransferase to elongate O-linked fucose residues
on the EGF repeats of Notch (Bruckner et al., 2000; Hicks et al., 2000; Moloney et al.,
2000). This post-translational modification of the receptor is thought to influence the
efficiency with which different ligands can engage receptor and stimulate NICD
proteolytic release. Three orthologues of this enzyme exist in mammals (lunatic fringe,
radical fringe, and manic fringe), all of which exhibit similar glycosyltransferase activity
(Moloney et al., 2000).
Numb was also characterized initially in the fly, where it was shown to be a
membrane-associated protein that segregates asymmetrically into one daughter cell of a
dividing sensory organ precursor in the peripheral nervous system (Rhyu et al., 1994).
Numb+ cells were shown to adopt the neural fate, as would be expected of cells which
turn off the inhibitory Notch pathway. It was later demonstrated that Numb physically
associates with the intracellular domain of membrane-bound Notch and prevents NICD
nuclear translocation (Wakamatsu et al., 1999). Ubiquitin-mediated degradation and
receptor endocytosis have been proposed as potential mechanisms for Numb-dependent
Notch downregulation (Berdnik et al., 2002; McGill and McGlade, 2003). Numb also
functions in Drosophila myogenesis (Baylies et al., 1998). In this lineage, Notch first acts
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via lateral inhibition in the singling out of a myogenic progenitor cell from a cluster of
embryonic mesodermal cells. This progenitor then undergoes asymmetric cell division to
generate two daughters, an adult muscle precursor (Numb−) and a founder myoblast
(Numb+). Adult muscle precursors (AMPs) remain undifferentiated and can be thought of
as the fly analogue of satellite cells. The asymmetric distribution of Numb in the muscle
progenitor daughter cells is consistent with the known inhibitory functions of Notch on
myogenic lineage progression. Furthermore, loss of Numb was shown to result in the
formation of two AMPs and loss of muscle founders, while forced Numb expression led
to the opposite phenotype (Ruiz Gomez and Bate, 1997). In mammals, whether Numb
and its homologue Numb-like always function as antagonists of Notch in vivo has been
more controversial. Knockout mice have yielded conflicting phenotypes in the
developing central nervous system, with reports either of reduced neural differentiation
(expected from increased Notch signaling) or premature neural differentiation (expected
from decreased Notch activity) (Petersen et al., 2002; Zhong et al., 2000; Zilian et al.,
2001).

Part 3: Regulation of skeletal myogenesis by Notch
In vivo roles of Notch in muscle
Recent studies have revealed that the Notch signaling cascade plays critical roles
in the regulation of embryonic and post-natal myogenesis. While it has been known for
over a decade that forced activation of Notch in cultured myoblasts inhibits their
differentiation (Kopan et al., 1994), newer work has demonstrated that this inhibitory
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effect in vitro reflects similar functions during development and regeneration in vivo
(Conboy et al., 2003; Conboy and Rando, 2002; Schuster-Gossler et al., 2007; Vasyutina
et al., 2007). In post-natal myogenesis, Rando and colleagues first made the important
observation that muscle injury results in activation of Notch signaling, as evidenced by
increased levels of cleaved Notch1, and that this increased signaling may reflect
induction of the Notch ligand Delta-like-1 (Dll1) (Conboy and Rando, 2002).
Interestingly, experiments in muscle explants further demonstrated that the Notch
pathway inhibitor Numb was asymmetrically segregated in dividing intermediate
myogenic progenitors. Numb+ daughter cells were found to express lineage progression
markers, such as Myf-5 and Desmin, but not the earlier pre-myoblast marker Pax3, while
Numb− cells exhibited the opposite expression profile. These data suggested that
cessation of Notch activity (Numb+) correlated with progression down the myogenic
pathway, while sustained signaling (Numb−) correlated with a maintenance of the
undifferentiated state. Additional studies showed that artificial activation of Notch via
retrovirally expressed NICD in primary myoblast cultures resulted in enhanced
proliferation, while siRNAs targeting the Notch1 receptor led to compromised
proliferation. Together, these findings suggested that activation of Notch signaling
following muscle injury promoted the expansion of satellite cells or myogenic precursors
and prevented differentiation, while termination of Notch activity allowed for subsequent
progression down the lineage pathway.
While this work revealed obvious parallels between vertebrate and Drosophila
myogenesis with respect to asymmetric Numb segregation, a key limitation was that
Rando and coworkers did not address whether Numb plays an actual causal role in
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shutting off Notch activity and permitting differentiation in vivo. Since Numb knockout
mice die early in gestation (Zhong et al., 2000), obtaining genetic proof of Numb’s
importance in this process would require the generation of a conditional muscle-specific
mutant. While the correlative evidence for Numb is compelling, other mechanisms could
also account for the segregation of Notch activity to one daughter cell of a dividing
satellite cell or progenitor. Indeed, the work of Rudnicki has revealed a potential role for
asymmetric expression of the Notch ligand Dll1 (Kuang et al., 2007). Dll1 was only
marginally detectable in the subset of satellite cells that are thought to exhibit true stem
cell potential (permanently Myf-5 negative), but was highly expressed in neighboring
sister satellite cells that at one point in their history expressed Myf-5. Notch receptors
were expressed in both pools of cells, although Notch3 was enriched in the SC stem cell
population. These findings suggest that elevated levels of Notch signaling in less
committed satellite (stem) cells could result in part from restriction of ligand expression
to neighboring sister cells.
Subsequent Notch gain- and loss-of-function studies in vivo built upon these
initial observations (Conboy et al., 2003). Inhibition of Notch signaling via a soluble
Jagged ligand was shown to impair regeneration following muscle injury, while
conversely, enhanced Notch activation via an antibody specific for Notch1, facilitated the
repair process. Intriguingly, the compromised regenerative ability of muscle from aged
mice was associated with reduced induction of the Notch ligand Dll1, suggesting a
potential defect in pathway activation. Consistent with this notion, forced induction of
Notch signaling improved the repair response in these animals. Remarkably, subsequent
studies in which the circulatory systems of old and young mice were united via parabiosis
40
32

suggested that circulating factors in the blood of young animals could help improve the
ability of aged muscle to induce Dll1 and ultimately mount a regenerative response
(Conboy et al., 2005). This result argued that compromised muscle regeneration in aged
animals may primarily reflect an impaired signaling environment, rather than an intrinsic
defect of the resident stem cell pool. Indeed, later work expanded on this notion and
revealed that aged muscle also exhibits hyperactivation of the Wnt and TGFβ signaling
pathways. Elevated Wnt signaling was postulated to account for increased fibrosis in old
muscle, as Wnt activation biased myogenic progenitors towards adopting a fibrogenic
fate (Brack et al., 2007). Increased levels of TGFβ, by contrast, were proposed to
contribute to the defect in satellite cell proliferation, via Smad3-mediated induction of the
cell cycle inhibitors p15, p16, p21, and p27 (Carlson et al., 2008). Interestingly, recent
work has suggested that Wnt signaling also functions in later phases of a normal
regenerative response to promote myogenic determination (Brack et al., 2008). The
precise nature of the crosstalk between these multiple signaling pathways in muscle
remains to be determined.
In addition to this work on post-natal myogenesis, other studies employed genetic
loss-of-function approaches to demonstrate an important role for Notch in embryonic
muscle development. Studies in different vertebrate model systems had shown previously
that Notch affects the process of somitogenesis, whether by helping to specify somite
borders or to impose anterior-posterior polarity (Lewis et al., 2009). It was not clear,
however, whether the pathway also functioned downstream in the actual generation
and/or maintenance of skeletal muscle. To circumvent the problem of early embryonic
lethality caused by a null mutation in the Notch ligand Dll1, Gossler and colleagues
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generated a Dll1 null/hypomorph heterozygote, which survived until birth but was found
to exhibit striking defects in the skeletal muscle lineage (Schuster-Gossler et al., 2007).
The central phenotype observed in this mouse, a dramatic hypotrophy of muscle tissue,
appeared to reflect premature, accelerated muscle differentiation, accompanied by loss of
the Pax3+/Pax7+ myogenic progenitor cell pool. A transient excess of myogenic cells was
generated early on in the embryo, but myogenesis terminated too soon to allow for the
ultimate generation of normal musculature. The conclusion was that Dll1-Notch signaling
is essential for maintaining myogenic progenitors and preventing their precocious
differentiation. Using a different approach, conditional CSL knockout mice, Birchmeier
and coworkers reported similar findings (Vasyutina et al., 2007). Genetic deletion of CSL
in either somitic or migrating myogenic precursors resulted in premature loss of these
progenitors due to enhanced early differentiation. An absence of satellite cells as assessed
by electron microscopy and Pax7 staining was also observed in these animals, consistent
with previous proposals that the Pax3+/Pax7+ pool of progenitors represents the cellular
origin of this stem cell population.

Mechanisms of Notch-mediated inhibition of myogenesis
While Notch carries out important functions in embryonic and post-natal skeletal
myogenesis, the molecular mechanisms by which Notch exerts its effects are not well
understood. In the last fifteen years, the question of how Notch represses muscle
differentiation has been tackled by a number of different studies but has remained
controversial and resistant to solution. In 1994, it was first observed by Weintraub and
colleagues that forced expression of NICD repressed myoblast differentiation and
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fibroblast conversion in culture (Kopan et al., 1994). This inhibitory effect was also
observed upon ligand-mediated activation of the pathway, in which myoblasts were cocultured with Jagged-expressing cells (Lindsell et al., 1995). The block to differentiation
imposed by NICD could be overcome by expression of a MyoD-VP16 fusion protein but
not a MyoD~E47 tethered dimer (Kopan et al., 1994). These initial results suggested that
NICD might target the transcriptional activity of MyoD without affecting its dimerization
or DNA-binding. Such conclusions, however, rested upon the use of an artificial MyoD
fusion construct and did not directly assess MyoD occupancy at target gene promoters.
Subsequent findings led to an alternative model of Notch action in muscle, whereby
Notch would signal through the transcriptional repressor protein Hes1. NICD was shown
to directly activate the Hes1 promoter via CSL (Jarriault et al., 1995), and forced
expression of Hes1 phenocopied the inhibitory effects of NICD on fibroblast conversion
(Sasai et al., 1992). It appeared that Hes1 functioned by disrupting the in vitro DNA
binding of MyoD/E47 heterodimers, likely via inactive dimer formation with E47. While
initially appealing, this model relied on the use of NICD overexpression and very high
levels of transiently transfected Hes1. Indeed, later work by Weinmaster and colleagues
demonstrated that Jagged1-mediated Notch signaling in C2C12 myoblasts repressed
myogenesis without inducing Hes1 transcription (Shawber et al., 1996). Another study
indicated that the Notch ligand Dll1 may in fact induce Hes1, albeit transiently and in an
oscillating pattern of expression (Kuroda et al., 1999). Stable myoblast lines expressing
Hes1, however, exhibited normal differentiation (Shawber et al., 1996), calling into
question the significance of Hes1 induction. In vivo data also revealed that myogenesis
was not perturbed in Hes1 knockout animals (Ishibashi et al., 1995).
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In parallel with their work on Hes1, Weinmaster and coworkers proposed an
alternative theory for Notch-mediated inhibition, arguing for the existence of a CSLindependent pathway. This idea was generated from the observation that mutant forms of
NICD that were unable to interact with CSL or activate CSL-dependent gene expression
were nevertheless capable of repressing myogenesis in C2C12 cells (Shawber et al.,
1996). Furthermore, forced expression of a dominant-negative CSL construct failed to
rescue myogenic inhibition imposed by Notch ligands (Nofziger et al., 1999). This
proposal was complicated, however, by the fact that residual CSL activity may have
persisted in the presence of the dominant negative, and the mutant forms of NICD may
still have retained a low-level ability to associate with and activate CSL (Kato et al.,
1997). Finally, the in vivo studies described previously revealed very similar phenotypes
in the Dll1 null/hypomorph as compared to the conditional CSL knockout, indicating that
CSL-dependent signaling accounts for the phenotypic effects of Notch activation, at least
in embryonic muscle development (Schuster-Gossler et al., 2007; Vasyutina et al., 2007).
Other reports speculated that Notch may target the Mef2C transcription factor or
the p38 signaling pathway, instead of directly antagonizing the muscle regulatory factors.
In one study, a physical association was reported between the ankyrin repeats of NICD
and Mef2C, which was proposed to account for NICD-mediated inhibition of Mef2C
DNA binding and transcriptional activity in reporter assays (Wilson-Rawls et al., 1999).
No attempts were made, however, to verify such an association downstream of ligandmediated signaling. Subsequent work reported that MAML can serve as a coactivator for
Mef2C and hypothesized that Notch signaling, via NICD, could titrate MAML away
from Mef2C to shut down myogenesis (Shen et al., 2006). While an intriguing idea, it
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remains uncertain that MAML is limiting within the nucleus. MAML KO animals
exhibited muscle defects and died within ten days of birth, but heterozygotes were
phenotypically normal. Further, actual physical interaction between Mef2C and MAML
was not demonstrated, and coIPs did not show disruption of NICD-MAML association
by Mef2C. Finally, a third study revealed that forced expression of NICD induces
expression of MKP-1, a phosphatase that targets p38 for inactivation (Kondoh et al.,
2007). While constitutive expression of MKP-1 was indeed shown to block
differentiation and reduce phospho-p38, the effects of NICD itself on p-p38 were
considerably more modest, and ligand-mediated signaling was not examined.
In summary, while much has been published on Notch and myogenesis, the
mechanisms by which this important pathway inhibits myogenic differentiation remain
controversial and require further elucidation. To this end, I have sought to define the key
transcriptional targets activated by Notch in muscle and explore how these effectors
function to inhibit the myogenic transcriptional program. In the first half of my work, I
performed a gene expression screen to identify genes upregulated by ligand-mediated
Notch activity in C2C12 myoblasts and carried out gain- and loss-of-function
experiments to ascertain which of these genes are sufficient and/or necessary for
myogenic repression. My results demonstrated that Notch induces the expression of over
80 transcripts after six hours of stimulation. At least two of these genes, the canonical
effector Hey1 and the novel responsive gene MyoR, were capable of recapitulating the
block to myogenic differentiation when constitutively expressed. siRNA knockdown of
these factors alone or in combination, however, did not alleviate repression by Notch,
suggesting the existence of multiple, potentially redundant pathways. In the second half
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of my studies, I focused my attention on the Notch effector Hey1 and employed a variety
of biochemical and functional assays to help uncover the mechanism by which this
protein interferes with myogenic transcription. My results indicated that Hey1 does not
target the intrinsic transcriptional activity of the skeletal muscle master regulator MyoD,
but rather associates with the promoter regions of two critical myogenic targets,
Myogenin and Mef2C, to silence their expression.
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Chapter II. Inhibition of Myogenesis by Notch:
Evidence for Multiple Pathways1

ABSTRACT

Notch signaling is critical for skeletal muscle development and regeneration,
permitting the expansion of progenitor cells by preventing premature differentiation. I
have interrogated the pathways through which ligand-mediated signaling inhibits
myogenesis by identifying Notch-responsive genes and assessing their impact on
differentiation in vitro. Notch activation led to the robust induction of the transcriptional
repressors Hey1 and HeyL in myoblasts, but only constitutive expression of Hey1
blocked myogenesis. siRNA-mediated knockdown of Hey1 had no effect on Notch’s
ability to inhibit differentiation, suggesting the existence of additional, possibly
redundant pathways. I identified 82 genes whose expression was activated when C2C12
myoblasts were cultured in the presence of the Notch ligand Dll4. One of these, MyoR, is
a novel Notch-responsive gene, whose protein product is known to repress myogenesis in
vitro. siRNA-mediated knockdown of MyoR alone, or in combination with Hey1, was
also ineffective at rescuing differentiation in the presence of Dll4. My data support a
model in which Notch signaling inhibits myogenesis through multiple pathways, two of
which are defined by the Notch-responsive genes Hey1 and MyoR.

1

Portions of this chapter are reprinted with permission from Buas, M.F., Kabak, S., and Kadesch, T.,
J Cell Physiol 218, 84-93 (2009).
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RESULTS
To study the mechanisms by which Notch signaling inhibits myogenic
differentiation, I employed the myoblast cell line C2C12. This cell line was derived
almost three decades ago by serial passaging of myoblasts isolated from an adult mouse
hind limb muscle 70 hours following crush injury (Blau et al., 1985; Yaffe and Saxel,
1977). C2C12 cells have long been used as an in vitro model system to investigate the
molecular regulation of skeletal muscle differentiation. These cells proliferate as
myoblasts in high serum, differentiate and fuse into multinucleated myotubes in low
serum, and maintain a population of undifferentiated “reserve cells”, which have been
likened to quiescent satellite cells (Yoshida et al., 1998).

Ligand-induced Notch signaling blocks an early step in myogenesis
To obtain physiological levels of Notch signaling, I exposed cells to Notch
ligands. Specifically, I grew cells in the presence of Fc-fusion proteins, containing either
the extracellular domain of Delta-like4 (Fc-Dll4) or Jagged1 (Fc-Jag1), adhered to the
surface of tissue culture dishes with an anti-Fc antibody (Varnum-Finney et al., 2000).
Plating C2C12 myoblasts on Fc-Dll4, but not on a control Fc-fusion protein (Fc linked to
a portion of the Trail receptor 4; dubbed “Fc-control” throughout), led to a robust
generation of the Notch intracellular domain (NICD) (Figure 2.1A). When transferred
from high serum (GM, growth medium) to low serum (DM, differentiation medium),
cells grown on Fc-Dll4 were unable to form myotubes (data not shown) or to induce the
expression of Myogenin, an early marker of myogenesis (Figure 2.1A). Similar results
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Figure 2.1. Ligand-induced Notch signaling blocks myogenesis. 6-well plates were
coated with 4.5 ml of ligand-containing supernatant per well. C2C12 cells were grown
on Fc-Dll4-coated or Fc-control-coated plates and switched from growth medium
(GM) to differentiation medium (DM) as indicated. Cells were analyzed after 24 hours
for (A) cleaved Notch1 and Myogenin proteins (Western immunoblot) and (B)
MEF2A, MEF2D, MEF2C and Myogenin RNAs (RT-PCR). The upper bands of the
MEF2A and MEF2D RNA doublets are the differentiation-induced splice variants. ßtubulin protein and HPRT were used as loading controls. Figure 2.1A was contributed
by Dr. Shara Kabak.
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were obtained using Fc-Jag1 as a Notch ligand. C2C12 cells whose differentiation is
blocked by Notch signaling remain myoblasts since they retain the ability to form
myotubes when transferred to normal culture dishes (data not shown).
Notch signaling also blocked the induction of RNAs encoding Mef2C and the
splicing isoforms of Mef2A and Mef2D normally induced upon muscle differentiation
(Figure 2.1B; (Zhu et al., 2005)). Expression of MyoD RNA was reduced in cells
exposed to Notch ligand, but a significant level (30-40% of that observed in cells plated
on Fc-control) still remained (Figure 2.2A). Additionally, Myf-5 RNA levels were
induced by approximately three-fold in cells grown on Fc-Dll4 (Figure 2.2B). These data
confirm the results of others that ligand-mediated Notch signaling blocks myogenesis
(Lindsell et al., 1995), but challenge the notion that down-regulation of MyoD expression
is the primary mechanism responsible for this inhibition (Kuroda et al., 1999). They also
suggest that direct antagonism of MEF2C activity by NICD (Wilson-Rawls et al., 1999)
is less likely to be important, as Notch signaling acts prior to the induction of Mef2C
RNA. Our results indicate instead that Notch functions by repressing the ability of MyoD
to induce Myogenin and Mef2C, two critical early mediators in the myogenic program
(Cheng et al., 1993; Wang et al., 2001).

Constitutive expression of Hey1 recapitulates the early block to myogenesis
I next determined if members of the Hey or Hes family of transcriptional
repressors might mediate the effects of Notch in C2C12 cells. I found that while all three
Hey family members (Hey1, Hey2 and HeyL) were induced as a consequence of Notch
signaling, the overall level of Hey2 was extremely low (Figure 2.3), consistent with a
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Figure 2.2. Effect of ligand-induced Notch signaling on MyoD and Myf-5 expression.
C2C12 cells were grown on Fc-Dll4-coated or Fc-control-coated plates and switched
from growth medium (GM) to differentiation medium (DM) as indicated. Cells were
analyzed after 24 hours for (A) MyoD and (B) Myf-5 RNAs by quantitative RT-PCR.
MyoD and Myf-5 levels are normalized to the Fc-control-GM condition (defined as
1). Data from two replicate samples are plotted.

51

Fc-control
Fc-Dll4

Expression Level

40
30
20
10
0

Hey1

Hey2

HeyL

Figure 2.3. Ligand-induced Notch signaling significantly induces Hey1 and HeyL
expression. 6-well plates were coated with 3 ml of ligand-containing supernatant per
well. C2C12 cells were plated on Fc-Dll4 or Fc-control ligand and propagated for 48
hours in growth medium (GM). Hey1, Hey2 and HeyL RNA levels were determined
by quantitative RT-PCR using 18S as a loading control. Expression levels (x) for
individual genes were computed from ∆Ct values (relative to 18S) according to the
formula (x) * 2∆Ct = (c), where c is an arbitrary constant, and plotted as the average +/standard deviation of three replicate samples.
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previous report (Iso et al., 2001a). Members of the Hes family regulated by Notch in
other cell types (Hes1, Hes5, Hes7) were not appreciably induced (Shara Kabak,
unpublished observation). To determine if constitutive expression of either Hey1 or HeyL
could mimic the effect of Notch on differentiation, I used retroviral vectors to express
FLAG-tagged versions of these repressors in C2C12 cells. Cells expressed comparable
amounts of Hey1/HeyL RNAs; however, when I assessed differentiation, only Hey1
blocked induction of Myogenin and Mef2C transcripts (Figure 2.4A) and reduced
myoblast fusion (data not shown). Western analysis demonstrated that FLAG-Hey1 and
FLAG-HeyL proteins were indeed expressed (the indicated bands migrated at the
expected mobility of 40-45 kD), albeit at a low level in the case of Hey1 (Figure 2.4B).
Induction of both Myogenin and Myosin heavy chain (MHC) proteins occurred normally
in the presence of constitutively expressed HeyL, whereas in Hey1-expressing cells, these
markers were completely repressed at early time-points and only became detectable by
day 4. My results are consistent with a previous report implicating Hey1 as an inhibitor of
myogenesis (Sun et al., 2001). While I also observed that a FLAG-tagged version of
Hey2 exhibited the ability, like Hey1, to inhibit Myogenin induction (Figure 2.5), I do not
consider Hey2 a major player in this system, given that ligand-mediated stimulation
induces only a negligible amount of Hey2 transcription. Fc-Dll4 also induced Hey1 in
primary human myoblasts, and this correlated with a block to Myogenin induction
(Figure 2.6). I conclude that constitutive expression of Hey1 strongly inhibits early
inductive events of myogenesis and ultimately delays the course of differentiation.
I next asked if Hey1 induction is necessary for Notch to inhibit myogenesis. I
reasoned that if I sufficiently reduced the level of Hey1 expression I might observe
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Figure 2.4. Constitutive expression of Hey1, but not HeyL, blocks myogenesis. (A)
C2C12 cells were stably transduced with parental retrovirus (pBABE-puro) or
retroviruses expressing FLAG-tagged Hey1 or HeyL, propagated in growth medium
(GM), shifted to differentiation medium (DM), and analyzed for expression of the
indicated cDNAs by RT-PCR, using HPRT as a loading control. RT, reverse
transcriptase. (B) Transduced cells were propagated in GM, shifted to DM and
analyzed for expression of Myogenin, MHC or FLAG-tagged proteins after 1, 2, or 4
days by Western immunoblotting, using ß-tubulin as a loading control.
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Figure 2.5. Constitutive expression of Hey2 inhibits myogenesis. C2C12 cells were
stably transduced with parental retrovirus (pBABE-puro) or a retrovirus expressing
FLAG-tagged Hey2. Lines were propagated in growth medium (GM) and then shifted
to differentiation medium (DM) for 24 hours and analyzed for expression of
Myogenin, Mef2C, and Hey2, by RT-PCR using HPRT as a loading control.
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Figure 2.6. Ligand-mediated Notch signaling induces Hey1 and blocks Myogenin
induction in primary myoblast cultures. Human myoblasts were grown on Fc-Dll4coated or Fc-control-coated plates and switched from growth medium (GM) to
differentiation medium (DM) for 24 hours as indicated. Myogenin protein was
assessed by Western immunoblotting using ß-tubulin as a loading control, and Hey1
RNA was determined by RT-PCR using GAPDH as a loading control. This figure was
contributed by Dr. Shara Kabak.
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normal Myogenin induction despite ongoing Notch signaling. Transfection of C2C12
cells with siRNAs directed against Hey1, relative to control siRNAs, did not appreciably
affect the low level of Hey1 RNA in cells plated on Fc-control (this was somewhat
variable across multiple experiments; see Figure 2.19), but led to a significant reduction
(~75 percent) in Hey1 expression when cells were plated on Fc-Dll4 (Figure 2.7, top).
However, the induction of Myogenin (Figure 2.7, bottom) and two other myogenic
markers, Mef2C and Myosin heavy polypeptide 3 (Myh3) (Figure 2.8), was still
inhibited. This result argues that the high levels of Hey1 expression induced by Notch are
not necessary for the inhibition of myogenesis, and that other, potentially redundant
pathways may contribute.

Identification of novel Notch-responsive genes in C2C12 cells
To identify additional effectors downstream of Notch, I performed a microarraybased expression screen using C2C12 cells. Myoblasts were plated on either Fc-Dll4 or
Fc-control ligand and maintained in growth medium (GM) for six hours prior to isolation
of RNA for expression profiling. The six-hour time-point was chosen to bias the screen
towards the detection of direct (early) targets of the pathway. Activation of Notch was
verified by Western blot of protein lysates harvested from a parallel set of cultures using
an antibody specific for cleaved Notch (data not shown). RNA was submitted to the Penn
Microarray Core Facility for processing on Affymetrix MOE430v2.0 gene chips.
With a false discovery rate set to 0% and a fold change cutoff of two, the
microarray identified 82 transcripts that were induced and five transcripts that were
repressed by Notch ligand stimulation. The top 30 induced genes are shown in Table 1.
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Figure 2.7. Ligand-induced Notch signaling effectively blocks Myogenin induction
in cells expressing reduced levels of Hey1. Individual tissue culture wells were treated
with Fc-Dll4 or Fc-control as indicated in the Methods. C2C12 cells transfected with
either non-silencing (NS) control siRNA oligonucleotides or Hey1-directed siRNAs
were propagated on the coated plates and then shifted to differentiation medium (DM)
for 24 hours. Expression of Hey1 (upper panel) and Myogenin (lower panel) RNA
was assessed by quantitative RT-PCR. Q-PCR values are presented as the average +/standard deviation of three replicate samples. p values were computed by a standard
unpaired t-test.
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Figure 2.8. Ligand-induced Notch signaling effectively blocks induction of Mef2C
and Myh3 in cells expressing reduced levels of Hey1. Individual tissue culture wells
were treated with Fc-Dll4 or Fc-control as indicated in the Methods. C2C12 cells
transfected with either non-silencing (NS) control siRNA oligonucleotides or Hey1directed siRNAs were propagated on the coated plates and then shifted to DM for 24
hours. Expression of (A) Mef2C and (B) Myh3 RNA was assessed by quantitative
RT-PCR. Q-PCR values are presented as the average +/- standard deviation of three
replicate samples. Note: While MHC protein levels were only appreciably induced in
control cells by 48 hours in DM, Myh3 RNA was elevated ~300 fold by 24 hours
(data not shown).
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Table 1. Genes induced by Notch in C2C12 myoblasts.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

Gene Symbol
Nrarp
Heyl
Hey1
Il6
Msc
Trib2
8430408G22Rik
Ntn4
Dio2
Jag1
BC031353
Myf5
BG143461
Mcf2l
Sec14l2
Gata3
Adora2b
4832420M10
Tgfb2
Gpr30
Egfr
4833422C13Rik
Vav3
Cyp1b1
A730054J21Rik
Kcnf1
Epha4
Calcrl
Id3
Ppp1r2

Fold changea
14.02 [C]
10.86 [C]
7.818 [C]
6.389 [C]
5.204 [C]
4.982 [C]
4.743 [C]
4.483 [C]
4.324 [NT]
4.066 [NT]
3.979 [C]
3.328 [C]
3.242 [NT]
3.151 [C]
3.122 [C]
3.104 [C]
3.093 [NT]
2.994 [C]
2.954 [NC]
2.927 [C]
2.923 [C]
2.85 [NT]
2.71 [C]
2.699 [NT]
2.656 [NT]
2.618 [NT]
2.601 [NT]
2.595 [NT]
2.579 [C]
2.557 [NT]

Description
Notch-regulated ankyrin repeat protein
hairy/enhancer-of-split related with YRPW motif-like
hairy/enhancer-of-split related with YRPW motif 1
interleukin 6
musculin [MyoR]
expressed sequence AW319517 [Tribbles2]
RIKEN cDNA 8430408G22 [G22]
netrin 4
deiodinase, iodothyronine, type II
jagged 1
cDNA sequence BC031353
myogenic factor 5
EST mab56d07.x1
mcf.2 transforming sequence-like
SEC14-like 2 (S. cerevisiae)
GATA binding protein 3
adenosine A2b receptor
hypothetical protein 4832420M10
transforming growth factor, beta 2
G protein-coupled receptor 30
epidermal growth factor receptor
RIKEN cDNA 4833422C13
vav 3 oncogene
cytochrome P450, family 1, subfamily b, polypeptide 1
RIKEN cDNA A730054J21
potassium voltage-gated channel, subfamily F, member 1
Eph receptor A4
calcitonin receptor-like
inhibitor of DNA binding 3
protein phosphatase 1, regulatory (inhibitor) subunit 2

a

Targets subsequently confirmed by RT-PCR are marked “C”, those not confirmed are
marked “NC”, and those not tested are marked “NT”.
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This observed skewing towards gene activation as opposed to repression suggests that our
list may indeed contain a large number of direct targets of the pathway, since Notch is
primarily thought to function as a transcriptional activator. Three known Notch targets—
Hey1, HeyL, and Nrarp—were at the top of the list of induced genes. Among the most
highly induced were the cytokine interleukin-6 (IL-6), the transcription factor MyoR, the
kinase-like protein Tribbles2 (Trib2), and the RIKEN cDNA 8430408G22 (G22).
I validated a subset of the Notch-responsive genes by RT-PCR. IL-6, MyoR,
Trib2, G22, and the known targets Nrarp, Hey1, and HeyL, were all induced to varying
extents in C2C12 cells exposed to Fc-Dll4 after six hours (Figure 2.9A). Quantitative RTPCR provided additional confirmation and revealed fold changes very similar to, or
greater than, those reported by the array for Hey1, MyoR, IL-6, and an additional
responsive gene, Id3 (Figure 2.9B). In total, 18 of the 30 most highly induced genes were
confirmed by RT-PCR, one was not confirmed, and 11 were not tested (Table 1). Further
studies demonstrated that the induction of three genes (MyoR, Trib2, and Hey1), was
maintained upon serum withdrawal, while Nrarp and IL-6 expression was reduced
(Figure 2.10). This result suggests that the expression of certain genes appears to require
the combined actions of Notch and undefined factors present in serum.

Expression of a subset of Notch-responsive genes inhibits C2C12 differentiation
I next asked if constitutive expression of any of our newly identified Notchresponsive genes could inhibit myogenesis. I chose to focus initially on a subset of those
most highly induced: Nrarp, Trib2, G22, and IL-6. Nrarp, Notch-regulated ankyrin repeat
protein, has been shown to function as a feedback inhibitor of the pathway in Xenopus
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Figure 2.9. Validation of Notch-responsive genes by RT-PCR. 10 cm dishes were
coated with 2.5 ml of ligand-containing supernatant. C2C12 myoblasts were plated on
either Fc-Dll4 or Fc-control ligand and propagated in growth medium (GM) for six
hours. RNA expression of selected genes was determined by (A) RT-PCR or (B)
quantitative RT-PCR using HPRT or 18S as a loading control, respectively.
Quantitative RT-PCR values for individual genes are normalized to the Fc-control
condition (defined as 1) and plotted as the average +/- standard deviation of three
replicate samples.
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Figure 2.10. Selected Notch-responsive genes are induced by ligand stimulation only
in the presence of serum. C2C12 cells were plated on Fc-control or Fc-Dll4 ligand,
propagated in growth medium (GM), and switched to differentiation medium (DM)
for 24 hours. RNA expression of indicated genes was analyzed by RT-PCR, using
HPRT as a loading control.
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and zebrafish, but was also reported to augment Notch-mediated transcriptional
activation in cultured cells (Ishitani et al., 2005; Lamar et al., 2001). Trib2 is a kinase-like
protein implicated in the pathogenesis of acute myelogenous leukemia and also reported
to inhibit phosphorylation of Akt, a signaling molecule important in myogenesis (Du et
al., 2003; Heron-Milhavet et al., 2007; Keeshan et al., 2006; Naiki et al., 2007; Wilson
and Rotwein, 2007). Interleukin-6 is an inflammatory cytokine that is expressed in
regenerating muscle and may promote satellite cell proliferation (Cantini et al., 1995;
Kami and Senba, 1998).
cDNAs for Nrarp and Trib2 were cloned into the pBABE-puro retroviral
expression vector, and individual viruses were used to infect C2C12 myoblasts. Resulting
stable cell lines clearly expressed the specified transcripts, but exhibited normal induction
of the early differentiation marker Myogenin when deprived of serum for 24 hours
(Figure 2.11). Similar results were obtained when cells were infected with a retrovirus
expressing the G22 cDNA (data not shown). C2C12 cells were also infected with
retroviruses encoding FLAG-tagged Nrarp or Trib2, and protein expression was verified
by Western blot (Figure 2.12A). Bands migrating at the appropriate mobility were
detected in cells transduced with either of the two retroviruses, while the FLAG-Trib2
signal ran at the same mobility as a non-specific background band (FLAG-Nrarp, ~20 kD
(*), FLAG-Trib2, ~45 kD (**)). Induction of Myogenin and MHC proteins occurred
normally in FLAG-Nrarp and FLAG-Trib2 cell lines over four days in DM (Figure
2.12B). Fusion of myoblasts into myotubes after three days in differentiation medium
was also unimpaired relative to that observed in the pBABE control cultures (Figure
2.12C). Nrarp-transduced cells were also evaluated for their ability to induce Hey1 when
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Figure 2.11. Constitutive expression of Nrarp or Trib2 does not inhibit Myogenin
induction. C2C12 cells were stably transduced with parental retrovirus (pBABE-puro)
or retroviruses expressing Nrarp or Trib2. Lines were propagated in growth medium
(GM) and then shifted to differentiation medium (DM) for 24 hours and analyzed for
expression of Myogenin or the indicated cDNAs by RT-PCR using HPRT as a loading
control. RT, reverse transcriptase.
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Figure 2.12. Constitutive expression of Nrarp or Trib2 does not impair myogenesis.
C2C12 cells were stably transduced with parental retrovirus (pBABE-puro) or
retroviruses expressing FLAG-tagged Nrarp or Trib2. (A) Lines were propagated in
growth medium (GM) and analyzed for expression of FLAG-tagged proteins by
Western immunoblotting. (*) indicates the position of FLAG-Nrarp, and (**) indicates
the position of FLAG-Trib2. (B) Transduced cells were propagated in GM, shifted to
differentiation medium (DM) and analyzed for expression of Myogenin, MHC or
FLAG-tagged proteins after 1, 2, or 4 days by Western immunoblotting using ßtubulin as a loading control. (C) Fusion of myoblasts into myotubes was examined in
the indicated cell lines after three days in DM.
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cultured on Fc-Dll4, testing the hypothesis that Nrarp is a feedback inhibitor of Notch
signaling. While the induction of Hey1 was moderately reduced, this occurred at a level
of Nrarp that exceeded that typically induced by ligand (data not shown). Thus, Nrarp
does not appear to exert a significant effect on overall Notch signaling in our system.
I also asked if IL-6 affects myogenesis. I observed a modest dose-dependent
inhibition of Myogenin induction after serum withdrawal when cells were bathed in
increasing concentrations of IL-6, with maximum inhibition of approximately two-fold
occurring at a dose of 100 ng/ml (Figure 2.13). Given that this effect occurred only at
high concentrations of the cytokine, which are likely to be supra-physiological, I am
hesitant to ascribe a major role to IL-6 in mediating the effects of Notch in muscle, but do
not rule out a potential contributory influence.
In contrast to the findings for Nrarp, Trib2, and G22, forced retroviral expression
of MyoR resulted in a complete block to C2C12 myogenesis, consistent with a previous
report that has implicated this bHLH protein as negative regulator of MyoD and of
myogenic conversion of fibroblasts (Lu et al., 1999). MyoR-expressing myoblasts failed
to induce Myogenin or Mef2C transcripts at 24 hours after serum withdrawal (Figure
2.14A), showed no induction of Myogenin or MHC proteins over four days in
differentiation medium (Figure 2.14B), and exhibited no evidence of fusion after three
days in DM (Figure 2.14C). Expression of MyoR in these cells was verified by RT-PCR
and Western blot analysis (Figure 2.14A-B). In parallel with these findings, I observed
that ligand-mediated Notch signaling also induced expression of ABF-1, the human
orthologue of MyoR, in primary human myoblasts (Figure 2.15). I conclude that Notch
signaling strongly induces the expression of Nrarp, Trib2, G22, IL-6, and MyoR, but of
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Figure 2.13. IL-6 inhibits myogenesis at high doses. C2C12 cells were maintained in
growth medium (GM) and then switched to differentiation medium (DM) for 24 hours
in the absence or presence of increasing concentrations of IL-6 (2.8, 10 and 100 ng/
ml). Myogenin RNA levels were assessed by RT-PCR using HPRT as a loading
control.
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Figure 2.14. Constitutive expression of MyoR inhibits myogenesis. C2C12 cells were
stably transduced with parental retrovirus (pBABE-puro) or a MyoR-expressing
retrovirus (pBABE-MyoR), propagated in growth medium (GM) and then shifted to
differentiation medium (DM). Expression levels of the indicated differentiation
markers and MyoR were determined by (A) RT-PCR, after 24 hours in DM or (B)
Western immunoblot, after 1, 2, or 4 days in DM. RT, reverse transcriptase. (C)
Myoblast fusion was examined in pBABE control cells or MyoR-expressing cells after
three days in DM.
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Figure 2.15. Ligand-mediated Notch signaling induces ABF-1 (human MyoR) in
primary myoblast cultures. ABF-1 RNA was assessed by quantitative RT-PCR in
human myoblasts plated on Fc-Dll4 or Fc-control and propagated in growth medium
(GM). Data from two independent myoblast isolations are plotted. Primary cultures
were prepared by Dr. Shara Kabak.
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these, only constitutively expressed MyoR is sufficient to recapitulate the inhibition
imposed by the pathway as a whole.
The precise manner by which MyoR expression is activated by Notch signaling
remains an open question. Importantly, I have excluded the possibility that MyoR
induction occurs downstream of Hey1, as MyoR RNA levels were essentially unchanged
under conditions of Hey1 retroviral expression (data not shown). Bioinformatic analysis
failed to reveal any conserved CSL binding sites within the MyoR 2kb proximal
promoter, which was found to be unresponsive to NICD in luciferase reporter assays, but
a far-upstream potential enhancer region containing three conserved CSL sites was
responsive to NICD. However, mutation of these sites did not compromise NICDresponsiveness (Figure 2.16). Accordingly, MyoR could well be an indirect target of
Notch, but further studies will be needed to clearly define its mode of regulation.

Knockdown of MyoR alone or in combination with Hey1 does not impair Notch
activity
Given that constitutive expression of either Hey1 or MyoR mimicked the
inhibitory effects of Notch in C2C12 cells, it appeared that Notch was acting through
multiple pathways, and that perhaps no single gene target would be required for Notch to
exert repression. To further test this notion, I performed an additional siRNA knockdown
experiment to reduce the level of MyoR. Transfection of C2C12 cells with MyoR
siRNAs, relative to control siRNAs, led to a significant reduction (>90 percent) in MyoR
expression when cells were plated on Fc-Dll4 (Figure 2.17, top). In this experiment, a
higher dose of Fc-Dll4 supernatant was employed relative to that depicted in Figure 2.7
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Figure 2.16. A 3.3kb conserved region upstream of the MyoR transcriptional start site
shows responsiveness to NICD. (A) VISTA plot depicting conservation between
human, mouse, and chicken sequences in a ~36 kilobase region encompassing the
MyoR locus. MyoR is a two-exon gene transcribed from right to left. Conserved region
1 (CR1), CR2, and CR3 correspond to elements that were cloned and tested for
induction by NICD in reporter assays. Three conserved CSL binding sites identified in
CR3 were mutated to generate pCR3-mut-luc. (B) C2C12 cells were transfected with
the indicated reporters (2.5 ng) in the absence (pcDNA) or presence (NICD) of an
NICD expression vector (25 ng). Values are normalized to the activity of a cotransfected Renilla luciferase vector and presented as averages of three replicate
samples +/- standard deviation.
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Figure 2.17. Ligand-induced Notch signaling effectively blocks Myogenin induction
in cells expressing reduced levels of MyoR. Individual tissue culture wells were
treated with Fc-Dll4 or Fc-control as indicated in the Methods. C2C12 cells
transfected with either non-silencing (NS) control siRNA oligonucleotides or MyoRdirected siRNAs were propagated on the coated plates and then shifted to DM for 24
hours. Expression of MyoR (upper panel) and Myogenin (lower panel) RNA was
assessed by quantitative RT-PCR. Q-PCR values are presented as the average +/standard deviation of three replicate samples.
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to obtain robust induction of MyoR, a less sensitive Notch-responsive gene than Hey1.
The reduced level of MyoR, however, did not compromise the ability of Notch to repress
the induction of Myogenin (Figure 2.17, bottom), or of two additional markers, Mef2C
and Myh3 (Figure 2.18). This result is consistent with our previous data indicating that
Hey1 appears sufficient to account for the effects of Notch on early myogenesis; in the
absence of MyoR, Hey1 would be expected to compensate.
To investigate the existence of any additional MyoR- and Hey1-independent
pathways, I employed siRNAs to simultaneously knock-down both Hey1 and MyoR
expression. Transfection of C2C12 cells with this mixture of siRNAs resulted in >85
percent reduction of both Hey1 and MyoR RNA levels when cultures were plated on FcDll4 (Figure 2.19, top). Despite the drastically reduced levels of Hey1 and MyoR,
exposure to Fc-Dll4 still effectively repressed induction of Myogenin at 24 hours in DM
(Figure 2.19, bottom). Similar results were obtained when cultures were taken out to
three days in DM and analyzed for Myh3 induction (Figure 2.20), with the caveat that
knock-down efficiency had declined to ~65 percent. Myoblast fusion at four days in DM
also continued to be repressed in cultures treated with Hey1/MyoR siRNAs and plated on
Fc-Dll4 (Figure 2.21). While I cannot rule out the possibility that low levels of residual
Hey1 or MyoR are sufficient to block myogenesis, our data suggest that Notch signaling
inhibits myogenesis through multiple pathways, and that yet additional mediators beyond
Hey1 and MyoR are likely to contribute to the pathway’s biological effects in our system.
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Figure 2.18. Ligand-induced Notch signaling effectively blocks induction of Mef2C
and Myh3 in cells expressing reduced levels of MyoR. Individual tissue culture wells
were treated with Fc-Dll4 or Fc-control as indicated in the Methods. C2C12 cells
transfected with either non-silencing (NS) control siRNA oligonucleotides or MyoRdirected siRNAs were propagated on the coated plates and then shifted to DM for 24
hours. Expression of (A) Mef2C and (B) Myh3 RNA was assessed by quantitative
RT-PCR. Q-PCR values are presented as the average +/- standard deviation of three
replicate samples. Note: While MHC protein levels were only appreciably induced in
control cells by 48 hours in DM, Myh3 RNA was elevated ~300 fold by 24 hours
(data not shown).
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Figure 2.19. Ligand-induced Notch signaling effectively blocks Myogenin induction in
cells expressing reduced levels of Hey1 and MyoR. Individual tissue culture wells were
treated with Fc-Dll4 or Fc-control as indicated in the Methods. C2C12 cells transfected
with either non-silencing (NS) control siRNA oligonucleotides or a mixture of Hey1directed and MyoR-directed siRNAs were propagated on the coated plates and then
shifted to DM for 24 hours. Expression of Hey1 (upper left panel), MyoR (upper right
panel), and Myogenin (lower panel) RNA was assessed by quantitative RT-PCR. QPCR values are presented as the average +/- standard deviation of three replicate
samples.
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Figure 2.20. Ligand-induced Notch signaling effectively blocks Myh3 induction in
cells expressing reduced levels of Hey1 and MyoR. Individual tissue culture wells were
treated with Fc-Dll4 or Fc-control as indicated in the Methods. C2C12 cells transfected
with either non-silencing (NS) control siRNA oligonucleotides or a mixture of Hey1directed and MyoR-directed siRNAs were propagated on the coated plates and then
shifted to DM for 72 hours. Expression of Hey1 (upper left panel), MyoR (upper right
panel), and Myh3 (lower panel) RNA was determined by quantitative RT-PCR. Q-PCR
values are presented as the average +/- standard deviation of three replicate samples.

77

Fc-control

Fc-Dll4

NS control

Fc-control

Fc-Dll4

Hey1+MyoR siRNA

Figure 2.21. Ligand-induced Notch signaling effectively blocks myoblast fusion in
cells expressing reduced levels of Hey1 and MyoR. Individual tissue culture wells were
treated with Fc-Dll4 or Fc-control as indicated in the Methods. C2C12 cells were
transfected with either non-silencing (NS) control siRNA oligonucleotides or a mixture
of Hey1-directed and MyoR-directed siRNAs. Cultures were propagated on the coated
plates in growth medium (GM), shifted to differentiation medium (DM) for four days,
and assessed for myoblast fusion.
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DISCUSSION
Notch signaling was shown over a decade ago to inhibit myogenesis in cultured
cells and more recently to prevent the premature differentiation of muscle progenitor cells
and satellite cells in-vivo (Conboy and Rando, 2002; Kopan et al., 1994; Lindsell et al.,
1995; Schuster-Gossler et al., 2007; Vasyutina et al., 2007). However, the molecular
pathways through which Notch exerts its inhibitory effects have not been clearly defined.
My results provide evidence that Notch acts through multiple pathways to repress
myogenesis. Notch induced the expression of a multitude of genes in cultured myoblasts,
and individual constitutive expression of at least two of them, Hey1 and MyoR, was
sufficient to block (or significantly delay) myogenesis. Consistent with a model in which
no single factor downstream of Notch is required for myogenic inhibition, siRNA
knockdown experiments directed against either Hey1 or MyoR revealed that significantly
reducing the dosage of either of these factors had no appreciable effect on the ability of
Notch to exert repression. Intriguingly, even simultaneous knockdown of both Hey1 and
MyoR did not appear to rescue repression by Notch in any substantial fashion, suggesting
the existence of additional contributory factors downstream of the pathway.
Notch affects myogenesis at an early step, inhibiting the induction of Myogenin
and Mef2C. While MyoD expression levels were moderately reduced in cells exposed to
Notch ligands, the extent of this down-regulation was not as severe as previously reported
(Kuroda et al., 1999) and is unlikely to account for the complete block to myogenesis.
Rather, it appears that Notch primarily functions to antagonize the ability of MyoD to
activate downstream myogenic target genes. Since past work has shown that MyoD can
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induce its own expression (Thayer et al., 1989), the observed reduction in MyoD RNA
levels may reflect an indirect consequence of compromised MyoD transcriptional
activity. Interestingly, Notch signaling led to a three-fold increase in Myf-5 transcripts.
This induction could potentially reflect either the direct action of NICD on the Myf-5
promoter, or an indirect effect of reduced MyoD expression, as Myf-5 levels are also
elevated in the MyoD knockout mouse (Rudnicki et al., 1992). Whether the skewed
expression pattern of increased Myf-5 (and reduced MyoD) has any functional
significance in our system remains an open question. At least one report has argued that
Myf-5 may be inherently less potent than MyoD as a driver of the differentiation program
in vitro (Ishibashi et al., 2005), although apparently compensates adequately for MyoD in
vivo (Rudnicki et al., 1992). Elevated Myf-5 expression levels alone do not appear to
exert a negative impact on myogenesis, as forced retroviral expression of Myf-5 in
C2C12 cells was compatible with normal differentiation (data not shown).
Members of both the Hes and Hey (HRT, HERP, CHF) families of bHLH
repressors can be induced by Notch. In agreement with others (Shawber et al., 1996),
Hes1 was expressed in C2C12 cells, but poorly induced, and was not effective at
blocking myogenesis (Shara Kabak, unpublished observation). Other Hes family
members were not appreciably induced. By contrast, all three members of the Hey
family, Hey1, Hey2 and HeyL, were induced by Fc-Dll4, but the overall level of Hey2
was very low. Constitutive expression of Hey1 repressed myogenesis while, surprisingly,
HeyL had no effect. This argues that, despite a high level of structural similarity, the
biological activities of the Hey proteins are distinct. Hey2, when expressed as a FLAGtagged construct, did exhibit the ability to repress myogenesis (Figure 2.5); however,
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given the very low level of endogenous Hey2 transcript induced by Fc-Dll4, I do not
consider Hey2 to be a significant player in the mediating the effects of Notch in this
system. My results do, however, implicate Hey1 as a potentially important Notch effector
in myoblasts. My data showing that a reduced level of Hey1 has no effect on the response
of cells to Notch were therefore unexpected. This was true even at levels of Notch
signaling that only partially induced Hey1 and partially restricted Myogenin induction.
In contrast to a simple model of Notch acting primarily to induce the transcription
of Hes or Hey family members, my expression screen revealed over 82 transcripts that
were upregulated after only six hours of ligand stimulation. Several strongly induced
genes did not inhibit myogenesis when tested functionally by constitutive expression
(Nrarp, Trib2, G22). However, whether or not these genes play any functional role in
muscle remains to be determined. For example, it is possible that these genes exhibit little
impact when expressed individually, but will affect myogenesis when expressed in
combination. Despite this possibility, my screen suggests that Notch may generally
induce a large number of genes, but employ only specific subsets of these to execute the
pathway’s effects in different cell types.
Importantly, my work has identified MyoR as a novel Notch-responsive gene that
appears to contribute to myogenic repression. MyoR was originally identified in a screen
for cDNAs with homology to capsulin, another bHLH transcription factor (Lu et al.,
1999). MyoR exhibits a skeletal muscle-specific pattern of embryonic expression and has
been shown to antagonize the activity of MyoD in reporter assays and bind to E-box
DNA elements in vitro. Accordingly, it was suggested that this bHLH inhibitor functions
to delay the progression of myogenesis during development. MyoR was also found to be
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induced during muscle regeneration, arguing for an additional role in satellite cells (Zhao
and Hoffman, 2006). ABF-1, the putative human orthologue of MyoR, was cloned
concurrently from activated B-cells (Massari et al., 1998), suggesting muscleindependent functions.
My data are consistent with a model in which Notch signaling acts through at
least two myogenic inhibitors, Hey1 and MyoR, to repress myoblast differentiation in
culture. It is tempting to speculate that these same proteins may also represent important
arms of the Notch pathway during embryonic and/or post-natal myogenesis in-vivo.
Impairment of Notch activity results in premature progenitor cell differentiation in the
embryo and compromised satellite cell proliferation in the adult (Conboy et al., 2003;
Schuster-Gossler et al., 2007; Vasyutina et al., 2007). While knockout mice deficient for
either Hey1 or MyoR have been generated and do not exhibit overt embryonic muscle
phenotypes (Fischer et al., 2004; Lu et al., 2002), the absence of such defects in singleknockout animals is consistent with a model in which multiple factors downstream of
Notch contribute to the pathway’s phenotypic effects. It has been observed that Hey1 and
MyoR collaborate with related transcription factors, Hey2 and Capsulin, respectively.
Hey1 and Hey2 act redundantly in the embryonic vasculature (Fischer et al., 2004), while
MyoR and Capsulin function redundantly in the formation of the facial musculature (Lu
et al., 2002). Preliminary in-situ hybridization studies have revealed a striking overlap in
the expression patterns of Hey1 and MyoR in E10.5 embryos (Figure 2.22), a finding
consistent with both distinct and coordinate regulation of these two genes.
In light of the results from my double knockdown experiment (Figures 2.19-2.21),
it appears likely that additional factors beyond Hey1 and MyoR are important in
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Figure 2.22. RNA expression patterns of Hey1 and MyoR. E10.5 day embryos (upper
panels) and transverse sections (lower panels) were analyzed by in situ hybridization
using probes specific for Hey1 or MyoR. The dashed line indicates the approximate
position of the sections shown. NT: neural tube. DML: dorsal medial lip.
Data courtesy of Dr. Doug Epstein.

83

contributing to Notch-mediated inhibition of myogenesis. The large number of Notchresponsive genes identified by my array is consistent with the notion that Notch activates
an extensive gene network in order to execute its critical functions in muscle. My followup studies have shown that at least two additional Notch-responsive genes, when
constitutively expressed, can recapitulate the block to C2C12 differentiation. First,
consistent with a previous report (Atherton et al., 1996), I demonstrated that forced
expression of the HLH protein Id3 inhibited myogenesis (Figure 2.23). Id proteins, which
lack a basic domain and cannot bind DNA, are thought to function by forming inactive
heterodimers with E proteins or MyoD (Benezra et al., 1990; Jen et al., 1992). Notch
activity has also been linked to Id3 induction in Xenopus (Reynaud-Deonauth et al.,
2002). Second, I later showed that another gene identified by the array, the transcription
factor GATA3, was indeed induced by Notch in C2C12 cells (Figure 2.24) and also
repressed differentiation (Figures 2.25 & 2.26). The work of others revealed that Notch
can induce GATA3 in T cells (Amsen et al., 2007; Fang et al., 2007), but an inhibitory
role for this protein in myogenesis has not been previously reported. Interestingly,
GATA3 binding sites are present within the Myogenin and Mef2C promoters, but the
mechanism by which this factor represses myogenic transcription remains to be
determined. While the levels of Id3 and GATA3 induction observed in our system in
response to Fc-Dll4 are relatively modest, these factors, in combination with other Notchresponsive genes, such as IL-6, or even the negligible level of Hey2 induced by ligand
stimulation, may indeed participate in myogenic repression.
The positioning of activated Notch as the hub of a transcriptional network
containing multiple effectors, many of which may contribute functionally to the
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Figure 2.23. Constitutive expression of Id3 inhibits myogenesis. C2C12 cells were
stably transduced with parental retrovirus (pBABE-puro) or a retrovirus expressing
HA-tagged Id3. (A) Lines were propagated in growth medium (GM) and then shifted
to differentiation medium (DM) for 24 hours and analyzed for expression of
Myogenin and Id3 by RT-PCR using HPRT as a loading control. (B) Lines were
propagated in GM, shifted to DM for 24 hours and analyzed for expression of
Myogenin by Western immunoblotting using ß-tubulin as a loading control.
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Figure 2.24. GATA3 is induced by ligand-mediated Notch signaling in myoblasts. 10
cm dishes were coated with 2.5 ml of ligand-containing supernatant. C2C12 myoblasts
were plated on either Fc-Dll4 or Fc-control ligand and propagated in growth medium
(GM) for six hours. GATA3 RNA levels were determined by quantitative RT-PCR
using 18S as a loading control. Data represent averages +/- standard deviation of three
replicate samples.
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Figure 2.25. Constitutive expression of GATA3 inhibits myoblast fusion. C2C12 cells
were stably transduced with parental retrovirus (pBABE-puro) or a retrovirus
expressing FLAG-tagged GATA3. Fusion of myoblasts into myotubes was examined
in the indicated cell lines after three days in DM.
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Figure 2.26. Constitutive expression of GATA3 inhibits myogenesis. C2C12 cells
were stably transduced with parental retrovirus (pBABE-puro) or a retrovirus
expressing FLAG-tagged GATA3. Lines were propagated in growth medium (GM)
and then shifted to differentiation medium (DM) for 24 hours and analyzed for
expression of Myogenin (upper left panel), Mef2C (upper right panel), and GATA3
(lower panel) by quantitative RT-PCR using 18S as a loading control.
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pathway’s biological effects, is likely to be applicable to tissues other than muscle.
Generally, such a framework may serve to render any one particular target of a signaling
cascade dispensable for the overall phenotypic consequences of the pathway. In the
mammalian nervous system, it appears that the transcriptional repressors Hes1 and Hes5
represent the primary mediators of the pathway’s inhibitory effects on differentiation
(Ohtsuka et al., 1999). By contrast, in the epidermis, Notch acts directly through both
Hes1 and the cell cycle inhibitor p21 (Mammucari et al., 2005; Rangarajan et al., 2001).
The specific targets (nodes) employed by Notch may differ from tissue to tissue, but the
principle of functional redundancy could represent a general feature that ensures a robust
signaling response. Redundancy and associated robustness are critical attributes of
complex physiological systems that enhance their capacity to evolve (Kirschner and
Gerhart, 1998).
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Chapter III. The Notch Effector Hey1 Associates with
Myogenic Target Genes to Repress Myogenesis

ABSTRACT

Members of the Hey family of transcriptional repressors are basic helix-loop-helix
proteins that are thought to act downstream of Notch in diverse tissues. While forced
expression of Hey1, a target of Notch in myoblasts, is sufficient to recapitulate the
pathway’s inhibitory effects on differentiation, how Hey1 interferes with myogenic
transcription has not been fully elucidated. I provide multiple lines of evidence that Hey1
does not target the intrinsic transcriptional activity of the skeletal muscle master regulator
MyoD. My results indicate instead that Hey1 is recruited to the promoter regions of
Myogenin and Mef2C, two genes whose induction is critical for myogenesis. Expression
of Hey1 in C2C12 myoblasts correlates with reduced recruitment of MyoD to these
promoters, arguing that Hey1 inhibits myogenesis by associating with and repressing
expression of key myogenic targets.
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RESULTS
My previous work suggested that ligand-mediated Notch signaling acts through
multiple pathways to repress myogenesis (Chapter II). I next sought to determine how
individual Notch effectors inhibit the myogenic transcriptional program. I focused my
initial analysis on Hey1, as the molecular mechanisms by which Hey proteins function in
specific biological contexts are not well understood. While induction of Hey1 was not
required for Notch-mediated inhibition, this finding likely reflects the fact that Hey1
functions together or in parallel with other repressors (eg. MyoR, Id3, or GATA3) to
mediate the effects of Notch. In systems where functional redundancy may be a defining
feature, it is only by unraveling the modes of action of individual effectors that we can
reach a complete understanding of the pathway as a whole.

Hey1 does not repress intrinsic MyoD transcriptional activity
Past studies have demonstrated that Hey1 inhibits MyoD-mediated myogenic
conversion of cultured fibroblasts (Sun et al., 2001) and the differentiation of C2C12
myoblasts (Chapter II). An important question relates to whether this inhibition reflects a
generalized block to MyoD-driven transcription, or rather a selective targeting of
individual myogenic promoters. To address this, I performed transfection assays in
10T1/2 fibroblasts. When these cells are transfected with a vector expressing MyoD, they
convert to a muscle phenotype and express a wide array of myogenic transcripts. I
reasoned that if Hey1 were repressing the inherent ability of MyoD to activate gene
expression, the induction of all targets downstream of MyoD should be compromised in
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the presence of Hey1. Two of the earliest markers activated in this system are the cell
adhesion molecule Cadherin-15 and the muscle regulatory factor Myogenin. While
transfection of 10T1/2 cells with a MyoD-expression plasmid robustly induced both of
these genes, as expected, co-expression of Hey1 inhibited the induction only of
Myogenin, and not Cadherin-15 (Figure 3.1). This apparent specificity in Hey1-mediated
repression was also observed in luciferase reporter assays. Two reporter constructs were
employed, one consisting of the proximal 133-bp Myogenin promoter (G133-luciferase),
and the other composed simply of four high-affinity MyoD consensus E-box elements
linked to a minimal promoter (4RE-tk-luciferase). 4RE-tk-luciferase has been used
previously as a readout of “pure” MyoD activity, as this construct does not contain
binding sites for any MyoD cofactors, such as Mef2 (Lu et al., 2000). While MyoD
robustly induced both reporters, Hey1 repressed the induction only of G133-luciferase,
and not 4RE-tk-luciferase (Figure 3.2). Together, these results strongly suggest that
Hey1’s inhibitory effects on myogenesis reflect promoter-specific repression of select
myogenic targets, rather than generalized inhibition of MyoD activity.

Hey1 does not form dimers with MyoD or E47 or disrupt endogenous MyoD:E47
complexes
While the above functional data revealed that not all MyoD-responsive promoters
are subject to repression by Hey1, a past report had proposed that Hey1 targets MyoD
itself, by sequestering it into inactive heterodimers (Sun et al., 2001). To revisit this
proposal, I evaluated whether Hey1 associates with MyoD or its binding partner E47 to
repress myogenic transcription. I first performed co-immunoprecipitation assays in which
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Figure 3.1. Hey1 exerts promoter-specific repression of myogenesis. 10T1/2 cells
were transfected with 30 ng of pEMSV-MyoD alone or in combination with
increasing amounts of pcDNA3.1-Hey1-V5 (60-180 ng). Myogenin (A) and
Cadherin-15 (B) RNA levels were determined by quantitative RT-PCR.
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Figure 3.2. Hey1 represses the induction of G133-luciferase but not 4RE-tkluciferase. 10T1/2 cells were transfected with 25 ng pRL-TK-Renilla, 25 ng G133luciferase (A) or 25 ng 4RE-tk-luciferase (B), 25 ng pEMSV-MyoD, and 25-100 ng of
pcDNA3.1-Hey1-V5. Firefly luciferase values were normalized to Renilla luciferase
and plotted as averages of three replicate samples +/- standard deviation.
94

I overexpressed either MyoD in combination with E47 or Hey1 (Figure 3.3), or E47 in
combination with MyoD or Hey1 (Figure 3.4). 293T cells were used for these
experiments, as they allow for very high transfection efficiencies and levels of expressed
proteins, raising the likelihood that even weak interactions can be detected. These studies
confirmed the expected binding of MyoD to E47 (Figure 3.3, lane 5; Figure 3.4, lane 5)
but failed to reveal any evidence of association between either of these factors and Hey1
(Figure 3.3, lane 6; Figure 3.4, lane 6). The ability of Hey1 to dimerize with itself was
verified independently using the Hey1 construct employed in these assays in combination
with a Myc-tagged Hey1 (data not shown).
In parallel, I used electrophoretic mobility shift assays (EMSAs) to determine
whether forced expression of Hey1 in C2C12 myoblasts would disrupt the formation of
endogenous MyoD:E47 complexes. Nuclear extracts were prepared from C2C12 cells
stably transduced with either the pBABE-puro or pBABE-FLAG-Hey1 retrovirus. As a
control, I examined extracts of control 293T cells or 293T cells co-transfected with
MyoD and E47 expression plasmids. When these 293T extracts were incubated with a
radio-labeled probe containing a high-affinity E-box, complexes corresponding to
MyoD:E47 heterodimers were readily observed (Figure 3.5A, compare lanes 2 and 3). A
MyoD antibody shifted the mobility of the complexes, confirming that they contain
MyoD (lane 4). Similar complexes were observed in the C2C12 cell extracts (Figure
3.5A, lanes 5-8). Importantly, these complexes were not appreciably affected by the
presence of Hey1 (compare lanes 5 and 6 to lanes 7 and 8). The complex migrating just
below what I tentatively identify as MyoD homodimers in extracts from the pBABEtransduced cells was not shifted by a MyoD antibody, but was shifted with a Myogenin
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Figure 3.3. Hey1 does not form heterodimers with MyoD. 293T cells were transfected
with 2 µg of pEMSV-MyoD alone or in combination with 2 µg CMV-E47 or 2 µg
pcDNA-3.1-TOPO-Hey1-V5. Lysates were harvested after 48 hours and subjected to
immunoprecipitation with MyoD-specific antibodies. Immunoprecipitates and input
samples were immuno-blotted with anti-V5, anti-E47, or anti-MyoD antibodies. HC,
heavy chain.
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Figure 3.4. Hey1 does not form heterodimers with E47. 293T cells were transfected
with 2 µg of CMV-E47 alone or in combination with 2 µg pEMSV-MyoD or 2 µg
pcDNA-3.1-TOPO-Hey1-V5. Lysates were harvested after 48 hours and subjected to
immunoprecipitation with E47-specific antibodies. Immunoprecipitates and input
samples were immuno-blotted with anti-V5, anti-MyoD, or anti-E47 antibodies. HC,
heavy chain.
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Figure 3.5. Hey1 does not disrupt endogenous MyoD:E47 complexes in C2C12 cells.
(A) Nuclear extracts were harvested from C2C12 cells stably transduced with
pBABE-puro or pBABE-FLAG-Hey1 and maintained in differentiation medium (DM)
for 24 hours. Nuclear extracts were also isolated from 293T cells transiently
transfected with either 6 µg pcDNA3.1 empty vector or 2 µg pEMSV-MyoD, 2 µg
CMV-E47, and 2 µg pcDNA3.1. Extracts were incubated with a 30-nucleotide 32Plabeled probe containing the high-affinity MyoD E-box (CAGGTG) found within the
Mef2C promoter and MCK enhancer. Protein-DNA complexes were incubated with or
without MyoD-specific antibodies prior to resolution via non-denaturing SDS-PAGE.
Supershifted MyoD-containing complexes are indicated “MyoD ss”. (B) Nuclear
extracts from pBABE or pBABE-Hey1 C2C12 cells used in (A) were Western blotted
with antibodies specific for Myogenin or Mre11 as a loading control.
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antibody (data not shown). As expected, this complex was not observed in extracts from
Hey1-expressing cells, consistent with the lack of Myogenin protein (Figure 3.5B). Taken
together, our results indicate that Hey1 does not disrupt MyoD:E47 heterodimers, a
finding in agreement with our initial functional data demonstrating promoter-specific
repression by Hey1.

A role for Mef2C inhibition in Hey1-mediated repression of myogenesis
Our previous results (Figures 3.1 & 3.2) showed that Hey1 inhibits MyoDmediated induction of the endogenous Myogenin gene and a transfected Myogenin
promoter, but not the endogenous Cadherin-15 gene or a transfected E-box-driven
reporter. I sought to investigate the basis for this specificity. Past work in cultured
fibroblasts by Tapscott and colleagues demonstrated that Cadherin-15, but not Myogenin,
is transcriptionally induced by MyoD in the absence of new protein synthesis (Bergstrom
et al., 2002). This finding suggested that MyoD must collaborate with a secondary
mediator or coactivator to activate Myogenin transcription. Indeed, other studies revealed
that Myogenin induction, which is absolutely required for myogenesis in vivo, requires
both MyoD and Mef2 proteins (Edmondson et al., 1992; Hasty et al., 1993; Nabeshima et
al., 1993). Mef2C is itself a target of MyoD (Dodou et al., 2003; Wang et al., 2001) and
has been shown to be the only Mef2 family member transcriptionally upregulated upon
differentiation in C2C12 cells (Figure 2.1B). I considered the possibility that Hey1
represses myogenesis primarily by repressing Mef2C activity and/or Mef2C gene
transcription, not the Myogenin promoter per se. To explore this possibility, I first
confirmed that Mef2 is critical for Myogenin promoter activity. Indeed, mutation of the
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single Mef2 element within the Myogenin proximal promoter dramatically reduced
MyoD-stimulated reporter activity (Figure 3.6). I next asked if Hey1 affects Mef2C
activity. I transfected 10T1/2 cells with a Mef2C expression vector along with a reporter
consisting of three Mef2 DNA binding elements upstream of a minimal promoter driving
luciferase. Induction of this reporter by Mef2C was unaffected by increasing amounts of
Hey1, indicating that Hey1 does not inhibit Mef2C transcriptional activity per se (Figure
3.7A). By contrast, transcriptional induction of the endogenous Mef2C gene by MyoD
was significantly repressed by Hey1 (Figure 3.7B), a result consistent with those obtained
with Hey1-transduced C1C12 cells (Figure 2.4A).
If Hey1 functions primarily by repressing Mef2C expression, then one would
expect exogenous Mef2C to rescue Hey1-mediated repression of Myogenin. Reporter
assays revealed that repression of the Myogenin promoter was reduced, but not
eliminated by a Mef2C expression plasmid (Figure 3.8). These data suggest that
inhibition of Mef2C expression likely contributes to Hey1-mediated repression of
myogenesis, but that Hey1 may also function through additional inhibitory mechanisms.

Evaluation of in-vitro DNA binding by Hey1 to myogenic promoter elements
I next asked if Hey1 inhibits transcription by binding DNA within target gene
promoters. As a first step, I determined the ability of Hey1 to bind elements within the
Myogenin and Mef2C proximal promoters in vitro. Prior studies employing SELEX
approaches derived an optimum binding site for Hey1, which is the E-box CACGTG.
Closely related variants of this sequence bind Hey1 less well (Fischer et al., 2002; Iso et
al., 2001b; Pichon et al., 2004). The 133-bp Myogenin promoter contains a single E-box
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Figure 3.6. MyoD-mediated induction of the Myogenin minimal promoter requires an
intact Mef2 element. 10T1/2 cells were transfected with 25 ng pRL-TK-Renilla, 25 ng
G133-luciferase or G133-mutMef2-luciferase, and 25 ng pEMSV-MyoD. Firefly
luciferase values were normalized to Renilla luciferase and plotted as averages of
three replicate samples +/- standard deviation.
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Figure 3.7. Hey1 inhibits the expression, but not the activity, of Mef2C. (A) 10T1/2
cells were transfected with 25 ng pRL-TK-Renilla, 25 ng 3X-Mef2-tk-luciferase, 25
ng pcDNA3.1-Mef2C (α1β), and 25-100 ng of pcDNA3.1-Hey1-V5. Firefly
luciferase values were normalized to Renilla luciferase and plotted as averages of
three replicate samples +/- standard deviation. (B) 10T1/2 cells were transfected
with 30 ng of pEMSV-MyoD alone or in combination with 180 ng pcDNA3.1Hey1-V5. Mef2C RNA levels were determined by quantitative RT-PCR.
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Figure 3.8. Forced Mef2C expression partially rescues MyoD-mediated induction of
the Myogenin promoter in the presence of Hey1. 10T1/2 cells were transfected with
25 ng pRL-TK-Renilla, 25 ng G133-luciferase, 25 ng of pEMSV-MyoD, 25-100 ng
pcDNA3.1-Hey1-V5, and 100 ng pcDNA3.1-Mef2C (α1β), as indicated. Firefly
luciferase values were normalized to Renilla luciferase and plotted as averages of
three replicate samples +/- standard deviation.
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(E1, CAGTTG), with an additional E-box (E2, CACATG) and N-box (N1, CACCAG)
located within the 400bp proximal to the start site. The Mef2C minimum promoter
contains a single E-box (2C, CAGGTG). I performed EMSAs using in vitro transcribed
and translated (TNT) Hey1-V5 and a labeled probe containing the Hey1 consensus E-box
(HCE). The Hey1 complex ran with the same mobility as a complex present in TNT
lysates, so I evaluated Hey1 binding after shifting the complex to a slower mobility with
an anti-V5 antibody (Figure 3.9, lanes 1-3). As expected, addition of cold HCE
competitor, but not mutant HCE, completely eliminated the binding of Hey1 to labeled
probe (lanes 4-5). Addition of competitor DNA containing the various E-boxes and Nbox found in the Myogenin and Mef2C promoters only marginally reduced formation of
the Hey1 complex, despite a 50X molar excess of cold DNA (Figure 3.9, lanes 6-9).
Other reports have also failed to show association of Hey1 with the high-affinity MyoD
E-box (CAGGTG) (Fischer et al., 2002; Pichon et al., 2004). These data argue against
robust DNA binding by Hey1 to known control elements within these myogenic
promoters. Consistent with this conclusion, when I mutated the E1 site within the
Myogenin promoter and carried out reporter assays in 10T1/2 cells, Hey1 still repressed
MyoD-induced activity, indicating that inhibition is independent of this particular E-box
(Figure 3.10). Efforts to map Hey1-responsive elements in the Myogenin promoter
distinct from those necessary for induced activity were unsuccessful (data not shown).

Evidence for association of Hey1 with the Myogenin and Mef2C promoters in vivo
Despite the above findings in vitro, I sought to determine if Hey1 associates with
the Myogenin and Mef2C promoters in vivo. Chromatin immunoprecipitation (ChIP)
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Figure 3.9. Evaluation of in-vitro DNA binding of Hey1 to myogenic promoter
elements. TNT lysates programmed with either pcDNA3.1-V5/HisA empty vector or
pcDNA3.1-TOPO-Hey1-V5 were incubated with a 22-nucleotide 32P-labeled probe
containing the Hey1 consensus target E-box (CACGTG). Anti-V5 antibodies and cold
competitor probes (50X excess relative to labeled probe) were added as indicated prior
to resolution of complexes by non-denaturing SDS-PAGE. HCE, Hey1-consensus Ebox; ∆HCE, mutant Hey1-consensus E-box; E1, E2, E-boxes within the Myogenin
proximal promoter; N1, N-box ~400bp upstream of Myogenin start site; 2C, highaffinity MyoD E-box within the Mef2C proximal promoter.
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Figure 3.10. Hey1 represses induction of a Myogenin minimal promoter with a
mutated E-box DNA element. 10T1/2 cells were transfected with 25 ng pRL-TKRenilla, 25 ng G133-luciferase or G133-mutE1-luciferase, 25 ng of pEMSV-MyoD,
and 25-100 ng pcDNA3.1-Hey1-V5. Firefly luciferase values were normalized to
Renilla luciferase and plotted as averages of three replicate samples +/- standard
deviation.
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assays yielded inconsistent and variable results; accordingly, I turned to DamID, an assay
that is better suited for detecting potentially weak or indirect interactions with DNA in
vivo (van Steensel and Henikoff, 2000, 2003). In this assay, a protein of interest is fused
with the bacterial DNA adenine methyltransferase (Dam) and then expressed at low
levels in mammalian cells. If the chimeric protein associates with particular regions of
DNA, then only the targeted DNA becomes methylated since mammalian cells lack Dam.
Methylated regions are revealed on the basis of cutting by the methylation-specific
restriction enzyme DpnI and subsequent amplification of digested fragments (Reddy et
al., 2008; Vogel et al., 2007). This assay is capable of detecting even transient and weak
interactions between the chimeric proteins and their target DNA.
I generated lentiviruses that express MyoD-Dam and Hey1-Dam. Expression and
activity of the fusion proteins were confirmed with Western immunoblots and reporter
assays, respectively (Figure 3.11). When transiently transfected, the pLgw-based
lentiviral vectors employ a strong CMV promoter to drive high-level expression. This
promoter is deleted following infection and integration, and subsequent low-level
expression from the virus DNA is controlled by an un-induced heat shock promoter. I
infected C2C12 cells with individual lentiviruses, and genomic DNA was isolated and
processed (see Materials and Methods). Amplified (i.e. methylated) DNA was
interrogated for genes of interest using quantitative PCR. Cells infected with a Dam-only
virus were used to control for background methylation. As expected, cells infected with
the MyoD-Dam virus gave rise to a ~3 fold relative increase in methylation in the vicinity
of the Myogenin and Mef2C promoters, but not in the vicinity of the GAPDH promoter
or immunoglobulin heavy-chain (IgH) enhancer (Figure 3.12A). Importantly, cells
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Figure 3.11. Evaluation of protein expression and activity of Dam fusion constructs.
(A) 293T cells were transiently transfected with 2 µg of either pLgw-V5-EcoDam,
pLgw-MyoD-V5-EcoDam, or pLgw-Hey1-V5-EcoDam and 2 µg CMV-GFP. Lysates
were harvested after 48 hours and subjected to Western immunoblot analysis with
anti-V5 or anti-GFP antibodies. (B) 10T1/2 cells were transfected with 25 ng pRLTK-Renilla, 25 ng G133-luciferase, 25 ng of pLgw-MyoD-V5-EcoDam, and 50 ng
pLgw-Hey1-V5-EcoDam, as indicated. Firefly luciferase values were normalized to
Renilla luciferase and plotted as averages of three replicate samples +/- standard
deviation.
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Figure 3.12. Hey1 associates with the promoter regions of endogenous target genes
in cultured myoblasts. C2C12 cells were infected with pLgw-V5-EcoDam, pLgwMyoD-V5-EcoDam, or pLgw-Hey1-V5-EcoDam lentiviruses, maintained for two
days in growth medium (GM), and then switched to differentiation medium (DM)
for 24 hours. Genomic DNA was harvested, subjected to the DamID protocol, and
analyzed by quantitative PCR using primers in proximity to the promoter regions of
Myogenin, Mef2C, and GAPDH, or within the immunoglobulin-heavy-chain
enhancer (IgH). PCR values are presented as ratios of the MyoD-Dam (A) or Hey1Dam (B) signal to the Dam-only signal. Data from two independent experiments are
plotted.

109

infected with the Hey1-Dam virus also generated significantly increased relative
methylation (~12 fold) in the vicinity of the Myogenin and Mef2C promoters (Figure
3.12B). These data indicate that Hey1 associates specifically with the Myogenin and
Mef2C genes, and this likely leads to their transcriptional repression.
I next asked if targeting of Hey1 has consequences for the recruitment of MyoD. I
transduced C2C12 cells with either a pBABE-puro or a pBABE-FLAG-Hey1 retrovirus
and switched the cultures from growth medium to differentiation medium for 40 hours. I
then used ChIP to evaluate the recruitment of MyoD to the Myogenin and Mef2C
promoters in each group of cells. I observed a reduction in MyoD recruitment in cells
transduced with FLAG-Hey1 relative to those harboring the parental virus (Figure 3.13).
As expected, Pol II recruitment was also reduced at the Myogenin promoter (Pol II was
not detected at the Mef2C promoter for unknown reasons). Only negligible recruitment of
either factor was observed at the silent immunoglobulin heavy-chain enhancer, which
was used to normalize the data. Reduced MyoD recruitment in vivo is not likely to result
from the downregulation of MyoD expression by Hey1, as MyoD RNA levels were only
marginally reduced (Figure 3.14), and MyoD:E47 heterodimers were still observed in
Hey1-expressing C2C12 cells (Figure 3.5). I conclude that forced expression of Hey1
results in compromised recruitment of the master regulator MyoD to its target gene
promoters.
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Figure 3.13. Constitutive expression of Hey1 in C2C12 myoblasts correlates with
reduced recruitment of MyoD to target gene promoters. C2C12 cells stably
transduced with either pBABE-puro or pBABE-FLAG-Hey1 retrovirus were
switched to DM for 40 hours prior to fixation and harvesting for ChIP assays.
Chromatin was immunoprecipitated with IgG or antibodies specific for MyoD or
RNA Pol II. Samples were analyzed by quantitative PCR using primers specific for
the Myogenin promoter (A) or Mef2C promoter (B) and IgH enhancer. Anti-MyoD
to IgG or anti-Pol II to IgG ratios at the Myogenin and Mef2C promoters were
normalized to those at the IgH enhancer. Data from two independent experiments
are plotted.

111

Relative Level

C2C12 MyoD
GM
DM

1.0

0.5

0.0

pBABE

Hey1

Figure 3.14. Determination of MyoD RNA levels in Hey1-expressing cells. C2C12
cells stably transduced with pBABE-puro or pBABE-FLAG-Hey1 retrovirus were
maintained in growth medium (GM) or switched to differentiation medium (DM) for
24 hours. RNA was isolated and MyoD RNA levels were determined by quantitative
RT-PCR.
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DISCUSSION
Hey1 is one of several transcription factors downstream of Notch activation
which may contribute to the pathway’s inhibitory effects in muscle. In this portion of my
thesis, I sought to determine the mechanism by which this canonical Notch effector
mediates transcriptional repression. My studies on Hey1 support a model in which this
bHLH inhibitor primarily functions by binding in the vicinity of the Myogenin and
Mef2C promoters to shut off target gene expression. I present three independent and
complementary lines of evidence that are consistent with this model and argue against a
proposal that Hey1 sequesters MyoD into inactive heterodimers (Sun et al., 2001). First,
MyoD-mediated induction of a direct MyoD target gene (Cadherin-15) or of an E-boxdriven reporter (4RE-tk-luc) was resistant to repression by Hey1. Second, MyoD did not
form heterodimers with Hey1 under the conditions of my co-immunoprecipitation assays,
yet readily formed heterodimers with E47 as expected. Importantly, Hey1 did form
homodimers. Third, MyoD:E47 heterodimers were unaffected in cells expressing Hey1,
despite the inability of these cells to differentiate. While the basis for the discrepancy
with a previous study (Sun et al., 2001) is currently unknown, my combination of
functional and biochemical data strongly argue that Hey1 does not repress the intrinsic
ability of MyoD to activate transcription.
Since Hey1 repressed the induction of Myogenin but not Cadherin-15, I sought to
determine the basis for this promoter specificity. Past work had implicated the Mef2
family of transcription factors as critical mediators of Myogenin induction, in particular
Mef2C (Dodou et al., 2003; Edmondson et al., 1992; Wang et al., 2001). While Hey1 did
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not inhibit Mef2C activity, it did repress Mef2C expression, suggesting that repression of
Myogenin might be due to the lack of Mef2C protein. However, forced expression of
Mef2C only partially restored Myogenin promoter activity in the presence of Hey1,
suggesting additional mechanisms. Indeed, DamID assays showed that Hey1 associates
with both the Mef2C and Myogenin promoter regions, indicating that its ability to inhibit
myogenesis may be due to the repression of multiple myogenic loci.
The work presented here raises several additional mechanistic questions of
interest. If Hey1 associates with DNA in proximity to the Myogenin and Mef2C
transcriptional start sites, where exactly does this binding occur, through what
intermediates if any, and how does Hey1’s presence translate into transcriptional
silencing? The resolution of DamID has been reported to be ~1 kb at best (Greil et al.,
2006) and thus cannot be used to identify specific binding sites occupied by Hey1 within
these target promoters. My EMSA data argue that Hey1 is not likely to bind directly to Eboxes or N-boxes at these loci, leaving open the possibility that Hey1 may associate
instead through distinct DNA-bound regulatory proteins. Aside from MyoD and Mef2,
additional transcription factors such as Pbx1/Meis, MSY-3, Six1/4, and Ski also
participate in the complex transcriptional control of the Myogenin locus (Berghella et al.,
2008; Berkes et al., 2004; Spitz et al., 1998; Zhang and Stavnezer, 2009). Hypothetically,
Hey1 could interact with any of these or other factors present at the Myogenin promoter.
An intriguing possibility is that Hey1 functions in conjunction with GATA proteins,
specifically GATA3. As noted previously, GATA3 is induced by Notch in C2C12 cells
and inhibits differentiation when constitutively expressed. Past work in other systems has
demonstrated physical interactions between Hey1 and GATA proteins (Elagib et al.,
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2004; Fischer et al., 2005; Kathiriya et al., 2004). If GATA3 is found to associate with
GATA binding sites in the Myogenin and/or Mef2C promoters, this factor could
potentially serve as an adaptor protein for Hey1 recruitment.
Hey1’s presence at these loci appears linked to a reduction in MyoD recruitment,
but how this occurs remains to be determined. Importantly, expression of Hey1 in C2C12
cells did not significantly reduce expression of MyoD or its inherent ability to bind a
target E-box in-vitro. Under one scenario, Hey1 could alter local chromatin structure by
recruiting histone modifying enzymes such as HDACs, and thereby impede MyoD
recruitment. Hey proteins have been shown to bind HDACs in vitro (Iso et al., 2001b),
but many studies have indicated Hey-mediated repression is insensitive to trichostatin A
(Elagib et al., 2004; Fischer et al., 2005; Garg et al., 2005; Nakagawa et al., 2000),
calling into question the relevance of such associations. Furthermore, I found that Hey1
failed to significantly repress a reporter construct in which the 133-bp Myogenin
proximal promoter fragment was fused to a strong basal thymidine kinase promoter (data
not shown). Repression of the nearby TK promoter would be expected if Hey1 were
binding to this DNA and recruiting HDACs. Under a different scenario, by associating
with myogenic promoters, Hey1 might sterically occlude access of MyoD to its target Ebox or interfere with its binding to Pbx1/Meis, homeodomain proteins postulated to
facilitate initial (weak) recruitment of MyoD to the Myogenin locus (Berkes et al., 2004).
While these questions require additional investigation, my data provide strong
evidence that Hey1 functions by physically associating with the promoter regions of two
critical myogenic genes, Myogenin and Mef2C. Previous reports have often proposed
that Hey family proteins silence transcription via protein-protein interactions with
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transcriptional activators, but seldom demonstrated association with target gene
promoters (Fischer and Gessler, 2007). My results using the sensitive DamID technique
imply that such protein-protein interactions may often serve to tether Hey proteins to
promoter regions rather than simply to sequester transcription factors away from DNA.
Given that Mef2C is required for Myogenin induction, I initially explored the possibility
that the Mef2C promoter alone may be the primary target of Hey1-mediated repression.
Instead, my results indicate that Hey1 acts on both promoters, perhaps as a means to
reinforce or lock in the repressed state through redundant mechanisms. It remains to be
seen whether Hey1 also directly targets a much broader set of myogenic promoters, or
whether specific features of the Myogenin and Mef2C loci render them uniquely
receptive to Hey1 recruitment.
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Chapter IV. Perspective and Future Directions

In total, my work has revealed an unanticipated level of complexity in the
molecular regulation of skeletal myogenesis by the Notch signaling pathway. Contrary to
past proposals that Notch functions simply by inducing the expression of the canonical
targets Hes1 or Hey1, my results suggest that multiple effectors downstream of Notch
activation likely contribute to myogenic repression. Some of these, like Hey1, appear to
target specific critical promoters rather than silencing generalized MyoD transcriptional
activity. The apparent redundancy of multiple mediators and the potential diversity of
inhibitory mechanisms underscore the critical role that the Notch pathway plays in the
developmental and regenerative biology of skeletal muscle.
When considered in the context of the Notch transcriptional network in muscle,
my results on Hey1 suggest that individual Notch effectors may function through distinct
yet complementary mechanisms to shut down myogenic gene expression. In contrast to
Hey1, which appears to exert promoter-specific repression of myogenesis via association
with key target loci, past studies on MyoR and Id3 have demonstrated that these factors
directly repress the inherent activity of MyoD, the master regulator. As mentioned
previously, Id3 likely acts by sequestering MyoD or E2A proteins into inactive
heterodimers (Benezra et al., 1990; Jen et al., 1992). MyoR has similarly been reported to
titrate E2A away from MyoD, but also directly binds E-box DNA elements in vitro (Lu et
al., 1999). My own data on MyoR were largely consistent with these past findings
(Figures 4.1-4.3). I found that MyoR dimerizes with E47 but not MyoD, binds to an Ebox probe in vitro, and represses MyoD-mediated induction of both the Myogenin
117
68

IP: Myc
+
+

+
-

+
-

+
+

: 6x-Myc-MyoR
: MyoD

-

+

-

-

+

-

: E47

MyoD

+
-

- HC
- MyoD

E47

+
-

- E47
- HC

Myc

: Blot

5% Input

- HC
- 6x-Myc-MyoR
1

2

3

4

5

6

Figure 4.1. MyoR forms heterodimers with E47, but not with MyoD. 293T cells were
transfected as indicated with 2 µg pcDNA-6X-Myc-MyoR alone or in combination
with 2 µg CMV-E47 or 2 µg pEMSV-MyoD. Lysates were harvested after 48 hours
and immunoprecipitated with Myc-specific antibodies. Immunoprecipitates and input
samples were Western immunoblotted with anti-MyoD, anti-E47, or anti-Myc
antibodies. HC, heavy chain.
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Figure 4.2. MyoR-E47 heterodimers and MyoR homodimers bind an E-box element
in vitro. Nuclear extracts were harvested from 293T cells transiently transfected with
either 6 µg pcDNA3.1 empty vector or 2 µg of individual plasmids as indicated
(CMV-E47, pEMSV-MyoD, pcDNA-6X-Myc-MyoR). Total transfected DNA was
kept constant (6 µg) by adding pcDNA3.1 empty vector as needed. Extracts were
incubated with a 30-nucleotide 32P-labeled probe containing the high-affinity MyoD
E-box (CAGGTG) found within the Mef2C promoter and MCK enhancer. ProteinDNA complexes were resolved via non-denaturing SDS-PAGE. Complexes were
identified (preliminarily) by expected altered mobility patterns relative to the E47
homodimer.
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Figure 4.3. MyoR inhibits MyoD-mediated activation of a Myogenin reporter and a
pure E-box-driven reporter. 10T1/2 cells were transfected with 25 ng pRL-TKRenilla, 25 ng G133-luciferase (A) or 25 ng 4RE-tk-luciferase (B), 25 ng pEMSVMyoD, and 25-100 ng of pcDNA3.1-MyoR-V5. Firefly luciferase values were
normalized to Renilla luciferase and plotted as averages of three replicate samples +/standard deviation.
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promoter and a pure E-box-driven reporter. Whether ligand-induced levels of MyoR and
Id3 are sufficient to bring about these effects on MyoD remains an open question.
Interestingly, formation of endogenous MyoD:E47 complexes in C2C12 cells was not
significantly affected by ligand stimulation (Figure 4.4). This finding suggests that
endogenous levels of MyoR and Id3, if important for myogenic inhibition, may
potentially act through mechanisms different from those described for the constitutively
expressed proteins.
In light of the above results, one general limitation of my work relates to the use
of constitutive overexpression in the functional analysis of Notch-responsive genes.
While my studies revealed that at least four such genes (Hey1, MyoR, Id3, Gata3) can
mimic the inhibitory effects of the pathway in muscle, my stably transduced cell lines
expressed these genes at levels substantially higher than those observed following ligandbased stimulation. Just as past work has revealed that NICD overexpression can result in
the activation of target genes not induced by Notch ligands (Iso et al., 2001a), so the use
of overexpressed effectors could result in artifactual functional effects on differentiation.
To address this concern, future studies will invoke an inducible system, in which
expression levels of stably integrated transgenes can be finely tuned to more faithfully
recapitulate ligand-mediated signaling. This approach will enable me to determine if
expression of a given individual target at physiological levels is indeed sufficient to
mimic Notch activation.
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Figure 4.4. Fc-Dll4-mediated Notch signaling does not disrupt endogenous MyoD:
E47 complexes in C2C12 cells. (A) Nuclear extracts were harvested from C2C12 cells
seeded on plates coated with Fc-control or Fc-Dll4 ligands and maintained in
differentiation medium (DM) for 24 hours. Nuclear extracts were also isolated from
293T cells transiently transfected with either 6 µg pcDNA3.1 empty vector or 2 µg
pEMSV-MyoD, 2 µg CMV-E47, and 2 µg pcDNA3.1. Extracts were incubated with a
30-nucleotide 32P-labeled probe containing the high-affinity MyoD E-box (CAGGTG)
found within the Mef2C promoter and MCK enhancer. Protein-DNA complexes were
incubated with or without MyoD-specific antibodies prior to resolution via nondenaturing SDS-PAGE. Supershifted MyoD-containing complexes are indicated
“MyoD ss”. (B) Nuclear extracts used in (A) were Western immunoblotted with
antibodies specific for Myogenin or Mre11 as a loading control.
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Functional studies in primary myoblast cultures and mice
A central future endeavor will be to extend my results in C2C12 cells to primary
myoblast cultures and in vivo mouse models. While C2C12 cells exhibit many of the core
properties of myoblasts in vivo, this cell line has undoubtedly undergone changes as a
consequence of immortalization and extended culturing over three decades, and cannot be
assumed to recapitulate all aspects of myoblast or satellite cell biology. Indeed, one
important observation made by Rando and colleagues was that Notch activation in
cultured primary myoblasts resulted in increased cellular proliferation (Conboy and
Rando, 2002). Work from our own lab, by contrast, has failed to detect a significant
effect of ligand-mediated stimulation on cell number or cell cycle exit in C2C12 cells;
furthermore, forced cell cycle exit via p21 adenoviral infection failed to rescue the block
to myogenesis (Shara Kabak, unpublished observations). If the proliferative effect of
NICD reported by Rando can be validated with ligand-based Notch signaling in primary
myoblasts, it would be interesting to revisit the possibility that Notch may function in
part by promoting the cell cycle to inhibit differentiation.
Along these lines, an intriguing feature of my array list of Notch-induced genes
was the presence of three growth factor receptors: epidermal growth factor receptor
(EGFR), leukemia inhibitory factor receptor (LIFR), and platelet-derived growth factor
receptor β (PDGFRβ). Furthermore, the cytoplasmic protein MIG6, a known inhibitor of
EGFR (Zhang et al., 2007), was one of the few genes that was downregulated by ligandmediated signaling. Induction of these cell-surface receptors by Notch (and repression of
receptor inhibitors) might sensitize dividing satellite cells or myogenic progenitors to
locally circulating growth cues and help maintain the proliferative, undifferentiated state.
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In C2C12 cells, I validated EGFR and MIG6 as Notch-responsive genes by RT-PCR
(Figure 4.5). I found that forced expression of EGFR is not sufficient to recapitulate the
Notch-mediated block to differentiation observed in low serum medium (DM), although
EGFR did sensitize cells to EGF-mediated inhibition (Figure 4.6). Given that
immortalized C2C12 cells do not exhibit a proliferative response to Notch, a top priority
will be to determine if constitutive expression of these growth factor receptors in primary
myoblasts, preferably at levels induced by Notch ligands, phenocopies the effects of
Notch activation; conversely, I will examine if siRNA knockdown of these receptors or
their pharmacological inhibition impairs Notch-mediated responses. Interestingly, two
studies in the past year have also reported EGFR as a target of Notch in different settings.
Fine and colleagues demonstrated that Notch upregulates EGFR expression in human
gliomas, potentially contributing to the pathway’s oncogenic effects (Purow et al., 2008).
Bray and colleagues, by contrast, showed that Notch directly induces EGFR in the
Drosophila muscle cell line DmD8 (Krejci et al., 2009). Consistent with the growth factor
model proposed above, further studies demonstrated that antagonism of EGFR signaling
or loss of Notch function both result in premature differentiation of adult muscle
progenitors in the fly (Krejci et al., 2009).
Beyond EGFR, the cytokine interleukin-6 (IL-6) is another validated Notchresponsive gene on my array list that deserves reexamination. While exposure of C2C12
cells to high levels of IL-6 had only modest inhibitory effects on differentiation (Figure
2.13), recent work has established a genetic requirement for IL-6 in satellite cell
proliferation in vivo (Serrano et al., 2008). Interestingly, past reports have demonstrated
that CSL associates with the IL-6 promoter in vitro (Kannabiran et al., 1997; Palmieri et
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Figure 4.5. EGFR is induced and MIG6 is repressed by ligand-mediated Notch
signaling in myoblasts. 10 cm dishes were coated with 2.5 ml of ligand-containing
supernatant. C2C12 myoblasts were plated on either Fc-Dll4 or Fc-control ligand and
propagated in growth medium (GM) for six hours. EGFR (A) and MIG6 (B) RNA
levels were determined by quantitative RT-PCR using 18S as a loading control. Data
represent averages +/- standard deviation of three replicate samples.
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Figure 4.6. Constitutive expression of EGFR does not repress myogenesis, but
sensitizes C2C12 cells to an EGF-mediated block to differentiation. C2C12 cells were
stably transduced with parental retrovirus (pBABE-puro) or a retrovirus expressing
EGFR. Lines were propagated in growth medium (GM) and then shifted to
differentiation medium (DM) for 24 hours in the absence or presence (DME) of 100
ng/ml EGF. Myogenin (upper panel) and EGFR (lower panel) RNA expression levels
were assessed by quantitative RT-PCR using 18S as a loading control.
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al., 1999; Vales and Friedl, 2002), suggesting that this gene could be directly activated by
Notch. It will be important to assess whether IL-6 levels increase upon muscle injury in a
Notch-dependent fashion, as induction of this cytokine may represent yet another
mechanism by which Notch could enhance the proliferative response of satellite cells.
This could be tested by injecting a Notch inhibitor into injured muscle, as Rando and
colleagues have described (Conboy et al., 2003), and examining local IL-6 production.
It remains to be determined whether the same Notch-responsive genes shown to
repress myogenesis in our in vitro system also account for key functions of Notch during
in vivo muscle development and regeneration. Single knockout animals for Hey1, MyoR,
and Id3 exhibit no overt skeletal muscle defects (Fischer et al., 2004; Lu et al., 2002; Pan
et al., 1999), suggesting that these effectors either play no role in myogenic development,
or function redundantly with each other or additional factors. GATA3 null mice die
during gestation (Pandolfi et al., 1995), necessitating the generation of a muscle-specific
conditional mutant. One approach would be to cross the normal single knockouts above
to generate double or triple knockout animals, and assess the formation of embryonic
skeletal muscle. If these effectors are critical for Notch function, the expected phenotype
would mirror that observed in the conditional CSL knockout or Dll1 null/hypomorph
heterozygote—premature progenitor cell differentiation and ultimate muscle hypotrophy
(Schuster-Gossler et al., 2007; Vasyutina et al., 2007). If the animals survive post-natally,
muscle regenerative capacity could be evaluated following injury, with the expectation of
compromised repair due to reduced satellite cell activation. Before initiating such studies,
however, I would first opt for functional analyses of these and other Notch-responsive
genes in primary myoblast cultures, as described above. If, for example, the EGF
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receptor, alone or in combination with other effectors is shown to be critical for enhanced
myoblast proliferation and impaired differentiation downstream of Notch activation, this
gene and its partners would instead become the new focus for future in vivo explorations.

Expression profiling of the temporal response to Notch activation
While my array list of Notch-responsive genes in C2C12 myoblasts provided a
solid starting point to probe the transcriptional output of the pathway in muscle, it
remains possible that important targets were missed due to the selection of an early 6hour time point. I chose this time point to bias the list of genes towards direct targets of
the pathway and indeed captured several known CSL-dependent primary Notch effectors
(Nrarp, Hey1, HeyL). To fully flesh out the broader scope of transcriptional changes
downstream of ligand-mediated signaling, however, the gene profiling analysis should be
extended to a time-course over 12-48 hours. Notch typically functions as a transcriptional
cascade, in which primary targets like Hes/Hey proteins act as repressors to shut off
expression of a set of secondary targets. However, in some cases, secondary or indirect
targets may also be induced, perhaps as a consequence of “feed-forward” collaboration
between NICD and one of its primary effectors. For example, in Th2 cells, Notch
activates expression of GATA3, which then synergizes with NICD to induce the
transcription of the cytokine IL-4 (Fang et al., 2007). In muscle, MyoR induction may
reflect an analogous mode of regulation, as its expression is delayed relative to that of
Hey1 and HeyL (Figure 4.7). By examining an extended temporal window following
ligand stimulation, I would gain a clearer sense of secondary expression changes in
muscle, whether positive or negative, which could offer important functional insights into
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Figure 4.7. Induction of MyoR by ligand-mediated Notch signaling exhibits a
temporal lag relative to that of Hey1 and HeyL. C2C12 cells were seeded on plates
coated with Fc-Dll4 ligands, propagated in growth medium (GM) for one to six hours,
and analyzed for expression of Hey1 (upper panel), HeyL (middle panel), and MyoR
(lower panel) by quantitative RT-PCR using 18S as a loading control. Q-PCR values
were normalized to the one hour time point, defined as “1”.
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the mechanisms of myogenic inhibition. My current list revealed only five genes, mostly
not well characterized, whose expression declined after 6 hours, suggesting that this time
point was too early to detect most secondarily repressed targets. Another interpretation,
however, is that some genes targeted for repression by primary effectors may be silent by
default in myoblasts, prior to differentiation, and hence would not be detected by my
arrays (eg. Myogenin or Mef2C). One way to circumvent this problem would be to
activate Notch signaling in cultures that had already initiated differentiation, and identify
the specific transcripts that decline in abundance after a short duration (whether Notch
activity can in fact reverse or impair the myogenic transcriptional program once initiated
must first be verified).

Further functional analysis of Notch-responsive genes
One of the strategic questions I faced in my thesis project was how to functionally
evaluate the list of genes obtained from my array experiment. The straightforward path
that I chose was first to determine which individual genes out of a restricted subset were
sufficient, when constitutively expressed in C2C12 cells, to phenocopy Notch-mediated
repression of differentiation. Subsequently, I employed siRNAs against one or more
genes capable of inhibition, in an attempt to define the set of effectors essential for the
pathway’s function. This approach had two main limitations, beyond the use of
constitutive retroviral overexpression. First, cloning individual cDNAs into a retroviral
construct and generating stable cell lines was a time- and labor-intensive process that
severely limited the number of genes I could realistically test for function. Second, my
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functional screening evaluated only single genes in parallel, without addressing potential
combinatorial, collaborative actions of multiple targets.
In the future evaluation of this array data set or subsequent ones, I would consider
alternative approaches. To address the above concerns, I would seek out higherthroughput strategies to functionally screen through the induced genes on my list. The
cost of purchasing cDNA clones ready for use in expression plasmids has dropped
significantly, which would facilitate the quick acquisition of a much larger pool of
cDNAs. As a first pass, rather than relying on stable cell line creation, I would likely
perform luciferase reporter assays in cultured myoblasts to screen for the ability of
individual or multiple Notch-responsive genes to inhibit MyoD-mediated activation of a
Myogenin reporter construct (G133-luciferase), a robust readout of the combined
activities of MyoD and Mef2. Use of this readout should capture most potential inhibitors
of the myogenic transcriptional program, as MyoD and Mef2 represent the central drivers
of transcription in muscle. While results from this initial screen would rely on transient
transfections and consequently on high levels of expressed gene products, I would then
move to a system of stable inducible expression in C2C12 myoblasts. A subset of genes
that exhibited the strongest inhibitory activity would be expressed under the control of a
TET-inducible retroviral promoter, to dial down expression to ligand-induced levels.
Ideally, this strategy would even allow for the assessment of potential synergistic or
collaborative effects between a pair of effectors expressed off vector backbones with
different selectable markers.
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Examination of potential post-transcriptional effects of Notch
Notch activates a transcriptional cascade, and hence most of my efforts have been
focused on identifying and investigating the function of genes upregulated in response to
ligand-mediated signaling. Past work, however, has revealed that Notch signaling can
also orchestrate the ubiquitin-mediated proteasomal degradation of various transcription
factors, such as E2A and Tal1/SCL (Nie et al., 2008; Nie et al., 2003). Exactly how
Notch facilitates the destruction of these proteins has not been elucidated, but such posttranscriptional effects may represent indirect consequences of Notch-mediated
transcription. Indeed, reduced protein stability of E2A and Tal1/SCL was shown to
depend on CSL function, suggesting that Notch may directly activate genes involved in
the ubiquitination pathway. While transcription downstream of Notch likely remains the
common denominator, these studies suggest that phenotypic consequences of Notch
activity in some instances reflect alterations in protein stability. In future work, I would
like to test the hypothesis that Notch signaling in muscle functions in part to promote (or
inhibit) the protein turnover of selected targets. My own work has shown that the effect
of Notch on E2A reported in lymphocytes appears to be tissue-specific, as ligandmediated signaling in C2C12 myoblasts did not affect E47 protein levels (Figure 4.8).
Nevertheless, other components of the myogenic program could potentially be targeted
post-transcriptionally.
To determine if Notch alters the stability of cellular proteins in proliferating
myoblasts, I would invoke a recently described high-throughput system devised by
Elledge and colleagues, called global protein stability profiling (Yen et al., 2008). This
approach relies on the use of fluorescence-activated cell sorting (FACS) and microarray
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Figure 4.8. Ligand-mediated Notch signaling does not alter E47 protein abundance in
proliferating or differentiating myoblasts. C2C12 cells were seeded on plates coated
with either Fc-control or Fc-Dll4 ligands. Cells were propagated in growth medium
(GM), shifted to differentiation medium (DM) for 1 or 2 days, and analyzed for
expression of E47, Myogenin, and cleaved Notch1 by Western immunoblotting using
ß-tubulin as a loading control.
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analysis to infer the stability of a vast number of proteins simultaneously. In basic terms,
the system employs a retroviral reporter construct that expresses a bicistronic message
with an internal ribosome entry site (IRES). This message codes for two fluorescent
proteins, a control protein DsRed, and a fusion protein between EGFP and a protein of
interest (X). Since these proteins are expressed off the same RNA, they should be
produced at the same ratio in transduced cells, and the EGFP/DsRed ratio reflects the
stability of protein X. A cDNA library in this retroviral vector is employed to generate
viruses and infect cells at low multiplicity of infection to make reporter cell collections.
The cell library is fractionated by FACS into several pools based on increasing
EGFP/DsRed ratios. Stability of a given protein “X” is inferred based on the distribution
of cells expressing the protein X-EGFP fusion within the different pools (cells expressing
a high-stability protein would be most concentrated in the pool with the highest ratio).
High-throughput determinations are made possible by PCR-amplification of integrated
virus-ORF identifier sequences from genomic DNA of sorted sub-pools and the total cell
library; microarrays are then used to quantify the representation of each cDNA in a given
sub-pool relative to the total cell population.
To apply this technology to my specific question, I would generate a C2C12
reporter cell library. One pool of library cells would be propagated on Fc-control ligands,
and another on Fc-Dll4. Clone distribution profiles for each condition would be
determined following cell library fractionation by FACS and microarray analysis. If a
particular protein exhibited altered stability in the presence of an active Notch signal, this
change would be reflected in a modified distribution of cells expressing that fusion
protein in the fractionated pools. Assuming I am able to identify such targets, I would
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first validate a subset of them by ascertaining the stability of the endogenous proteins via
more traditional methods, such as pulse-chase experiments. Additional studies would be
guided by several questions: Are these proteins functionally important in myogenesis? Is
altered stability mediated through the ubiquitin-proteasome pathway? Does the effect
depend on CSL-directed transcription?

135
78

Chapter V. Materials and Methods

Plasmids
Plasmids expressing the extracellular domains of Dll4 and Trail Receptor4 as Fc-fusion
proteins were provided by Dr. Marion Dorsch (Millennium Pharmaceuticals, Cambridge,
MA). Retroviral vectors encoding FLAG-tagged Hey1, Hey2, and HeyL were generated
by sub-cloning the murine cDNAs, provided by Dr. Eric Olson (University of Texas),
into the EcoRI site of the multiple cloning site of pBABE-puro-FLAG. Retroviral vectors
for Nrarp, Trib2, and MyoR were generated by PCR amplification of the respective
cDNAs from Notch ligand-stimulated C2C12 myoblasts followed by insertion into
pBABE-puro at the BamHI/SalI sites (Nrarp) or the BamHI/EcoRI sites (Trib2, MyoR).
The MyoR cDNA was also subcloned into the BamH1/EcoR1 sites of the expression
vectors pcDNA-6X-Myc and pcDNA3.1-V5/HisA (Invitrogen, Carlsbad, CA). FLAGtagged Nrarp and Trib2 were generated by PCR-subcloning the respective cDNAs into
the SalI site (Nrarp) or EcoRI site (Trib2) of pBABE-puro-FLAG. G22Riken cDNA was
obtained from Invitrogen (Carlsbad, CA) (clone 2649431) and sub-cloned by PCR into
the BamHI/EcoRI sites of pBABE-puro. pBABE-HA-Id3 was generated by sub-cloning
the HA-Id3 cDNA from RSV-HA-Id3 into the EcoRI site of pBABE-puro. The GATA3
retroviral vector was generated by PCR-subcloning the murine GATA3 cDNA, provided
by Dr. Steve Reiner, into the EcoRI site of pBABE-puro-FLAG. The human EGFR
cDNA, provided by Dr. Mark Lemmon, was excised from pcDNA3.1-EGFR using the
PmeI and XhoI restriction sites and ligated into the SnaBI and SalI sites of pBABE-puro.
MyoR reporter constructs were generated by PCR amplification of the indicated elements
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from BAC RP23-398C14 (Invitrogen, Carlsbad, CA) followed by ligation into the
KpnI/BglII sites of pGL3-basic (CR1), the KpnI/BglII sites of pGL2-promoter (CR2), or
the KpnI site of pGL2-promoter (CR3). Three CSL sites present within CR3 were
mutated using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) as
follows: CSL site #1 was changed from “TTCCCACA” to “GGTACCCA”; CSL site #2
was changed from “TTCCCACG” to “GGTACCCG”; CSL site #3 was changed from
“TTCCCA” to “TGTACA”. CMV-NICD has been described previously (Ross and
Kadesch, 2001).
G133-luciferase was provided by Vittorio Sartorelli (National Institutes of Health)
and contains the 133-bp Myogenin proximal promoter fused to luciferase (Xu and Wu,
2000). pcDNA3.1-Mef2C (α1ß splice isoform) and 3x-Mef2-tk-luciferase were provided
by Tod Gulick (Harvard Medical School). 3x-Mef2-tk-luciferase contains three copies of
a Mef2 binding element fused to a minimal thymidine kinase (tk) promoter driving firefly
luciferase (Zhu and Gulick, 2004). pEMSV-MyoD and 4RE-tk-luciferase were provided
by Eric Olson (University of Texas). 4RE-tk-luciferase contains 4 copies of the MCK
enhancer right E-box fused to a minimal tk promoter driving firefly luciferase (Lu et al.,
2000). pcDNA3.1-TOPO-Hey1-V5 was generated by inserting the Hey1 cDNA
(provided by Eric Olson) into the TOPO recognition site of pcDNA3.1D/V5-His-TOPO
(Invitrogen, Carlsbad, CA). pcDNA3.1-Hey1-V5 was generated by PCR sub-cloning the
Hey1 cDNA into the BamHI/EcoR1 sites of pcDNA3.1-V5/HisA (Invitrogen). G133mutMef2-luciferase and G133-mutE1-luciferase were generated by QuikChangemediated mutagenesis of the G133-luciferase Mef2 element (from [CTATATTTAT] to
[CTATACTTTAT] (Edmondson et al., 1992)) or E1 element (from [CAGTTG] to
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[AATTCG]), respectively. CMV-E47 has been described (Shen and Kadesch, 1995).
DamID lentiviral vectors pLgw-RFC1-V5-EcoDam and pLgw-V5-EcoDam (Vogel et al.,
2007) were provided by Bas Van Steensel (Netherlands Cancer Institute). pLgw-MyoDV5-EcoDam and pLgw-Hey1-V5-EcoDam were generated via the Gateway
recombination system (Invitrogen, Carlsbad, CA). The MyoD and Hey1 cDNAs were
first sub-cloned by PCR into the Gateway entry vector pENTR-3C. Resulting entry
clones were then recombined using LR Clonase II with the lentiviral destination vector
pLgw-RFC1-V5-EcoDam. pVSVG, pGag/Pol, and pRSV-REV were provided by Carl
June (University of Pennsylvania). All plasmids generated by PCR were verified by
sequencing.

Cell culture
C2C12 myoblasts, C3H 10T1/2 fibroblasts, and 293T cells were cultured in Dulbecco’s
modified Eagle medium (DMEM) containing 10% fetal bovine serum (FBS)
supplemented with L-glutamine and penicillin-streptomycin (growth medium, GM).
Human skeletal muscle myoblasts (SkMC and HSMM) were purchased from Cambrex
(East Rutherford, NJ) and maintained as directed by the manufacturer. For differentiation
of myoblasts, cells were grown to near confluence and then shifted to DMEM containing
0.5% FBS (differentiation medium, DM).
Notch signaling was induced by exposing the cells to immobilized ligand.
Conditioned medium was first prepared from 293T cells transfected with plasmids coding
for fusion proteins between Fcγ of human IgG and either the extracellular domain of
Notch ligand Delta-like-4 (Fc-Dll4) or that of Trail Receptor 4 (Fc-control). Culture
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plates were initially coated for 1 hour at room temperature with 10 µg/ml anti-Fc
antibody (Jackson Immunoresearch, West Grove, PA). The anti-Fc PBS solution was
then aspirated and replaced by filtered conditioned medium described above. Following 1
hour incubation, supernatant was aspirated and cells were plated.

Transfections and luciferase assays
10T1/2 cells were transfected according to the FuGENE 6 protocol (Roche Diagnostics,
Indianapolis, IN). For quantitative RT-PCR experiments, cells were seeded at a density of
5x104 cells per well in 6-well plates and transfected with a total of 1.5 µg of DNA per
well (pcDNA3.1/V5-HisA empty vector was used to keep the total amount of DNA
constant). Cultures were maintained in growth medium (GM) for 1 day post-transfection
and then switched to differentiation medium (DM) for 24 hours prior to isolation of
RNA. For luciferase assays, cells were seeded at a density of 1x104 cells per well in 24well plates and transfected with a total of 300 ng DNA. Cultures were maintained for 1
day in GM post-transfection and then switched to DM for 24 hours prior to harvesting of
lysates. Luciferase activity was determined using the Dual-Luciferase Reporter Assay
System (Promega, Madison, WI). Transfections were normalized to Renilla luciferase
(pRL-TK; Promega).

Microarray expression screen
2.5x106 C2C12 cells were plated on 10-cm dishes coated with either Fc-Dll4 or Fccontrol ligand (2.5 ml per dish) and grown in GM for 6 hours. RNA was harvested with
the RNeasy Kit (Qiagen, Valencia, CA). Three replicates were included for each
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condition. RNA was submitted to the University of Pennsylvania Microarray Core
Facility for subsequent transcript profiling analysis on Affymetrix MOE430v2.0
GeneChip arrays. Raw data was processed at the Penn Bioinformatics Core Facility using
Array Assist Lite (Stratagene, La Jolla, CA), Spotfire (Tibco,
Somerville, MA), and Significance Analysis of Microarrays (Stanford University).

Retroviral infections
Infections were performed as previously described (Pear et al., 1993) with minor
modifications. Briefly, retroviral supernatants were harvested from 293T cells two days
following FuGENE6 (Roche Diagnostics, Indianapolis, IN)-mediated transfection with 8
µg of the indicated pBABE vector and 2 µg of gag/pol and env helper plasmids.
Supernatants were filtered (0.4 µm) to remove non-adherent 293T cells prior to direct use
or storage at –80ºC. 18-24 hours prior to infection, C2C12 cells were plated on 6-well
plates at a density of ~1x105 cells/well. Each well was incubated for 4-6 hours with 1.5
ml viral supernatant supplemented with 8 µg/ml polybrene. 24-48 hours following
infection and subsequent re-plating on 10-cm dishes, selection was initiated with 2 µg/ml
puromycin and continued for 3-5 days to obtain stable lines.

siRNA knockdown
C2C12 cells were transfected with 100-150 nM of the indicated SMARTpool siRNA
oligonucleotides purchased from Dharmacon (Lafayette, CO). Transfections were
performed as specified by the manufacturer using the Dharmafect#3 reagent. Briefly,
myoblasts were plated on 12-well dishes at a density of ~1x104 cells per well the day
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prior to transfection. One day post-transfection, cells were trypsinized and re-plated on
ligand-coated 12-well plates. Wells were coated with 400 µl of Fc-control supernatant
and either 15 µl (Figures 2.7 & 2.8), 100 µl (Figures 2.17 & 2.18), or 80 µl (Figures 2.192.21) of Fc-Dll4 supernatant; the total ligand volume on Fc-Dll4-coated wells was kept
constant (400 µl) by mixing Fc-control supernatant as required. Cultures were switched
from GM to DM one day following re-plating and harvested for RNA after an additional
24-72 hours as indicated. For the double knockdown, a mixture of 110 nM Hey1 siRNA
and 40 nM MyoR siRNA was employed.

Semi-quantitative and quantitative RT-PCR
Total RNA was isolated from C2C12 cultures using the RNeasy kit (Qiagen, Valencia,
CA). 0.125 to 2 µg of RNA was used to generate cDNA with the High Capacity cDNA
Archive Kit (Applied Biosystems, Foster City, CA). For semi-quantitative RT-PCR, 5%
of the cDNA was included in each PCR reaction. Products were run out on 1.5% agarose
gels and visualized by ethidium bromide staining. For quantitative PCR, TaqMan gene
expression assays were employed for MyoD, Myf-5, Myogenin, Mef2C, Myh3, Hey1,
Hey2, HeyL, MyoR, IL-6, Id3, ABF-1, Cadherin-15, GATA3, EGFR, MIG6, and 18S as
an endogenous control (Applied Biosystems). 1-4% of a given cDNA reaction, 10 µl of
2X Taq Universal Mastermix, and 1 µl of the indicated 20X TaqMan assay were included
in a 20 µl reaction volume per well. All reactions were performed in triplicate. Results
were analyzed using the SDS2.2 Software (Applied Biosystems). Primer sequences used
for SQ-RT-PCR are as follows:
HPRT 5’-GTTGGATACAGGCCAGACTTTGTTG-3’ and
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5’-TGGGGACGCAGCAACTGACATTTCT-3’;
Myogenin 5'-GCGGACTGAGCTCAGCTTAAG-3' and
5'- GCTGTCCACGATGGACGTAAG-3';
MEF2A, 5'-TTGGAATGAACAGTCGGAAAC-3' and 5'CTAGTCCCTGTGGAGGCAAG-3’;
MEF2C, 5'-GAGAAGCAGAAAGGCACTGG-3' and 5'ATCTCACAGTCGCACAGCAC-3’;
MEF2D, 5'-AGCTCTCTGGTCACTCCTTCC-3' and 5'GCCCTGGCTGAGTAAACTTG-3';
GAPDH, 5'-AACGGATTTGGTCGTATTGGG-3' and
5'-TGGAAGGATGGTGATGGGATTTC-3';
Hey1 5’- GAAGCGCCGACGAGACCGAATCAA-3’ and
5’-CAGGGCGTGCGCGTCAAAATAACC-3’;
Hey2 5'-CGACGTGGGGAGCGAGAACAAT-3’ and
5'-GGCAAGAGCATGGGCATCAAAGTA-3';
HeyL 5’- GGTCCCCACTGCCTTTGAGA-3’ and
5’- TAGCTGACTGCTCAGGGAAGGCAA-3’;
Nrarp 5’- TGGTGAAGCTGTTGGTCAAG-3’ and 5’GTAGTTGGCGGGAAGGTACA-3’;
IL-6 5’- CCGGAGAGGAGACTTCACAG-3’ and 5’GGAAATTGGGGTAGGAAGGA-3’;
Trib2 5’- GCAACATCAACCAAATCACG-3’ and 5’GCGTCTTCCAAACTCTCCAG-3’; 8430408G22Rik 5’-CTCCTGCCACCCTGACTG142
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3’ and 5’- TGGGCTGTGACCTTGTCC-3’; MyoR (Figures 2.9 & 2.10) 5’GCTACGAGGACAGCTATGTGC-3’ and
5’-AGGAGGGCAAACAACACTTG-3’;
MyoR (Figure 2.14) 5’-GGGAGGATGCAAGAGGAAG-3’ and
5’-CGTCCAGAGACCACGAATG-3’;
Id3 5’-GCCTCTTGGACGACATGAA-3’ and 5’-GGCGTTGAGTTCAGGGTAAG-3’.

Western immunoblot analysis
Protein lysates for Western blots were prepared from cultured cells using RIPA lysis
buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1%
SDS) or a modified lysis buffer (10 mM Tris pH 7.3, 150 mM NaCl, 1% NP-40)
supplemented with freshly added protease inhibitor cocktail (Roche Diagnostics,
Indianapolis, IN), 10 mM sodium fluoride, and 400 µM sodium orthovanadate. Lysates
were incubated on ice for 15 minutes and cleared by centrifugation. Protein
concentrations were determined using the DC Assay (Bio-Rad, Hercules, CA). 25-50 µg
of lysate was added to 2X or 6X SDS sample buffer and boiled for 5 minutes prior to
analysis by SDS-PAGE. Proteins were transferred to nitrocellulose and blotted with the
following antibodies at the indicated dilutions: 1:1000 ß-tubulin (Sigma T-5293, St.
Louis, MO), 1:500 Myogenin (Santa Cruz M-225, Santa Cruz, CA), 1:20 MHC (MF20,
Developmental Studies Hybridoma Bank), 1:2000 cleaved Notch1 (Cell Signaling 2421,
Danvers, MA), 1:500 FLAG (Abcam ab6711-200, Cambridge, MA) or 1:1000 FLAG
(Sigma M2), 1:500 MyoR (Santa Cruz M-20), 1:5000 anti-Mre11 (Novus NB 100142G1, Littleton, CO), 1:500 anti-GFP (Santa Cruz sc-8334), 1:1000 anti-E47
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(BD/Pharmingen G127-32, San Jose, CA). After incubation with 1:2000 dilutions of
HRP-conjugated anti-rabbit, anti-mouse, or anti-goat secondary antibodies (Amersham,
Piscataway, NJ), bands were visualized via the LumiLight or LumiLight-plus detection
system (Roche, Indianapolis, IN).

Co-immunoprecipitation assays
For immunoprecipitations, 293T cells were harvested ~48 hours post-transfection by
scraping into lysis buffer (20 mM Tris-HCl pH 8.0, 100 mM KCl, 0.1% NP-40, 5 mM
MgCl2, 10% glycerol) supplemented with freshly added protease inhibitor cocktail
(Roche Diagnostics, Indianapolis, IN), 10 mM sodium fluoride, and 400 µM sodium
orthovanadate (Iso et al., 2001b). Lysates were incubated on ice for 15 minutes and
cleared by centrifugation. Protein concentrations were determined using the DC Assay
(Bio-Rad Laboratories, Hercules, CA). Lysates were pre-cleared in lysis buffer
supplemented with 50 µl proteinA/G PLUS-agarose and 4 µg normal rabbit IgG (Santa
Cruz Biotechnology sc-2027, Santa Cruz, CA) for 2 hours at 4°C. 500 µg of pre-cleared
lysate was incubated with 2 µg of anti-MyoD (Novocastra 5.8A, Newcastle upon Tyne,
United Kingdom), anti-E47 (BD/Pharmingen G127-32, San Jose, CA), or anti-Myc
(Santa Cruz Biotechnology sc-40 9E10, Santa Cruz, CA) antibody and 15 µl of protein
A/G PLUS-agarose at 4°C overnight. Immune complexes were washed 4X with lysis
buffer, eluted in 2X SDS sample buffer, and boiled for 5 minutes prior to resolution by
SDS-PAGE. Proteins were transferred to nitrocellulose and blotted with the following
antibodies at the indicated dilutions: 1:5000 anti-V5 (Invitrogen, Carlsbad, CA), 1:1000
anti-E47 (BD/Pharmingen), 1:500 anti-MyoD (Novocastra 5.8A), 1:1000 anti-Myc
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(Santa Cruz 9E10). After incubation with a 1:2000 dilution of HRP-conjugated antimouse secondary antibody (Amersham, Piscataway, NJ), bands were visualized via the
LumiLight or LumiLight-plus detection system (Roche Diagnostics, Indianapolis, IN).

Electrophoretic mobility shift assays (EMSAs)
Nuclear extracts for EMSAs were prepared from 293T or C2C12 cells using the
NXTRACT CelLytic NuCLEAR Extraction Kit (Sigma, St. Louis, MO). 293T cells were
transiently transfected with either 2 µg EMSV-MyoD and 2 µg CMV-E47, or 4 µg
pcDNA3.1/Myc-HisC (Invitrogen, Carlsbad, CA), 48 hours prior to harvesting of
extracts. C2C12 cells seeded on Fc-control or Fc-Dll4 ligands or stably transduced with
pBABE-puro or pBABE-FLAG-Hey1 were maintained in 0.5% serum for 24 hours prior
to extract isolation. Hey1-V5 was transcribed and translated in-vitro using the TNT T7
Coupled Reticulocyte Lysate System (Promega, Madison, WI). 32P-labeled
oligonucleotide probes containing the Mef2C E-box (Wang et al., 2001) or the Hey1
consensus target E-box (Fischer et al., 2002; Pichon et al., 2004) were prepared by endlabeling annealed oligonucleotides with [γ-32P] ATP using T4 polynucleotide kinase
(New England Biolabs, Ipswich, MA). Labeled probes were purified through G-25 Quick
Spin Sephadex Columns (Roche Diagnostics, Indianapolis, IN) as specified by the
manufacturer. 8 µg of nuclear extract or 8 µl of TNT lysate was incubated for 15 minutes
at room temperature with 100,000 cpm of probe in a 15 µl binding reaction consisting of
0.2-1.0 µg poly dI:dC, 10 mM Tris pH 7.5, 50 mM NaCl, 1 mM EDTA, 1 mM DTT, and
5.4% glycerol. Prior to addition of probe, extract was pre-incubated in binding buffer at
room temperature for ten minutes. Where indicated, 50X excess of cold competitor probe
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was added to the reaction. For supershifts, 1 µg of anti-MyoD (Novocastra 5.8A,
Newcastle upon Tyne, United Kingdom) or 1 µg of anti-V5 (Invitrogen) antibody was
added to the sample and incubated for an additional 15 minutes. Binding reactions were
run out on 5% non-denaturing polyacrylamide TBE Ready Gels (Bio-Rad Laboratories,
Hercules, CA) in 0.5X TBE. Gels were dried and visualized by autoradiography.
Oligonucleotide sequences used for the generation of labeled probes and cold competitors
are as follows, with E-boxes or N-boxes underlined: MEF2C.F
GAGTGACATGAACAGGTGCACCCTGGCCT; MEF2C.R
AGGCCAGGGTGCACCTGTTCATGTCACTC; HCE.F
TCCAATGGCACGTGCCACTGCC; HCE.R GGCAGTGGCACGTGCCATTGGA;
ΔHCE.F TCCAATGGGCCGTACCACTGCC; ΔHCE.R
GGCAGTGGTACGGCCCATTGGA; E1.F CACCCAGCAGTTGGTGTGAG; E1.R
CTCACACCAACTGCTGGGTG; N1.F TGCCCTGTCCACCAGCTGCCTTG; N1.R
CAAGGCAGCTGGTGGACAGGGCA; E2.F
GAAGGGGAATCACATGTAATCCACTG; E2.R
CAGTGGATTACATGTGATTCCCCTTC.

DamID
DamID assays were carried out essentially as described (Vogel et al., 2007), with minor
modifications. Briefly, lentiviral supernatants were harvested from 10-cm dishes of 293T
cells on three consecutive days, two days following FuGENE6 (Roche Diagnostics,
Indianapolis, IN)-mediated transfection with 10 µg of the indicated pLgw lentiviral
vector, 3.5 µg of pVSVG, 6.5 µg of pGag/Pol, and 2.5 µg of pRSV-REV. Supernatants
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were filtered (0.4 µm) to remove non-adherent 293T cells prior to storage at –80ºC. ~18
hours prior to infection, C2C12 cells were plated on 6-well plates at a density of 1x105
cells/well. Each well was incubated overnight with 1.5 ml viral supernatant, diluted ~2:1
in growth medium. After removal of virus, cultures were maintained for two days in GM
and then switched to DM for an additional 24 hours. Genomic DNA was isolated with the
DNeasy Tissue Kit (Qiagen, Valencia, CA). Following ethanol precipitation of gDNA,
DpnI digestion, ligation of adaptors, DpnII digestion, and ligation-mediated PCR (11
cycles of amplification in the final stage of PCR), samples were purified with Qiagen
columns and diluted 1:60 in buffer EB prior to Q-PCR analysis (Reddy et al., 2008). 8 µl
of a diluted sample was mixed with 10 µl 2X Power-SYBR green mastermix (Applied
Biosystems, Foster City, CA), 1 µl of 2 µM forward primer, and 1 µl of 2 µM reverse
primer. PCR primers were first tested on genomic DNA via semi-quantitative PCR to
verify amplification of a single product of the expected size. Q-PCR reactions were also
subjected to dissociation curve analysis. Primer sequences are as follows: Myog.F
GTGGACTGGCACAGGAGAAC; Myog.R GTGGACTTGGGACAAAGCAG;
Mef2C.F GAGAAGCAGAAAGGCACTGG; Mef2C.R
CATTTCCAGCTCACTCATCATC; IgH.F GTCATGTGGCAAGGCTATTTG; IgH.R
TTTGCTCAGCCTGGACTTTC; GAPDH.F CTCACGTCCCAACTCTCCAC;
GAPDH.R GGCCTCCTATAGTATCCCTCCTC.
Primers for GAPDH and IgH are located directly within the proximal promoter and
enhancer, respectively. Primers for Mef2C and Myogenin are located ~200 bp and ~700
bp downstream of the transcriptional start sites, respectively, due to the unfavorable
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distribution of DpnI sites within the promoter regions; DpnI-generated fragments larger
than 2 kb are not efficiently amplified in the ligation-mediated PCR step.

Chromatin immunoprecipitation assays
chIP was performed as previously described (Caretti et al., 2004), with minor
modifications. C2C12 cells stably transduced with pBABE-puro or pBABE-FLAG-Hey1
were seeded on 15-cm dishes at a density of 1.25-1.4 x 106 cells per plate, maintained in
GM for 2 days, and then switched to DM for 40 hours. Cultures were fixed in 1%
formaldehyde for 10 minutes at room temperature, incubated for 5 minutes in 0.125 M
glycine, washed twice in cold PBS, and scraped into 3 ml PBS. Following brief
centrifugation, cell pellets were resuspended in 500 µl cell lysis buffer (5 mM Pipes pH
8.0, 85 mM KCl, 0.5% NP-40) supplemented with 1 mM PMSF and protease inhibitor
cocktail (Roche Diagnostics, Indianapolis, IN), incubated on ice for 10 minutes, and
dounced 15X to facilitate nuclei release. After a 5-minute centrifugation at 5000 rpm,
nuclei were resuspended in 300 µl nuclei lysis buffer (50 mM Tris-Cl pH 8.1, 10 mM
EDTA, 1% SDS, 1 mM PMSF, protease inhibitor cocktail) and incubated on ice for 10
minutes. Samples were sonicated in ice water using a Misonix 3000 sonicator for three
10-second intervals interrupted by 1 minute rests, followed by a 10-minute centrifugation
at 14,000 rpm at 4°C. Supernatants were transferred to clean tubes, diluted 1:10 with
dilution buffer (0.5% Trition X-100, 2 mM EDTA, 20 mM Tris-Cl pH 8.1, 150 mM
NaCl), and pre-cleared with protein A/G agarose-ssDNA (Upstate Biotechnology,
Billerica, MA) for 2 hours. 250 µg pre-cleared chromatin was incubated with 4 µg of
normal rabbit IgG (Santa Cruz sc-2027, Santa Cruz, CA), 4 µg of anti-MyoD (Santa Cruz
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M-318X), or 4 µg anti-RNA-Pol II (Santa Cruz H-224X) antibody overnight with
rotation at 4°C. Immune complexes were collected with BSA-blocked protein A/G
agarose-ssDNA for 2 hours. Beads were washed eight times as follows: 2X buffer 1
(0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris, pH 8.1, 150 mM NaCl), 2X
buffer 2 (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris, pH 8.1, 500 mM
NaCl), 2X buffer 1, 1X buffer 3 (0.25 M LiCl, 1% NP-40, 1% deoxycholate, 1 mM
EDTA, 10 mM Tris, pH 8.1), 1X TE. Washed beads were incubated twice in 150 µl
elution buffer (1% SDS, 100 mM NaHC03) for 15 minutes at 65°C. Pooled eluates were
treated with DNase-free RNase (Roche Diagnostics, Indianapolis, IN) and incubated at
65°C overnight to reverse crosslinks. Following proteinase K treatment,
phenol:chloroform extraction, and ethanol precipitation, samples were analyzed by QPCR. 2 µl of a 50 µl sample was mixed with 10 µl 2X Power-SYBR green mastermix
(Applied Biosystems, Foster City, CA), 6 µl water, 1 µl of 2 µM forward primer, and 1 µl
of 2 µM reverse primer. PCR primer sequences for the Myogenin promoter and IgH
enhancer have been published (Bergstrom et al., 2002; Mal and Harter, 2003). Primers
for the Mef2C promoter are as follows: Mef2C.F2 GAGCAGTTCTGTGTTCTTTTGC;
Mef2C.R2 ATCCCTCTGCACAAGTGTCTG.
(Iso et al., 2003)

149
92

Chapter VI. References
Amsen, D., Antov, A., Jankovic, D., Sher, A., Radtke, F., Souabni, A., Busslinger, M.,
McCright, B., Gridley, T., and Flavell, R.A. (2007). Direct regulation of Gata3
expression determines the T helper differentiation potential of Notch. Immunity 27, 8999.
Andres, V., and Walsh, K. (1996). Myogenin expression, cell cycle withdrawal, and
phenotypic differentiation are temporally separable events that precede cell fusion upon
myogenesis. J Cell Biol 132, 657-666.
Artavanis-Tsakonas, S., Rand, M.D., and Lake, R.J. (1999). Notch signaling: cell fate
control and signal integration in development. Science 284, 770-776.
Atherton, G.T., Travers, H., Deed, R., and Norton, J.D. (1996). Regulation of cell
differentiation in C2C12 myoblasts by the Id3 helix-loop-helix protein. Cell Growth
Differ 7, 1059-1066.
Bae, G.U., Kim, B.G., Lee, H.J., Oh, J.E., Lee, S.J., Zhang, W., Krauss, R.S., and Kang,
J.S. (2009). Cdo binds Abl to promote p38alpha/beta mitogen-activated protein kinase
activity and myogenic differentiation. Mol Cell Biol 29, 4130-4143.
Bailey, A.M., and Posakony, J.W. (1995). Suppressor of hairless directly activates
transcription of enhancer of split complex genes in response to Notch receptor activity.
Genes Dev 9, 2609-2622.
Barolo, S., Stone, T., Bang, A.G., and Posakony, J.W. (2002). Default repression and
Notch signaling: Hairless acts as an adaptor to recruit the corepressors Groucho and
dCtBP to Suppressor of Hairless. Genes Dev 16, 1964-1976.
Barton-Davis, E.R., Shoturma, D.I., Musaro, A., Rosenthal, N., and Sweeney, H.L.
(1998). Viral mediated expression of insulin-like growth factor I blocks the aging-related
loss of skeletal muscle function. Proc Natl Acad Sci U S A 95, 15603-15607.
Baylies, M.K., Bate, M., and Ruiz Gomez, M. (1998). Myogenesis: a view from
Drosophila. Cell 93, 921-927.
Benezra, R., Davis, R.L., Lockshon, D., Turner, D.L., and Weintraub, H. (1990). The
protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell 61, 49-59.

150
93

Berdnik, D., Torok, T., Gonzalez-Gaitan, M., and Knoblich, J.A. (2002). The endocytic
protein alpha-Adaptin is required for numb-mediated asymmetric cell division in
Drosophila. Dev Cell 3, 221-231.
Berghella, L., De Angelis, L., De Buysscher, T., Mortazavi, A., Biressi, S., Forcales,
S.V., Sirabella, D., Cossu, G., and Wold, B.J. (2008). A highly conserved molecular
switch binds MSY-3 to regulate myogenin repression in postnatal muscle. Genes Dev 22,
2125-2138.
Bergstrom, D.A., Penn, B.H., Strand, A., Perry, R.L., Rudnicki, M.A., and Tapscott, S.J.
(2002). Promoter-specific regulation of MyoD binding and signal transduction cooperate
to pattern gene expression. Mol Cell 9, 587-600.
Bergstrom, D.A., and Tapscott, S.J. (2001). Molecular distinction between specification
and differentiation in the myogenic basic helix-loop-helix transcription factor family.
Mol Cell Biol 21, 2404-2412.
Berkes, C.A., Bergstrom, D.A., Penn, B.H., Seaver, K.J., Knoepfler, P.S., and Tapscott,
S.J. (2004). Pbx marks genes for activation by MyoD indicating a role for a
homeodomain protein in establishing myogenic potential. Mol Cell 14, 465-477.
Bessho, Y., Miyoshi, G., Sakata, R., and Kageyama, R. (2001). Hes7: a bHLH-type
repressor gene regulated by Notch and expressed in the presomitic mesoderm. Genes
Cells 6, 175-185.
Black, B.L., and Olson, E.N. (1998). Transcriptional control of muscle development by
myocyte enhancer factor-2 (MEF2) proteins. Annu Rev Cell Dev Biol 14, 167-196.
Blau, H.M., Pavlath, G.K., Hardeman, E.C., Chiu, C.P., Silberstein, L., Webster, S.G.,
Miller, S.C., and Webster, C. (1985). Plasticity of the differentiated state. Science 230,
758-766.
Blaumueller, C.M., Qi, H., Zagouras, P., and Artavanis-Tsakonas, S. (1997). Intracellular
cleavage of Notch leads to a heterodimeric receptor on the plasma membrane. Cell 90,
281-291.
Bober, E., Franz, T., Arnold, H.H., Gruss, P., and Tremblay, P. (1994). Pax-3 is required
for the development of limb muscles: a possible role for the migration of dermomyotomal
muscle progenitor cells. Development 120, 603-612.

151
94

Brack, A.S., Conboy, I.M., Conboy, M.J., Shen, J., and Rando, T.A. (2008). A temporal
switch from notch to Wnt signaling in muscle stem cells is necessary for normal adult
myogenesis. Cell Stem Cell 2, 50-59.
Brack, A.S., Conboy, M.J., Roy, S., Lee, M., Kuo, C.J., Keller, C., and Rando, T.A.
(2007). Increased Wnt signaling during aging alters muscle stem cell fate and increases
fibrosis. Science 317, 807-810.
Braun, T., Bober, E., Winter, B., Rosenthal, N., and Arnold, H.H. (1990). Myf-6, a new
member of the human gene family of myogenic determination factors: evidence for a
gene cluster on chromosome 12. EMBO J 9, 821-831.
Braun, T., Buschhausen-Denker, G., Bober, E., Tannich, E., and Arnold, H.H. (1989). A
novel human muscle factor related to but distinct from MyoD1 induces myogenic
conversion in 10T1/2 fibroblasts. EMBO J 8, 701-709.
Braun, T., Rudnicki, M.A., Arnold, H.H., and Jaenisch, R. (1992). Targeted inactivation
of the muscle regulatory gene Myf-5 results in abnormal rib development and perinatal
death. Cell 71, 369-382.
Briata, P., Forcales, S.V., Ponassi, M., Corte, G., Chen, C.Y., Karin, M., Puri, P.L., and
Gherzi, R. (2005). p38-dependent phosphorylation of the mRNA decay-promoting factor
KSRP controls the stability of select myogenic transcripts. Mol Cell 20, 891-903.
Brou, C., Logeat, F., Gupta, N., Bessia, C., LeBail, O., Doedens, J.R., Cumano, A., Roux,
P., Black, R.A., and Israel, A. (2000). A novel proteolytic cleavage involved in Notch
signaling: the role of the disintegrin-metalloprotease TACE. Mol Cell 5, 207-216.
Bruckner, K., Perez, L., Clausen, H., and Cohen, S. (2000). Glycosyltransferase activity
of Fringe modulates Notch-Delta interactions. Nature 406, 411-415.
Cabrera, C.V. (1990). Lateral inhibition and cell fate during neurogenesis in Drosophila:
the interactions between scute, Notch and Delta. Development 110, 733-742.
Cantini, M., Massimino, M.L., Rapizzi, E., Rossini, K., Catani, C., Dalla Libera, L., and
Carraro, U. (1995). Human satellite cell proliferation in vitro is regulated by autocrine
secretion of IL-6 stimulated by a soluble factor(s) released by activated monocytes.
Biochem Biophys Res Commun 216, 49-53.
Caretti, G., Di Padova, M., Micales, B., Lyons, G.E., and Sartorelli, V. (2004). The
Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle
differentiation. Genes Dev 18, 2627-2638.
152
95

Carlson, B.M. (1973). The regeneration of skeletal muscle. A review. Am J Anat 137,
119-149.
Carlson, M.E., Hsu, M., and Conboy, I.M. (2008). Imbalance between pSmad3 and
Notch induces CDK inhibitors in old muscle stem cells. Nature 454, 528-532.
Cerletti, M., Jurga, S., Witczak, C.A., Hirshman, M.F., Shadrach, J.L., Goodyear, L.J.,
and Wagers, A.J. (2008). Highly efficient, functional engraftment of skeletal muscle stem
cells in dystrophic muscles. Cell 134, 37-47.
Cheng, T.C., Wallace, M.C., Merlie, J.P., and Olson, E.N. (1993). Separable regulatory
elements governing myogenin transcription in mouse embryogenesis. Science 261, 215218.
Chitnis, A.B. (1995). The role of Notch in lateral inhibition and cell fate specification.
Mol Cell Neurosci 6, 311-321.
Cole, F., Zhang, W., Geyra, A., Kang, J.S., and Krauss, R.S. (2004). Positive regulation
of myogenic bHLH factors and skeletal muscle development by the cell surface receptor
CDO. Dev Cell 7, 843-854.
Collins, C.A., Olsen, I., Zammit, P.S., Heslop, L., Petrie, A., Partridge, T.A., and
Morgan, J.E. (2005). Stem cell function, self-renewal, and behavioral heterogeneity of
cells from the adult muscle satellite cell niche. Cell 122, 289-301.
Conboy, I.M., Conboy, M.J., Smythe, G.M., and Rando, T.A. (2003). Notch-mediated
restoration of regenerative potential to aged muscle. Science 302, 1575-1577.
Conboy, I.M., Conboy, M.J., Wagers, A.J., Girma, E.R., Weissman, I.L., and Rando,
T.A. (2005). Rejuvenation of aged progenitor cells by exposure to a young systemic
environment. Nature 433, 760-764.
Conboy, I.M., and Rando, T.A. (2002). The regulation of Notch signaling controls
satellite cell activation and cell fate determination in postnatal myogenesis. Dev Cell 3,
397-409.
Conlon, R.A., Reaume, A.G., and Rossant, J. (1995). Notch1 is required for the
coordinate segmentation of somites. Development 121, 1533-1545.
Coolican, S.A., Samuel, D.S., Ewton, D.Z., McWade, F.J., and Florini, J.R. (1997). The
mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling
pathways. J Biol Chem 272, 6653-6662.
153
96

Cooper, R.N., Tajbakhsh, S., Mouly, V., Cossu, G., Buckingham, M., and ButlerBrowne, G.S. (1999). In vivo satellite cell activation via Myf5 and MyoD in regenerating
mouse skeletal muscle. J Cell Sci 112 ( Pt 17), 2895-2901.
Cornelison, D.D., and Wold, B.J. (1997). Single-cell analysis of regulatory gene
expression in quiescent and activated mouse skeletal muscle satellite cells. Dev Biol 191,
270-283.
Davis, R.L., and Weintraub, H. (1992). Acquisition of myogenic specificity by
replacement of three amino acid residues from MyoD into E12. Science 256, 1027-1030.
Davis, R.L., Weintraub, H., and Lassar, A.B. (1987). Expression of a single transfected
cDNA converts fibroblasts to myoblasts. Cell 51, 987-1000.
de Angelis, L., Zhao, J., Andreucci, J.J., Olson, E.N., Cossu, G., and McDermott, J.C.
(2005). Regulation of vertebrate myotome development by the p38 MAP kinase-MEF2
signaling pathway. Dev Biol 283, 171-179.
de la Serna, I.L., Carlson, K.A., and Imbalzano, A.N. (2001). Mammalian SWI/SNF
complexes promote MyoD-mediated muscle differentiation. Nat Genet 27, 187-190.
de la Serna, I.L., Ohkawa, Y., Berkes, C.A., Bergstrom, D.A., Dacwag, C.S., Tapscott,
S.J., and Imbalzano, A.N. (2005). MyoD targets chromatin remodeling complexes to the
myogenin locus prior to forming a stable DNA-bound complex. Mol Cell Biol 25, 39974009.
De Strooper, B., Annaert, W., Cupers, P., Saftig, P., Craessaerts, K., Mumm, J.S.,
Schroeter, E.H., Schrijvers, V., Wolfe, M.S., Ray, W.J., et al. (1999). A presenilin-1dependent gamma-secretase-like protease mediates release of Notch intracellular domain.
Nature 398, 518-522.
Dodou, E., Xu, S.M., and Black, B.L. (2003). mef2c is activated directly by myogenic
basic helix-loop-helix proteins during skeletal muscle development in vivo. Mech Dev
120, 1021-1032.
Du, K., Herzig, S., Kulkarni, R.N., and Montminy, M. (2003). TRB3: a tribbles homolog
that inhibits Akt/PKB activation by insulin in liver. Science 300, 1574-1577.
Edmondson, D.G., Cheng, T.C., Cserjesi, P., Chakraborty, T., and Olson, E.N. (1992).
Analysis of the myogenin promoter reveals an indirect pathway for positive
autoregulation mediated by the muscle-specific enhancer factor MEF-2. Mol Cell Biol
12, 3665-3677.
154
97

Elagib, K.E., Xiao, M., Hussaini, I.M., Delehanty, L.L., Palmer, L.A., Racke, F.K.,
Birrer, M.J., Shanmugasundaram, G., McDevitt, M.A., and Goldfarb, A.N. (2004). Jun
blockade of erythropoiesis: role for repression of GATA-1 by HERP2. Mol Cell Biol 24,
7779-7794.
Epstein, J.A., Shapiro, D.N., Cheng, J., Lam, P.Y., and Maas, R.L. (1996). Pax3
modulates expression of the c-Met receptor during limb muscle development. Proc Natl
Acad Sci U S A 93, 4213-4218.
Fang, T.C., Yashiro-Ohtani, Y., Del Bianco, C., Knoblock, D.M., Blacklow, S.C., and
Pear, W.S. (2007). Notch directly regulates Gata3 expression during T helper 2 cell
differentiation. Immunity 27, 100-110.
Fehon, R.G., Kooh, P.J., Rebay, I., Regan, C.L., Xu, T., Muskavitch, M.A., and
Artavanis-Tsakonas, S. (1990). Molecular interactions between the protein products of
the neurogenic loci Notch and Delta, two EGF-homologous genes in Drosophila. Cell 61,
523-534.
Ferrari, G., Cusella-De Angelis, G., Coletta, M., Paolucci, E., Stornaiuolo, A., Cossu, G.,
and Mavilio, F. (1998). Muscle regeneration by bone marrow-derived myogenic
progenitors. Science 279, 1528-1530.
Fischer, A., and Gessler, M. (2007). Delta-Notch--and then? Protein interactions and
proposed modes of repression by Hes and Hey bHLH factors. Nucleic Acids Res 35,
4583-4596.
Fischer, A., Klattig, J., Kneitz, B., Diez, H., Maier, M., Holtmann, B., Englert, C., and
Gessler, M. (2005). Hey basic helix-loop-helix transcription factors are repressors of
GATA4 and GATA6 and restrict expression of the GATA target gene ANF in fetal
hearts. Mol Cell Biol 25, 8960-8970.
Fischer, A., Leimeister, C., Winkler, C., Schumacher, N., Klamt, B., Elmasri, H., Steidl,
C., Maier, M., Knobeloch, K.P., Amann, K., et al. (2002). Hey bHLH factors in
cardiovascular development. Cold Spring Harb Symp Quant Biol 67, 63-70.
Fischer, A., Schumacher, N., Maier, M., Sendtner, M., and Gessler, M. (2004). The
Notch target genes Hey1 and Hey2 are required for embryonic vascular development.
Genes Dev 18, 901-911.
Fischer, A., Steidl, C., Wagner, T.U., Lang, E., Jakob, P.M., Friedl, P., Knobeloch, K.P.,
and Gessler, M. (2007). Combined loss of Hey1 and HeyL causes congenital heart
defects because of impaired epithelial to mesenchymal transition. Circ Res 100, 856-863.
155
98

Fleming, R.J., Scottgale, T.N., Diederich, R.J., and Artavanis-Tsakonas, S. (1990). The
gene Serrate encodes a putative EGF-like transmembrane protein essential for proper
ectodermal development in Drosophila melanogaster. Genes Dev 4, 2188-2201.
Fortini, M.E., and Artavanis-Tsakonas, S. (1994). The suppressor of hairless protein
participates in notch receptor signaling. Cell 79, 273-282.
Fryer, C.J., Lamar, E., Turbachova, I., Kintner, C., and Jones, K.A. (2002). Mastermind
mediates chromatin-specific transcription and turnover of the Notch enhancer complex.
Genes Dev 16, 1397-1411.
Fryer, C.J., White, J.B., and Jones, K.A. (2004). Mastermind recruits CycC:CDK8 to
phosphorylate the Notch ICD and coordinate activation with turnover. Mol Cell 16, 509520.
Garg, V., Muth, A.N., Ransom, J.F., Schluterman, M.K., Barnes, R., King, I.N.,
Grossfeld, P.D., and Srivastava, D. (2005). Mutations in NOTCH1 cause aortic valve
disease. Nature 437, 270-274.
Gerber, A.N., Klesert, T.R., Bergstrom, D.A., and Tapscott, S.J. (1997). Two domains of
MyoD mediate transcriptional activation of genes in repressive chromatin: a mechanism
for lineage determination in myogenesis. Genes Dev 11, 436-450.
Gessler, M., Knobeloch, K.P., Helisch, A., Amann, K., Schumacher, N., Rohde, E.,
Fischer, A., and Leimeister, C. (2002). Mouse gridlock: no aortic coarctation or
deficiency, but fatal cardiac defects in Hey2 -/- mice. Curr Biol 12, 1601-1604.
Ghosh, B., and Leach, S.D. (2006). Interactions between hairy/enhancer of split-related
proteins and the pancreatic transcription factor Ptf1-p48 modulate function of the PTF1
transcriptional complex. Biochem J 393, 679-685.
Gordon, W.R., Vardar-Ulu, D., Histen, G., Sanchez-Irizarry, C., Aster, J.C., and
Blacklow, S.C. (2007). Structural basis for autoinhibition of Notch. Nat Struct Mol Biol
14, 295-300.
Goulding, M., Lumsden, A., and Paquette, A.J. (1994). Regulation of Pax-3 expression in
the dermomyotome and its role in muscle development. Development 120, 957-971.
Greil, F., Moorman, C., and van Steensel, B. (2006). DamID: mapping of in vivo proteingenome interactions using tethered DNA adenine methyltransferase. Methods Enzymol
410, 342-359.
156
99

Gros, J., Manceau, M., Thome, V., and Marcelle, C. (2005). A common somitic origin for
embryonic muscle progenitors and satellite cells. Nature 435, 954-958.
Gussoni, E., Soneoka, Y., Strickland, C.D., Buzney, E.A., Khan, M.K., Flint, A.F.,
Kunkel, L.M., and Mulligan, R.C. (1999). Dystrophin expression in the mdx mouse
restored by stem cell transplantation. Nature 401, 390-394.
Hasty, P., Bradley, A., Morris, J.H., Edmondson, D.G., Venuti, J.M., Olson, E.N., and
Klein, W.H. (1993). Muscle deficiency and neonatal death in mice with a targeted
mutation in the myogenin gene. Nature 364, 501-506.
Heitzler, P., and Simpson, P. (1991). The choice of cell fate in the epidermis of
Drosophila. Cell 64, 1083-1092.
Heron-Milhavet, L., Mamaeva, D., Rochat, A., Lamb, N.J., and Fernandez, A. (2007).
Akt2 is implicated in skeletal muscle differentiation and specifically binds
Prohibitin2/REA. J Cell Physiol 214, 158-165.
Hicks, C., Johnston, S.H., diSibio, G., Collazo, A., Vogt, T.F., and Weinmaster, G.
(2000). Fringe differentially modulates Jagged1 and Delta1 signalling through Notch1
and Notch2. Nat Cell Biol 2, 515-520.
Holderfield, M.T., Henderson Anderson, A.M., Kokubo, H., Chin, M.T., Johnson, R.L.,
and Hughes, C.C. (2006). HESR1/CHF2 suppresses VEGFR2 transcription independent
of binding to E-boxes. Biochem Biophys Res Commun 346, 637-648.
Hrabe de Angelis, M., McIntyre, J., 2nd, and Gossler, A. (1997). Maintenance of somite
borders in mice requires the Delta homologue DII1. Nature 386, 717-721.
Huang, Q., Raya, A., DeJesus, P., Chao, S.H., Quon, K.C., Caldwell, J.S., Chanda, S.K.,
Izpisua-Belmonte, J.C., and Schultz, P.G. (2004). Identification of p53 regulators by
genome-wide functional analysis. Proc Natl Acad Sci U S A 101, 3456-3461.
Huppert, S.S., Le, A., Schroeter, E.H., Mumm, J.S., Saxena, M.T., Milner, L.A., and
Kopan, R. (2000). Embryonic lethality in mice homozygous for a processing-deficient
allele of Notch1. Nature 405, 966-970.
Ishibashi, J., Perry, R.L., Asakura, A., and Rudnicki, M.A. (2005). MyoD induces
myogenic differentiation through cooperation of its NH2- and COOH-terminal regions. J
Cell Biol 171, 471-482.

157
100

Ishibashi, M., Ang, S.L., Shiota, K., Nakanishi, S., Kageyama, R., and Guillemot, F.
(1995). Targeted disruption of mammalian hairy and Enhancer of split homolog-1 (HES1) leads to up-regulation of neural helix-loop-helix factors, premature neurogenesis, and
severe neural tube defects. Genes Dev 9, 3136-3148.
Ishibashi, M., Moriyoshi, K., Sasai, Y., Shiota, K., Nakanishi, S., and Kageyama, R.
(1994). Persistent expression of helix-loop-helix factor HES-1 prevents mammalian
neural differentiation in the central nervous system. EMBO J 13, 1799-1805.
Ishitani, T., Matsumoto, K., Chitnis, A.B., and Itoh, M. (2005). Nrarp functions to
modulate neural-crest-cell differentiation by regulating LEF1 protein stability. Nat Cell
Biol 7, 1106-1112.
Iso, T., Chung, G., Hamamori, Y., and Kedes, L. (2002). HERP1 is a cell type-specific
primary target of Notch. J Biol Chem 277, 6598-6607.
Iso, T., Kedes, L., and Hamamori, Y. (2003). HES and HERP families: multiple effectors
of the Notch signaling pathway. J Cell Physiol 194, 237-255.
Iso, T., Sartorelli, V., Chung, G., Shichinohe, T., Kedes, L., and Hamamori, Y. (2001a).
HERP, a new primary target of Notch regulated by ligand binding. Mol Cell Biol 21,
6071-6079.
Iso, T., Sartorelli, V., Poizat, C., Iezzi, S., Wu, H.Y., Chung, G., Kedes, L., and
Hamamori, Y. (2001b). HERP, a novel heterodimer partner of HES/E(spl) in Notch
signaling. Mol Cell Biol 21, 6080-6089.
Itoh, M., Kim, C.H., Palardy, G., Oda, T., Jiang, Y.J., Maust, D., Yeo, S.Y., Lorick, K.,
Wright, G.J., Ariza-McNaughton, L., et al. (2003). Mind bomb is a ubiquitin ligase that is
essential for efficient activation of Notch signaling by Delta. Dev Cell 4, 67-82.
Jarriault, S., Brou, C., Logeat, F., Schroeter, E.H., Kopan, R., and Israel, A. (1995).
Signalling downstream of activated mammalian Notch. Nature 377, 355-358.
Jen, Y., Weintraub, H., and Benezra, R. (1992). Overexpression of Id protein inhibits the
muscle differentiation program: in vivo association of Id with E2A proteins. Genes Dev
6, 1466-1479.
Jennings, B., Preiss, A., Delidakis, C., and Bray, S. (1994). The Notch signalling pathway
is required for Enhancer of split bHLH protein expression during neurogenesis in the
Drosophila embryo. Development 120, 3537-3548.
158
101

Jones, N.C., Tyner, K.J., Nibarger, L., Stanley, H.M., Cornelison, D.D., Fedorov, Y.V.,
and Olwin, B.B. (2005). The p38alpha/beta MAPK functions as a molecular switch to
activate the quiescent satellite cell. J Cell Biol 169, 105-116.
Kadesch, T. (2004). Notch signaling: the demise of elegant simplicity. Curr Opin Genet
Dev 14, 506-512.
Kami, K., and Senba, E. (1998). Localization of leukemia inhibitory factor and
interleukin-6 messenger ribonucleic acids in regenerating rat skeletal muscle. Muscle
Nerve 21, 819-822.
Kang, J.S., Bae, G.U., Yi, M.J., Yang, Y.J., Oh, J.E., Takaesu, G., Zhou, Y.T., Low,
B.C., and Krauss, R.S. (2008). A Cdo-Bnip-2-Cdc42 signaling pathway regulates
p38alpha/beta MAPK activity and myogenic differentiation. J Cell Biol 182, 497-507.
Kannabiran, C., Zeng, X., and Vales, L.D. (1997). The mammalian transcriptional
repressor RBP (CBF1) regulates interleukin-6 gene expression. Mol Cell Biol 17, 1-9.
Kao, H.Y., Ordentlich, P., Koyano-Nakagawa, N., Tang, Z., Downes, M., Kintner, C.R.,
Evans, R.M., and Kadesch, T. (1998). A histone deacetylase corepressor complex
regulates the Notch signal transduction pathway. Genes Dev 12, 2269-2277.
Kassar-Duchossoy, L., Gayraud-Morel, B., Gomes, D., Rocancourt, D., Buckingham, M.,
Shinin, V., and Tajbakhsh, S. (2004). Mrf4 determines skeletal muscle identity in
Myf5:Myod double-mutant mice. Nature 431, 466-471.
Kassar-Duchossoy, L., Giacone, E., Gayraud-Morel, B., Jory, A., Gomes, D., and
Tajbakhsh, S. (2005). Pax3/Pax7 mark a novel population of primitive myogenic cells
during development. Genes Dev 19, 1426-1431.
Kathiriya, I.S., King, I.N., Murakami, M., Nakagawa, M., Astle, J.M., Gardner, K.A.,
Gerard, R.D., Olson, E.N., Srivastava, D., and Nakagawa, O. (2004). Hairy-related
transcription factors inhibit GATA-dependent cardiac gene expression through a signalresponsive mechanism. J Biol Chem 279, 54937-54943.
Kato, H., Taniguchi, Y., Kurooka, H., Minoguchi, S., Sakai, T., Nomura-Okazaki, S.,
Tamura, K., and Honjo, T. (1997). Involvement of RBP-J in biological functions of
mouse Notch1 and its derivatives. Development 124, 4133-4141.
Keeshan, K., He, Y., Wouters, B.J., Shestova, O., Xu, L., Sai, H., Rodriguez, C.G.,
Maillard, I., Tobias, J.W., Valk, P., et al. (2006). Tribbles homolog 2 inactivates
C/EBPalpha and causes acute myelogenous leukemia. Cancer Cell 10, 401-411.
159
102

Kelly, A.M., and Zacks, S.I. (1969). The histogenesis of rat intercostal muscle. J Cell
Biol 42, 135-153.
Kirschner, M., and Gerhart, J. (1998). Evolvability. Proc Natl Acad Sci U S A 95, 84208427.
Klinakis, A., Szabolcs, M., Politi, K., Kiaris, H., Artavanis-Tsakonas, S., and Efstratiadis,
A. (2006). Myc is a Notch1 transcriptional target and a requisite for Notch1-induced
mammary tumorigenesis in mice. Proc Natl Acad Sci U S A 103, 9262-9267.
Kondoh, K., Sunadome, K., and Nishida, E. (2007). Notch signaling suppresses p38
MAPK activity via induction of MKP-1 in myogenesis. J Biol Chem 282, 3058-3065.
Koo, B.K., Lim, H.S., Song, R., Yoon, M.J., Yoon, K.J., Moon, J.S., Kim, Y.W., Kwon,
M.C., Yoo, K.W., Kong, M.P., et al. (2005). Mind bomb 1 is essential for generating
functional Notch ligands to activate Notch. Development 132, 3459-3470.
Kopan, R., and Ilagan, M.X. (2009). The canonical Notch signaling pathway: unfolding
the activation mechanism. Cell 137, 216-233.
Kopan, R., Nye, J.S., and Weintraub, H. (1994). The intracellular domain of mouse
Notch: a constitutively activated repressor of myogenesis directed at the basic helix-loophelix region of MyoD. Development 120, 2385-2396.
Kopan, R., Schroeter, E.H., Weintraub, H., and Nye, J.S. (1996). Signal transduction by
activated mNotch: importance of proteolytic processing and its regulation by the
extracellular domain. Proc Natl Acad Sci U S A 93, 1683-1688.
Krejci, A., Bernard, F., Housden, B.E., Collins, S., and Bray, S.J. (2009). Direct response
to Notch activation: signaling crosstalk and incoherent logic. Sci Signal 2, ra1.
Krejci, A., and Bray, S. (2007). Notch activation stimulates transient and selective
binding of Su(H)/CSL to target enhancers. Genes Dev 21, 1322-1327.
Kuang, S., Kuroda, K., Le Grand, F., and Rudnicki, M.A. (2007). Asymmetric selfrenewal and commitment of satellite stem cells in muscle. Cell 129, 999-1010.
Kuroda, K., Tani, S., Tamura, K., Minoguchi, S., Kurooka, H., and Honjo, T. (1999).
Delta-induced Notch signaling mediated by RBP-J inhibits MyoD expression and
myogenesis. J Biol Chem 274, 7238-7244.

160
103

Lamar, E., Deblandre, G., Wettstein, D., Gawantka, V., Pollet, N., Niehrs, C., and
Kintner, C. (2001). Nrarp is a novel intracellular component of the Notch signaling
pathway. Genes Dev 15, 1885-1899.
Lassar, A.B., Davis, R.L., Wright, W.E., Kadesch, T., Murre, C., Voronova, A.,
Baltimore, D., and Weintraub, H. (1991). Functional activity of myogenic HLH proteins
requires hetero-oligomerization with E12/E47-like proteins in vivo. Cell 66, 305-315.
Lassar, A.B., Paterson, B.M., and Weintraub, H. (1986). Transfection of a DNA locus
that mediates the conversion of 10T1/2 fibroblasts to myoblasts. Cell 47, 649-656.
Le Grand, F., Jones, A.E., Seale, V., Scime, A., and Rudnicki, M.A. (2009). Wnt7a
activates the planar cell polarity pathway to drive the symmetric expansion of satellite
stem cells. Cell Stem Cell 4, 535-547.
Lecourtois, M., and Schweisguth, F. (1995). The neurogenic suppressor of hairless DNAbinding protein mediates the transcriptional activation of the enhancer of split complex
genes triggered by Notch signaling. Genes Dev 9, 2598-2608.
Lepper, C., Conway, S.J., and Fan, C.M. (2009). Adult satellite cells and embryonic
muscle progenitors have distinct genetic requirements. Nature 460, 627-631.
Lewis, J., Hanisch, A., and Holder, M. (2009). Notch signaling, the segmentation clock,
and the patterning of vertebrate somites. J Biol 8, 44.
Lindsell, C.E., Shawber, C.J., Boulter, J., and Weinmaster, G. (1995). Jagged: a
mammalian ligand that activates Notch1. Cell 80, 909-917.
Liu, J.P., Baker, J., Perkins, A.S., Robertson, E.J., and Efstratiadis, A. (1993). Mice
carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type
1 IGF receptor (Igf1r). Cell 75, 59-72.
Lluis, F., Ballestar, E., Suelves, M., Esteller, M., and Munoz-Canoves, P. (2005). E47
phosphorylation by p38 MAPK promotes MyoD/E47 association and muscle-specific
gene transcription. EMBO J 24, 974-984.
Logeat, F., Bessia, C., Brou, C., LeBail, O., Jarriault, S., Seidah, N.G., and Israel, A.
(1998). The Notch1 receptor is cleaved constitutively by a furin-like convertase. Proc
Natl Acad Sci U S A 95, 8108-8112.

161
104

Lu, J., McKinsey, T.A., Zhang, C.L., and Olson, E.N. (2000). Regulation of skeletal
myogenesis by association of the MEF2 transcription factor with class II histone
deacetylases. Mol Cell 6, 233-244.
Lu, J., Webb, R., Richardson, J.A., and Olson, E.N. (1999). MyoR: a muscle-restricted
basic helix-loop-helix transcription factor that antagonizes the actions of MyoD. Proc
Natl Acad Sci U S A 96, 552-557.
Lu, J.R., Bassel-Duby, R., Hawkins, A., Chang, P., Valdez, R., Wu, H., Gan, L., Shelton,
J.M., Richardson, J.A., and Olson, E.N. (2002). Control of facial muscle development by
MyoR and capsulin. Science 298, 2378-2381.
Lutolf, S., Radtke, F., Aguet, M., Suter, U., and Taylor, V. (2002). Notch1 is required for
neuronal and glial differentiation in the cerebellum. Development 129, 373-385.
Maier, M.M., and Gessler, M. (2000). Comparative analysis of the human and mouse
Hey1 promoter: Hey genes are new Notch target genes. Biochem Biophys Res Commun
275, 652-660.
Mal, A., and Harter, M.L. (2003). MyoD is functionally linked to the silencing of a
muscle-specific regulatory gene prior to skeletal myogenesis. Proc Natl Acad Sci U S A
100, 1735-1739.
Mal, A., Sturniolo, M., Schiltz, R.L., Ghosh, M.K., and Harter, M.L. (2001). A role for
histone deacetylase HDAC1 in modulating the transcriptional activity of MyoD:
inhibition of the myogenic program. EMBO J 20, 1739-1753.
Mal, A.K. (2006). Histone methyltransferase Suv39h1 represses MyoD-stimulated
myogenic differentiation. EMBO J 25, 3323-3334.
Mammucari, C., Tommasi di Vignano, A., Sharov, A.A., Neilson, J., Havrda, M.C.,
Roop, D.R., Botchkarev, V.A., Crabtree, G.R., and Dotto, G.P. (2005). Integration of
Notch 1 and calcineurin/NFAT signaling pathways in keratinocyte growth and
differentiation control. Dev Cell 8, 665-676.
Maroto, M., Reshef, R., Munsterberg, A.E., Koester, S., Goulding, M., and Lassar, A.B.
(1997). Ectopic Pax-3 activates MyoD and Myf-5 expression in embryonic mesoderm
and neural tissue. Cell 89, 139-148.
Massari, M.E., Rivera, R.R., Voland, J.R., Quong, M.W., Breit, T.M., van Dongen, J.J.,
de Smit, O., and Murre, C. (1998). Characterization of ABF-1, a novel basic helix-loop162
105

helix transcription factor expressed in activated B lymphocytes. Mol Cell Biol 18, 31303139.
Mauro, A. (1961). Satellite cell of skeletal muscle fibers. J Biophys Biochem Cytol 9,
493-495.
McGill, M.A., and McGlade, C.J. (2003). Mammalian numb proteins promote Notch1
receptor ubiquitination and degradation of the Notch1 intracellular domain. J Biol Chem
278, 23196-23203.
Megeney, L.A., Kablar, B., Garrett, K., Anderson, J.E., and Rudnicki, M.A. (1996).
MyoD is required for myogenic stem cell function in adult skeletal muscle. Genes Dev
10, 1173-1183.
Mohr, O.L. (1919). Character Changes Caused by Mutation of an Entire Region of a
Chromosome in Drosophila. Genetics 4, 275-282.
Molkentin, J.D., Black, B.L., Martin, J.F., and Olson, E.N. (1995). Cooperative activation
of muscle gene expression by MEF2 and myogenic bHLH proteins. Cell 83, 1125-1136.
Moloney, D.J., Panin, V.M., Johnston, S.H., Chen, J., Shao, L., Wilson, R., Wang, Y.,
Stanley, P., Irvine, K.D., Haltiwanger, R.S., et al. (2000). Fringe is a glycosyltransferase
that modifies Notch. Nature 406, 369-375.
Montarras, D., Morgan, J., Collins, C., Relaix, F., Zaffran, S., Cumano, A., Partridge, T.,
and Buckingham, M. (2005). Direct isolation of satellite cells for skeletal muscle
regeneration. Science 309, 2064-2067.
Mumm, J.S., Schroeter, E.H., Saxena, M.T., Griesemer, A., Tian, X., Pan, D.J., Ray,
W.J., and Kopan, R. (2000). A ligand-induced extracellular cleavage regulates gammasecretase-like proteolytic activation of Notch1. Mol Cell 5, 197-206.
Munsterberg, A.E., Kitajewski, J., Bumcrot, D.A., McMahon, A.P., and Lassar, A.B.
(1995). Combinatorial signaling by Sonic hedgehog and Wnt family members induces
myogenic bHLH gene expression in the somite. Genes Dev 9, 2911-2922.
Musaro, A., McCullagh, K., Paul, A., Houghton, L., Dobrowolny, G., Molinaro, M.,
Barton, E.R., Sweeney, H.L., and Rosenthal, N. (2001). Localized Igf-1 transgene
expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet
27, 195-200.

163
106

Nabeshima, Y., Hanaoka, K., Hayasaka, M., Esumi, E., Li, S., and Nonaka, I. (1993).
Myogenin gene disruption results in perinatal lethality because of severe muscle defect.
Nature 364, 532-535.
Naiki, T., Saijou, E., Miyaoka, Y., Sekine, K., and Miyajima, A. (2007). TRB2, a mouse
Tribbles ortholog, suppresses adipocyte differentiation by inhibiting AKT and
C/EBPbeta. J Biol Chem 282, 24075-24082.
Nakagawa, O., McFadden, D.G., Nakagawa, M., Yanagisawa, H., Hu, T., Srivastava, D.,
and Olson, E.N. (2000). Members of the HRT family of basic helix-loop-helix proteins
act as transcriptional repressors downstream of Notch signaling. Proc Natl Acad Sci U S
A 97, 13655-13660.
Nam, Y., Sliz, P., Song, L., Aster, J.C., and Blacklow, S.C. (2006). Structural basis for
cooperativity in recruitment of MAML coactivators to Notch transcription complexes.
Cell 124, 973-983.
Nicolas, M., Wolfer, A., Raj, K., Kummer, J.A., Mill, P., van Noort, M., Hui, C.C.,
Clevers, H., Dotto, G.P., and Radtke, F. (2003). Notch1 functions as a tumor suppressor
in mouse skin. Nat Genet 33, 416-421.
Nie, L., Wu, H., and Sun, X.H. (2008). Ubiquitination and degradation of Tal1/SCL are
induced by notch signaling and depend on Skp2 and CHIP. J Biol Chem 283, 684-692.
Nie, L., Xu, M., Vladimirova, A., and Sun, X.H. (2003). Notch-induced E2A
ubiquitination and degradation are controlled by MAP kinase activities. EMBO J 22,
5780-5792.
Nishimura, M., Isaka, F., Ishibashi, M., Tomita, K., Tsuda, H., Nakanishi, S., and
Kageyama, R. (1998). Structure, chromosomal locus, and promoter of mouse Hes2 gene,
a homologue of Drosophila hairy and Enhancer of split. Genomics 49, 69-75.
Nofziger, D., Miyamoto, A., Lyons, K.M., and Weinmaster, G. (1999). Notch signaling
imposes two distinct blocks in the differentiation of C2C12 myoblasts. Development 126,
1689-1702.
Ohsako, S., Hyer, J., Panganiban, G., Oliver, I., and Caudy, M. (1994). Hairy function as
a DNA-binding helix-loop-helix repressor of Drosophila sensory organ formation. Genes
Dev 8, 2743-2755.

164
107

Ohtsuka, T., Ishibashi, M., Gradwohl, G., Nakanishi, S., Guillemot, F., and Kageyama,
R. (1999). Hes1 and Hes5 as notch effectors in mammalian neuronal differentiation.
EMBO J 18, 2196-2207.
Oswald, F., Kostezka, U., Astrahantseff, K., Bourteele, S., Dillinger, K., Zechner, U.,
Ludwig, L., Wilda, M., Hameister, H., Knochel, W., et al. (2002). SHARP is a novel
component of the Notch/RBP-Jkappa signalling pathway. EMBO J 21, 5417-5426.
Oswald, F., Tauber, B., Dobner, T., Bourteele, S., Kostezka, U., Adler, G., Liptay, S., and
Schmid, R.M. (2001). p300 acts as a transcriptional coactivator for mammalian Notch-1.
Mol Cell Biol 21, 7761-7774.
Oswald, F., Winkler, M., Cao, Y., Astrahantseff, K., Bourteele, S., Knochel, W., and
Borggrefe, T. (2005). RBP-Jkappa/SHARP recruits CtIP/CtBP corepressors to silence
Notch target genes. Mol Cell Biol 25, 10379-10390.
Ott, M.O., Bober, E., Lyons, G., Arnold, H., and Buckingham, M. (1991). Early
expression of the myogenic regulatory gene, myf-5, in precursor cells of skeletal muscle
in the mouse embryo. Development 111, 1097-1107.
Oustanina, S., Hause, G., and Braun, T. (2004). Pax7 directs postnatal renewal and
propagation of myogenic satellite cells but not their specification. EMBO J 23, 34303439.
Palmieri, M., Sasso, M.P., Monese, R., Merola, M., Faggioli, L., Tovey, M., and Furia,
A. (1999). Interaction of the nuclear protein CBF1 with the kappaB site of the IL-6 gene
promoter. Nucleic Acids Res 27, 2785-2791.
Pan, L., Sato, S., Frederick, J.P., Sun, X.H., and Zhuang, Y. (1999). Impaired immune
responses and B-cell proliferation in mice lacking the Id3 gene. Mol Cell Biol 19, 59695980.
Pandolfi, P.P., Roth, M.E., Karis, A., Leonard, M.W., Dzierzak, E., Grosveld, F.G.,
Engel, J.D., and Lindenbaum, M.H. (1995). Targeted disruption of the GATA3 gene
causes severe abnormalities in the nervous system and in fetal liver haematopoiesis. Nat
Genet 11, 40-44.
Panin, V.M., Papayannopoulos, V., Wilson, R., and Irvine, K.D. (1997). Fringe
modulates Notch-ligand interactions. Nature 387, 908-912.

165
108

Parks, A.L., Klueg, K.M., Stout, J.R., and Muskavitch, M.A. (2000). Ligand endocytosis
drives receptor dissociation and activation in the Notch pathway. Development 127,
1373-1385.
Paroush, Z., Finley, R.L., Jr., Kidd, T., Wainwright, S.M., Ingham, P.W., Brent, R., and
Ish-Horowicz, D. (1994). Groucho is required for Drosophila neurogenesis,
segmentation, and sex determination and interacts directly with hairy-related bHLH
proteins. Cell 79, 805-815.
Pear, W.S., Nolan, G.P., Scott, M.L., and Baltimore, D. (1993). Production of high-titer
helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A 90, 83928396.
Penn, B.H., Bergstrom, D.A., Dilworth, F.J., Bengal, E., and Tapscott, S.J. (2004). A
MyoD-generated feed-forward circuit temporally patterns gene expression during skeletal
muscle differentiation. Genes Dev 18, 2348-2353.
Petersen, P.H., Zou, K., Hwang, J.K., Jan, Y.N., and Zhong, W. (2002). Progenitor cell
maintenance requires numb and numblike during mouse neurogenesis. Nature 419, 929934.
Pichon, B., Taelman, V., Bellefroid, E.J., and Christophe, D. (2004). Transcriptional
repression by the bHLH-Orange factor XHRT1 does not involve the C-terminal YRPW
motif. Biochim Biophys Acta 1680, 46-52.
Polesskaya, A., Seale, P., and Rudnicki, M.A. (2003). Wnt signaling induces the
myogenic specification of resident CD45+ adult stem cells during muscle regeneration.
Cell 113, 841-852.
Pui, J.C., Allman, D., Xu, L., DeRocco, S., Karnell, F.G., Bakkour, S., Lee, J.Y.,
Kadesch, T., Hardy, R.R., Aster, J.C., et al. (1999). Notch1 expression in early
lymphopoiesis influences B versus T lineage determination. Immunity 11, 299-308.
Puri, P.L., Iezzi, S., Stiegler, P., Chen, T.T., Schiltz, R.L., Muscat, G.E., Giordano, A.,
Kedes, L., Wang, J.Y., and Sartorelli, V. (2001). Class I histone deacetylases sequentially
interact with MyoD and pRb during skeletal myogenesis. Mol Cell 8, 885-897.
Puri, P.L., Sartorelli, V., Yang, X.J., Hamamori, Y., Ogryzko, V.V., Howard, B.H.,
Kedes, L., Wang, J.Y., Graessmann, A., Nakatani, Y., et al. (1997). Differential roles of
p300 and PCAF acetyltransferases in muscle differentiation. Mol Cell 1, 35-45.

166
109

Purow, B.W., Sundaresan, T.K., Burdick, M.J., Kefas, B.A., Comeau, L.D., Hawkinson,
M.P., Su, Q., Kotliarov, Y., Lee, J., Zhang, W., et al. (2008). Notch-1 regulates
transcription of the epidermal growth factor receptor through p53. Carcinogenesis 29,
918-925.
Radtke, F., Wilson, A., Stark, G., Bauer, M., van Meerwijk, J., MacDonald, H.R., and
Aguet, M. (1999). Deficient T cell fate specification in mice with an induced inactivation
of Notch1. Immunity 10, 547-558.
Rand, M.D., Grimm, L.M., Artavanis-Tsakonas, S., Patriub, V., Blacklow, S.C., Sklar, J.,
and Aster, J.C. (2000). Calcium depletion dissociates and activates heterodimeric notch
receptors. Mol Cell Biol 20, 1825-1835.
Rangarajan, A., Talora, C., Okuyama, R., Nicolas, M., Mammucari, C., Oh, H., Aster,
J.C., Krishna, S., Metzger, D., Chambon, P., et al. (2001). Notch signaling is a direct
determinant of keratinocyte growth arrest and entry into differentiation. EMBO J 20,
3427-3436.
Rebay, I., Fleming, R.J., Fehon, R.G., Cherbas, L., Cherbas, P., and Artavanis-Tsakonas,
S. (1991). Specific EGF repeats of Notch mediate interactions with Delta and Serrate:
implications for Notch as a multifunctional receptor. Cell 67, 687-699.
Reddy, K.L., Zullo, J.M., Bertolino, E., and Singh, H. (2008). Transcriptional repression
mediated by repositioning of genes to the nuclear lamina. Nature 452, 243-247.
Relaix, F., Montarras, D., Zaffran, S., Gayraud-Morel, B., Rocancourt, D., Tajbakhsh, S.,
Mansouri, A., Cumano, A., and Buckingham, M. (2006). Pax3 and Pax7 have distinct and
overlapping functions in adult muscle progenitor cells. J Cell Biol 172, 91-102.
Relaix, F., Rocancourt, D., Mansouri, A., and Buckingham, M. (2005). A Pax3/Pax7dependent population of skeletal muscle progenitor cells. Nature 435, 948-953.
Reshef, R., Maroto, M., and Lassar, A.B. (1998). Regulation of dorsal somitic cell fates:
BMPs and Noggin control the timing and pattern of myogenic regulator expression.
Genes Dev 12, 290-303.
Reynaud-Deonauth, S., Zhang, H., Afouda, A., Taillefert, S., Beatus, P., Kloc, M., Etkin,
L.D., Fischer-Lougheed, J., and Spohr, G. (2002). Notch signaling is involved in the
regulation of Id3 gene transcription during Xenopus embryogenesis. Differentiation 69,
198-208.

167
110

Rhyu, M.S., Jan, L.Y., and Jan, Y.N. (1994). Asymmetric distribution of numb protein
during division of the sensory organ precursor cell confers distinct fates to daughter cells.
Cell 76, 477-491.
Ridgeway, A.G., Wilton, S., and Skerjanc, I.S. (2000). Myocyte enhancer factor 2C and
myogenin up-regulate each other's expression and induce the development of skeletal
muscle in P19 cells. J Biol Chem 275, 41-46.
Ross, D.A., and Kadesch, T. (2001). The notch intracellular domain can function as a
coactivator for LEF-1. Mol Cell Biol 21, 7537-7544.
Rudnicki, M.A., Braun, T., Hinuma, S., and Jaenisch, R. (1992). Inactivation of MyoD in
mice leads to up-regulation of the myogenic HLH gene Myf-5 and results in apparently
normal muscle development. Cell 71, 383-390.
Rudnicki, M.A., Schnegelsberg, P.N., Stead, R.H., Braun, T., Arnold, H.H., and Jaenisch,
R. (1993). MyoD or Myf-5 is required for the formation of skeletal muscle. Cell 75,
1351-1359.
Ruiz Gomez, M., and Bate, M. (1997). Segregation of myogenic lineages in Drosophila
requires numb. Development 124, 4857-4866.
Sacco, A., Doyonnas, R., Kraft, P., Vitorovic, S., and Blau, H.M. (2008). Self-renewal
and expansion of single transplanted muscle stem cells. Nature 456, 502-506.
Sandri, M., Sandri, C., Gilbert, A., Skurk, C., Calabria, E., Picard, A., Walsh, K.,
Schiaffino, S., Lecker, S.H., and Goldberg, A.L. (2004). Foxo transcription factors induce
the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117,
399-412.
Sartorelli, V., Huang, J., Hamamori, Y., and Kedes, L. (1997). Molecular mechanisms of
myogenic coactivation by p300: direct interaction with the activation domain of MyoD
and with the MADS box of MEF2C. Mol Cell Biol 17, 1010-1026.
Sartorelli, V., Puri, P.L., Hamamori, Y., Ogryzko, V., Chung, G., Nakatani, Y., Wang,
J.Y., and Kedes, L. (1999). Acetylation of MyoD directed by PCAF is necessary for the
execution of the muscle program. Mol Cell 4, 725-734.
Sasai, Y., Kageyama, R., Tagawa, Y., Shigemoto, R., and Nakanishi, S. (1992). Two
mammalian helix-loop-helix factors structurally related to Drosophila hairy and Enhancer
of split. Genes Dev 6, 2620-2634.
168
111

Sassoon, D., Lyons, G., Wright, W.E., Lin, V., Lassar, A., Weintraub, H., and
Buckingham, M. (1989). Expression of two myogenic regulatory factors myogenin and
MyoD1 during mouse embryogenesis. Nature 341, 303-307.
Schroeter, E.H., Kisslinger, J.A., and Kopan, R. (1998). Notch-1 signalling requires
ligand-induced proteolytic release of intracellular domain. Nature 393, 382-386.
Schuster-Gossler, K., Cordes, R., and Gossler, A. (2007). Premature myogenic
differentiation and depletion of progenitor cells cause severe muscle hypotrophy in
Delta1 mutants. Proc Natl Acad Sci U S A 104, 537-542.
Seale, P., Sabourin, L.A., Girgis-Gabardo, A., Mansouri, A., Gruss, P., and Rudnicki,
M.A. (2000). Pax7 is required for the specification of myogenic satellite cells. Cell 102,
777-786.
Serra, C., Palacios, D., Mozzetta, C., Forcales, S.V., Morantte, I., Ripani, M., Jones,
D.R., Du, K., Jhala, U.S., Simone, C., et al. (2007). Functional interdependence at the
chromatin level between the MKK6/p38 and IGF1/PI3K/AKT pathways during muscle
differentiation. Mol Cell 28, 200-213.
Serrano, A.L., Baeza-Raja, B., Perdiguero, E., Jardi, M., and Munoz-Canoves, P. (2008).
Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle
hypertrophy. Cell Metab 7, 33-44.
Shawber, C., Nofziger, D., Hsieh, J.J., Lindsell, C., Bogler, O., Hayward, D., and
Weinmaster, G. (1996). Notch signaling inhibits muscle cell differentiation through a
CBF1-independent pathway. Development 122, 3765-3773.
Shen, C.P., and Kadesch, T. (1995). B-cell-specific DNA binding by an E47 homodimer.
Mol Cell Biol 15, 4518-4524.
Shen, H., McElhinny, A.S., Cao, Y., Gao, P., Liu, J., Bronson, R., Griffin, J.D., and Wu,
L. (2006). The Notch coactivator, MAML1, functions as a novel coactivator for MEF2Cmediated transcription and is required for normal myogenesis. Genes Dev 20, 675-688.
Sherwood, R.I., Christensen, J.L., Conboy, I.M., Conboy, M.J., Rando, T.A., Weissman,
I.L., and Wagers, A.J. (2004). Isolation of adult mouse myogenic progenitors: functional
heterogeneity of cells within and engrafting skeletal muscle. Cell 119, 543-554.
Simone, C., Forcales, S.V., Hill, D.A., Imbalzano, A.N., Latella, L., and Puri, P.L.
(2004). p38 pathway targets SWI-SNF chromatin-remodeling complex to muscle-specific
loci. Nat Genet 36, 738-743.
169
112

Skapek, S.X., Rhee, J., Spicer, D.B., and Lassar, A.B. (1995). Inhibition of myogenic
differentiation in proliferating myoblasts by cyclin D1-dependent kinase. Science 267,
1022-1024.
Spitz, F., Demignon, J., Porteu, A., Kahn, A., Concordet, J.P., Daegelen, D., and Maire,
P. (1998). Expression of myogenin during embryogenesis is controlled by Six/sine oculis
homeoproteins through a conserved MEF3 binding site. Proc Natl Acad Sci U S A 95,
14220-14225.
Stitt, T.N., Drujan, D., Clarke, B.A., Panaro, F., Timofeyva, Y., Kline, W.O., Gonzalez,
M., Yancopoulos, G.D., and Glass, D.J. (2004). The IGF-1/PI3K/Akt pathway prevents
expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription
factors. Mol Cell 14, 395-403.
Struhl, G., and Adachi, A. (1998). Nuclear access and action of notch in vivo. Cell 93,
649-660.
Struhl, G., and Greenwald, I. (1999). Presenilin is required for activity and nuclear access
of Notch in Drosophila. Nature 398, 522-525.
Sun, J., Kamei, C.N., Layne, M.D., Jain, M.K., Liao, J.K., Lee, M.E., and Chin, M.T.
(2001). Regulation of myogenic terminal differentiation by the hairy-related transcription
factor CHF2. J Biol Chem 276, 18591-18596.
Taelman, V., Van Wayenbergh, R., Solter, M., Pichon, B., Pieler, T., Christophe, D., and
Bellefroid, E.J. (2004). Sequences downstream of the bHLH domain of the Xenopus
hairy-related transcription factor-1 act as an extended dimerization domain that
contributes to the selection of the partners. Dev Biol 276, 47-63.
Tagami, S., Okochi, M., Yanagida, K., Ikuta, A., Fukumori, A., Matsumoto, N., IshizukaKatsura, Y., Nakayama, T., Itoh, N., Jiang, J., et al. (2008). Regulation of Notch
signaling by dynamic changes in the precision of S3 cleavage of Notch-1. Mol Cell Biol
28, 165-176.
Tajbakhsh, S., Rocancourt, D., Cossu, G., and Buckingham, M. (1997). Redefining the
genetic hierarchies controlling skeletal myogenesis: Pax-3 and Myf-5 act upstream of
MyoD. Cell 89, 127-138.
Tamir, Y., and Bengal, E. (2000). Phosphoinositide 3-kinase induces the transcriptional
activity of MEF2 proteins during muscle differentiation. J Biol Chem 275, 34424-34432.

170
113

Tapscott, S.J. (2005). The circuitry of a master switch: Myod and the regulation of
skeletal muscle gene transcription. Development 132, 2685-2695.
Thayer, M.J., Tapscott, S.J., Davis, R.L., Wright, W.E., Lassar, A.B., and Weintraub, H.
(1989). Positive autoregulation of the myogenic determination gene MyoD1. Cell 58,
241-248.
Vales, L.D., and Friedl, E.M. (2002). Binding of C/EBP and RBP (CBF1) to overlapping
sites regulates interleukin-6 gene expression. J Biol Chem 277, 42438-42446.
Van Doren, M., Bailey, A.M., Esnayra, J., Ede, K., and Posakony, J.W. (1994). Negative
regulation of proneural gene activity: hairy is a direct transcriptional repressor of achaete.
Genes Dev 8, 2729-2742.
van Steensel, B., and Henikoff, S. (2000). Identification of in vivo DNA targets of
chromatin proteins using tethered dam methyltransferase. Nat Biotechnol 18, 424-428.
van Steensel, B., and Henikoff, S. (2003). Epigenomic profiling using microarrays.
Biotechniques 35, 346-350, 352-344, 356-347.
Varnum-Finney, B., Wu, L., Yu, M., Brashem-Stein, C., Staats, S., Flowers, D., Griffin,
J.D., and Bernstein, I.D. (2000). Immobilization of Notch ligand, Delta-1, is required for
induction of notch signaling. J Cell Sci 113 Pt 23, 4313-4318.
Vassin, H., Bremer, K.A., Knust, E., and Campos-Ortega, J.A. (1987). The neurogenic
gene Delta of Drosophila melanogaster is expressed in neurogenic territories and encodes
a putative transmembrane protein with EGF-like repeats. EMBO J 6, 3431-3440.
Vasyutina, E., Lenhard, D.C., Wende, H., Erdmann, B., Epstein, J.A., and Birchmeier, C.
(2007). RBP-J (Rbpsuh) is essential to maintain muscle progenitor cells and to generate
satellite cells. Proc Natl Acad Sci U S A 104, 4443-4448.
Vogel, M.J., Peric-Hupkes, D., and van Steensel, B. (2007). Detection of in vivo proteinDNA interactions using DamID in mammalian cells. Nat Protoc 2, 1467-1478.
Wakamatsu, Y., Maynard, T.M., Jones, S.U., and Weston, J.A. (1999). NUMB localizes
in the basal cortex of mitotic avian neuroepithelial cells and modulates neuronal
differentiation by binding to NOTCH-1. Neuron 23, 71-81.
Wang, D.Z., Valdez, M.R., McAnally, J., Richardson, J., and Olson, E.N. (2001). The
Mef2c gene is a direct transcriptional target of myogenic bHLH and MEF2 proteins
during skeletal muscle development. Development 128, 4623-4633.
171
114

Wang, Y., and Jaenisch, R. (1997). Myogenin can substitute for Myf5 in promoting
myogenesis but less efficiently. Development 124, 2507-2513.
Weintraub, H., Dwarki, V.J., Verma, I., Davis, R., Hollenberg, S., Snider, L., Lassar, A.,
and Tapscott, S.J. (1991). Muscle-specific transcriptional activation by MyoD. Genes
Dev 5, 1377-1386.
Weintraub, H., Genetta, T., and Kadesch, T. (1994). Tissue-specific gene activation by
MyoD: determination of specificity by cis-acting repression elements. Genes Dev 8,
2203-2211.
Weintraub, H., Tapscott, S.J., Davis, R.L., Thayer, M.J., Adam, M.A., Lassar, A.B., and
Miller, A.D. (1989). Activation of muscle-specific genes in pigment, nerve, fat, liver, and
fibroblast cell lines by forced expression of MyoD. Proc Natl Acad Sci U S A 86, 54345438.
Weng, A.P., Millholland, J.M., Yashiro-Ohtani, Y., Arcangeli, M.L., Lau, A., Wai, C.,
Del Bianco, C., Rodriguez, C.G., Sai, H., Tobias, J., et al. (2006). c-Myc is an important
direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev 20,
2096-2109.
Wharton, K.A., Johansen, K.M., Xu, T., and Artavanis-Tsakonas, S. (1985). Nucleotide
sequence from the neurogenic locus notch implies a gene product that shares homology
with proteins containing EGF-like repeats. Cell 43, 567-581.
Wilson-Rawls, J., Molkentin, J.D., Black, B.L., and Olson, E.N. (1999). Activated notch
inhibits myogenic activity of the MADS-Box transcription factor myocyte enhancer
factor 2C. Mol Cell Biol 19, 2853-2862.
Wilson, E.M., and Rotwein, P. (2007). Selective control of skeletal muscle differentiation
by Akt1. J Biol Chem 282, 5106-5110.
Wilson, J.J., and Kovall, R.A. (2006). Crystal structure of the CSL-Notch-Mastermind
ternary complex bound to DNA. Cell 124, 985-996.
Wright, W.E., Sassoon, D.A., and Lin, V.K. (1989). Myogenin, a factor regulating
myogenesis, has a domain homologous to MyoD. Cell 56, 607-617.
Wu, L., Aster, J.C., Blacklow, S.C., Lake, R., Artavanis-Tsakonas, S., and Griffin, J.D.
(2000a). MAML1, a human homologue of Drosophila mastermind, is a transcriptional
co-activator for NOTCH receptors. Nat Genet 26, 484-489.
172
115

Wu, Z., Woodring, P.J., Bhakta, K.S., Tamura, K., Wen, F., Feramisco, J.R., Karin, M.,
Wang, J.Y., and Puri, P.L. (2000b). p38 and extracellular signal-regulated kinases
regulate the myogenic program at multiple steps. Mol Cell Biol 20, 3951-3964.
Xu, Q., and Wu, Z. (2000). The insulin-like growth factor-phosphatidylinositol 3-kinaseAkt signaling pathway regulates myogenin expression in normal myogenic cells but not
in rhabdomyosarcoma-derived RD cells. J Biol Chem 275, 36750-36757.
Xue, Y., Gao, X., Lindsell, C.E., Norton, C.R., Chang, B., Hicks, C., Gendron-Maguire,
M., Rand, E.B., Weinmaster, G., and Gridley, T. (1999). Embryonic lethality and
vascular defects in mice lacking the Notch ligand Jagged1. Hum Mol Genet 8, 723-730.
Yaffe, D., and Saxel, O. (1977). Serial passaging and differentiation of myogenic cells
isolated from dystrophic mouse muscle. Nature 270, 725-727.
Yang, X.M., Vogan, K., Gros, P., and Park, M. (1996). Expression of the met receptor
tyrosine kinase in muscle progenitor cells in somites and limbs is absent in Splotch mice.
Development 122, 2163-2171.
Yee, S.P., and Rigby, P.W. (1993). The regulation of myogenin gene expression during
the embryonic development of the mouse. Genes Dev 7, 1277-1289.
Yen, H.C., Xu, Q., Chou, D.M., Zhao, Z., and Elledge, S.J. (2008). Global protein
stability profiling in mammalian cells. Science 322, 918-923.
Yoshida, N., Yoshida, S., Koishi, K., Masuda, K., and Nabeshima, Y. (1998). Cell
heterogeneity upon myogenic differentiation: down-regulation of MyoD and Myf-5
generates 'reserve cells'. J Cell Sci 111 ( Pt 6), 769-779.
Zammit, P.S., Golding, J.P., Nagata, Y., Hudon, V., Partridge, T.A., and Beauchamp, J.R.
(2004). Muscle satellite cells adopt divergent fates: a mechanism for self-renewal? J Cell
Biol 166, 347-357.
Zammit, P.S., Relaix, F., Nagata, Y., Ruiz, A.P., Collins, C.A., Partridge, T.A., and
Beauchamp, J.R. (2006). Pax7 and myogenic progression in skeletal muscle satellite
cells. J Cell Sci 119, 1824-1832.
Zhang, H., and Stavnezer, E. (2009). Ski regulates muscle terminal differentiation by
transcriptional activation of Myog in a complex with Six1 and Eya3. J Biol Chem 284,
2867-2879.

173
116

Zhang, W., Behringer, R.R., and Olson, E.N. (1995). Inactivation of the myogenic bHLH
gene MRF4 results in up-regulation of myogenin and rib anomalies. Genes Dev 9, 13881399.
Zhang, X., Pickin, K.A., Bose, R., Jura, N., Cole, P.A., and Kuriyan, J. (2007). Inhibition
of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature
450, 741-744.
Zhao, P., and Hoffman, E.P. (2006). Musculin isoforms and repression of MyoD in
muscle regeneration. Biochem Biophys Res Commun 342, 835-842.
Zhong, W., Jiang, M.M., Schonemann, M.D., Meneses, J.J., Pedersen, R.A., Jan, L.Y.,
and Jan, Y.N. (2000). Mouse numb is an essential gene involved in cortical neurogenesis.
Proc Natl Acad Sci U S A 97, 6844-6849.
Zhu, B., and Gulick, T. (2004). Phosphorylation and alternative pre-mRNA splicing
converge to regulate myocyte enhancer factor 2C activity. Mol Cell Biol 24, 8264-8275.
Zhu, B., Ramachandran, B., and Gulick, T. (2005). Alternative pre-mRNA splicing
governs expression of a conserved acidic transactivation domain in myocyte enhancer
factor 2 factors of striated muscle and brain. J Biol Chem 280, 28749-28760.
Zilian, O., Saner, C., Hagedorn, L., Lee, H.Y., Sauberli, E., Suter, U., Sommer, L., and
Aguet, M. (2001). Multiple roles of mouse Numb in tuning developmental cell fates. Curr
Biol 11, 494-501.

174
117

